array:23 [
  "pii" => "S2666275223000504"
  "issn" => "26662752"
  "doi" => "10.1016/j.abdp.2023.02.022"
  "estado" => "S300"
  "fechaPublicacion" => "2023-05-01"
  "aid" => "723"
  "copyright" => "Sociedade Brasileira de Dermatologia"
  "copyrightAnyo" => "2023"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "rev"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "en" => array:18 [
      "pii" => "S0365059623000247"
      "issn" => "03650596"
      "doi" => "10.1016/j.abd.2022.09.005"
      "estado" => "S300"
      "fechaPublicacion" => "2023-05-01"
      "aid" => "723"
      "copyright" => "Sociedade Brasileira de Dermatologia"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "rev"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:12 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
        "titulo" => "Cutaneous lupus erythematosus&#58; a review of etiopathogenic&#44; clinical&#44; diagnostic and therapeutic aspects"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "355"
            "paginaFinal" => "372"
          ]
        ]
        "contieneResumen" => array:1 [
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:8 [
            "identificador" => "fig0010"
            "etiqueta" => "Figure 2"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr2.jpeg"
                "Alto" => 1397
                "Ancho" => 2925
                "Tamanyo" => 255607
              ]
            ]
            "detalles" => array:1 [
              0 => array:3 [
                "identificador" => "at0050"
                "detalle" => "Figure "
                "rol" => "short"
              ]
            ]
            "descripcion" => array:1 [
              "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; Subacute cutaneous lupus erythematosus&#58; annular&#44; erythematous&#44; papulosquamous plaques&#44; confluent on the chest and upper limbs&#46; &#40;B&#41; Neonatal lupus erythematosus&#58; circular and polycyclic erythematous plaques on the face&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Everton Carlos Siviero do Vale, Lucas Campos Garcia"
            "autores" => array:2 [
              0 => array:2 [
                "nombre" => "Everton Carlos Siviero do"
                "apellidos" => "Vale"
              ]
              1 => array:2 [
                "nombre" => "Lucas Campos"
                "apellidos" => "Garcia"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "pt" => array:9 [
          "pii" => "S2666275223000504"
          "doi" => "10.1016/j.abdp.2023.02.022"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "pt"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275223000504?idApp=UINPBA00008Z"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059623000247?idApp=UINPBA00008Z"
      "url" => "/03650596/0000009800000003/v3_202305121633/S0365059623000247/v3_202305121633/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "S2666275223000413"
    "issn" => "26662752"
    "doi" => "10.1016/j.abdp.2023.02.014"
    "estado" => "S300"
    "fechaPublicacion" => "2023-05-01"
    "aid" => "715"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "pt" => array:9 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Carta &#8208; Investiga&#231;&#227;o</span>"
      "titulo" => "Associa&#231;&#227;o entre caracter&#237;sticas cl&#237;nicas e n&#237;veis plasm&#225;ticos de Hsp70 em adultos com vitiligo n&#227;o segmentar&#58; estudo transversal"
      "tienePdf" => "pt"
      "tieneTextoCompleto" => "pt"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "373"
          "paginaFinal" => "375"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "pt" => true
      ]
      "contienePdf" => array:1 [
        "pt" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Helena Zenedin Marchioro, Caio C&#233;sar Silva de Castro, Isabella Gizzi Jiacomini, H&#233;lio Amante Miot"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "Helena Zenedin"
              "apellidos" => "Marchioro"
            ]
            1 => array:2 [
              "nombre" => "Caio C&#233;sar Silva de"
              "apellidos" => "Castro"
            ]
            2 => array:2 [
              "nombre" => "Isabella Gizzi"
              "apellidos" => "Jiacomini"
            ]
            3 => array:2 [
              "nombre" => "H&#233;lio Amante"
              "apellidos" => "Miot"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "pt"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S036505962300020X"
        "doi" => "10.1016/j.abd.2022.09.002"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S036505962300020X?idApp=UINPBA00008Z"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275223000413?idApp=UINPBA00008Z"
    "url" => "/26662752/0000009800000003/v3_202305121556/S2666275223000413/v3_202305121556/pt/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S2666275223000498"
    "issn" => "26662752"
    "doi" => "10.1016/j.abdp.2023.02.021"
    "estado" => "S300"
    "fechaPublicacion" => "2023-05-01"
    "aid" => "722"
    "copyright" => "Sociedade Brasileira de Dermatologia"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "rev"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "pt" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Revis&#227;o</span>"
      "titulo" => "Infec&#231;&#227;o por COVID&#8208;19 e vacinas&#58; poss&#237;veis gatilhos de reativa&#231;&#227;o de v&#237;rus da fam&#237;lia Herpesviridae"
      "tienePdf" => "pt"
      "tieneTextoCompleto" => "pt"
      "tieneResumen" => "pt"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "347"
          "paginaFinal" => "354"
        ]
      ]
      "contieneResumen" => array:1 [
        "pt" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "pt" => true
      ]
      "contienePdf" => array:1 [
        "pt" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 2092
              "Ancho" => 3341
              "Tamanyo" => 556277
            ]
          ]
          "descripcion" => array:1 [
            "pt" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Manifesta&#231;&#245;es de infec&#231;&#245;es por herpesv&#237;rus associadas &#224; COVID&#8208;19&#46; HSV&#8208;1&#44; herpesv&#237;rus simples tipo&#8208;1&#59; HSV&#8208;2&#44; herpesv&#237;rus simples tipo&#8208;2&#59; VZV&#44; v&#237;rus varicela&#8208;z&#243;ster&#59; EBV&#44; v&#237;rus Epstein&#8208;Barr&#59; CMV&#44; citomegalov&#237;rus&#59; HHV&#8208;6&#44; herpesv&#237;rus humano tipo 6&#59; HHV&#8208;7&#44; herpesv&#237;rus humano tipo 7&#59; HHV8&#44; herpesv&#237;rus humano tipo 8&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Alba Navarro&#8208;Bielsa, Tamara Gracia&#8208;Caza&#241;a, Beatriz Aldea&#8208;Manrique, Isabel Abad&#237;as&#8208;Granado, Adri&#225;n Ballano, Isabel Bernad, Yolanda Gilaberte"
          "autores" => array:7 [
            0 => array:2 [
              "nombre" => "Alba"
              "apellidos" => "Navarro&#8208;Bielsa"
            ]
            1 => array:2 [
              "nombre" => "Tamara"
              "apellidos" => "Gracia&#8208;Caza&#241;a"
            ]
            2 => array:2 [
              "nombre" => "Beatriz"
              "apellidos" => "Aldea&#8208;Manrique"
            ]
            3 => array:2 [
              "nombre" => "Isabel"
              "apellidos" => "Abad&#237;as&#8208;Granado"
            ]
            4 => array:2 [
              "nombre" => "Adri&#225;n"
              "apellidos" => "Ballano"
            ]
            5 => array:2 [
              "nombre" => "Isabel"
              "apellidos" => "Bernad"
            ]
            6 => array:2 [
              "nombre" => "Yolanda"
              "apellidos" => "Gilaberte"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "pt"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S0365059623000235"
        "doi" => "10.1016/j.abd.2022.09.004"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059623000235?idApp=UINPBA00008Z"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275223000498?idApp=UINPBA00008Z"
    "url" => "/26662752/0000009800000003/v3_202305121556/S2666275223000498/v3_202305121556/pt/main.assets"
  ]
  "pt" => array:19 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Revis&#227;o</span>"
    "titulo" => "L&#250;pus eritematoso cut&#226;neo&#58; revis&#227;o dos aspectos etiopatog&#234;nicos&#44; cl&#237;nicos&#44; diagn&#243;sticos e terap&#234;uticos"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "355"
        "paginaFinal" => "372"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Everton Carlos Siviero do Vale, Lucas Campos Garcia"
        "autores" => array:2 [
          0 => array:4 [
            "nombre" => "Everton Carlos Siviero do"
            "apellidos" => "Vale"
            "email" => array:1 [
              0 => "everton.siviero@gmail.com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Lucas Campos"
            "apellidos" => "Garcia"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Servi&#231;o de Dermatologia&#44; Hospital das Cl&#237;nicas&#44; Universidade Federal de Minas Gerais&#44; Belo Horizonte&#44; MG&#44; Brasil"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Departamento de Cl&#237;nica M&#233;dica&#44; Faculdade de Medicina&#44; Universidade Federal de Minas Gerais&#44; Belo Horizonte&#44; MG&#44; Brasil"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspond&#234;ncia&#46;"
          ]
        ]
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0025"
        "etiqueta" => "Figura 5"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr5.jpeg"
            "Alto" => 3171
            "Ancho" => 1675
            "Tamanyo" => 439940
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; L&#250;pus eritematoso t&#250;mido&#58; les&#245;es eritemato&#8208;edematosas arciformes e anulares na face e regi&#227;o cervical&#46; &#40;B&#41; L&#250;pus eritematoso bolhoso&#58; les&#245;es bolhosas&#44; ulcerocrostosas hem&#225;ticas e les&#245;es residuais hipocr&#244;micas&#44; localizadas na regi&#227;o cervical&#44; tronco&#44; axilas e membros superiores&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Introdu&#231;&#227;o</span><p id="par0005" class="elsevierStylePara elsevierViewall">O l&#250;pus eritematoso &#40;LE&#41; &#233; doen&#231;a autoimune com amplo espectro de express&#227;o cl&#237;nica&#44; que varia desde doen&#231;a cut&#226;nea limitada at&#233; doen&#231;a sist&#234;mica grave e potencialmente fatal&#44; por comprometimento de &#243;rg&#227;os vitais&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> O LE cut&#226;neo &#40;LEC&#41; apresenta&#8208;se como doen&#231;a cut&#226;nea exclusiva ou comp&#245;e uma das m&#250;ltiplas manifesta&#231;&#245;es do LE sist&#234;mico &#40;LES&#41;&#46; Les&#245;es cut&#226;neas est&#227;o presentes em&#160;70&#37;&#8208;80&#37; dos casos de LES&#44; em algum momento de sua evolu&#231;&#227;o&#44; e podem ser a manifesta&#231;&#227;o inicial da doen&#231;a em at&#233;&#160;25&#37; dos pacientes&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Com base em caracter&#237;sticas cl&#237;nicas&#44; achados histopatol&#243;gicos&#44; altera&#231;&#245;es laboratoriais e dura&#231;&#227;o&#44; as les&#245;es cut&#226;neas espec&#237;ficas do LE s&#227;o subdivididas em tr&#234;s subtipos principais&#58; o LEC agudo &#40;LECA&#41;&#44; o LEC subagudo &#40;LECS&#41; e o LEC cr&#244;nico &#40;LECC&#41;&#46; A identifica&#231;&#227;o desses subtipos &#233; fundamental&#44; porque eles costumam ocorrer em contextos cl&#237;nicos distintos&#44; com implica&#231;&#245;es diagn&#243;sticas&#44; progn&#243;sticas e terap&#234;uticas&#46;<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">2</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">O LEC exclusivo &#233; 2&#8208;3 vezes mais frequente que o LES&#44; com incid&#234;ncia anual de&#160;4&#44;3&#47;100&#46;000&#160;indiv&#237;duos na Europa e nos EUA&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#8211;3</span></a> H&#225; predomin&#226;ncia de LE em mulheres&#44; em que a incid&#234;ncia de LES adulto &#233;&#160;7&#8208;15&#160;vezes maior e de LES infantil&#44; 3&#8208;4&#160;vezes maior&#46; Essa preponder&#226;ncia feminina &#233; menos evidente nas formas cut&#226;neas isoladas de LE&#44; com rela&#231;&#227;o de&#160;4&#58;1&#44; e &#233; ainda menos expressiva&#44; com rela&#231;&#227;o de&#160;3&#58;1&#44; no LE discoide &#40;LED&#41;&#44; forma mais comum de LECC&#46;<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">2&#44;4</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">H&#225; ainda diferen&#231;as raciais na ocorr&#234;ncia do LEC&#44; com risco&#160;5&#44;4&#160;vezes maior de LECC nos afro&#8208;americanos em rela&#231;&#227;o aos caucasianos&#46;<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">4</span></a> Na Nova Zel&#226;ndia&#44; quando comparados &#224; popula&#231;&#227;o de origem europeia&#44; os ind&#237;genas Maori mostram risco relativo de&#160;2&#44;47&#160;para desenvolver todos os subtipos de LEC e&#160;5&#44;96&#160;para LECC&#46;<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">5</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">O pico de incid&#234;ncia do LES acontece na meia&#8208;idade adulta&#44; por&#233;m mais tardiamente nos homens&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> Ainda que tamb&#233;m acometa crian&#231;as e idosos&#44; o LEC exclusivo &#233; mais comum entre&#160;20&#160;e&#160;40&#160;anos&#44; com idade m&#233;dia de instala&#231;&#227;o aos&#160;43&#160;anos&#44; por&#233;m com varia&#231;&#227;o conforme o subtipo&#46;<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">3</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">As les&#245;es cut&#226;neas do LE constituem consider&#225;vel morbidade&#44; sobretudo devido &#224; natureza cr&#244;nica&#44; ao acometimento preferencial das partes expostas do corpo e car&#225;ter desfigurante de suas sequelas&#44; que resultam em significante preju&#237;zo da qualidade de vida dos pacientes&#46;<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">7</span></a></p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Classifica&#231;&#227;o</span><p id="par0035" class="elsevierStylePara elsevierViewall">Os crit&#233;rios diagn&#243;sticos para classifica&#231;&#227;o do LES n&#227;o s&#227;o uniformes e universalmente aceitos&#59; s&#227;o precursores aqueles propostos em&#160;1971 pelo American College of Rheumatology &#40;ACR&#41;&#44; revistos em&#160;1997 &#40;ACR 1997&#41;&#59; posteriormente&#44; surgiram mais dois sistemas de classifica&#231;&#227;o &#8211; o da Systemic Lupus International Collaborating Clinics &#40;SLICC&#160;2012&#41; e o conjunto entre a European League Against Rheumatism e o ACR &#40;EULAR&#47;ACR&#160;2019&#41;&#44; que est&#227;o discriminados e podem ser comparados na <a class="elsevierStyleCrossRef" href="#tbl0005">tabela 1</a>&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">4&#44;8&#44;9</span></a> Cada um desses tr&#234;s sistemas contempla quatro achados dermatol&#243;gicos como crit&#233;rios diagn&#243;sticos do LES&#46; Estudo australiano atual&#44; que avaliou a performance dos diferentes crit&#233;rios de classifica&#231;&#227;o do LES&#44; concluiu que o ACR&#160;1997 detinha a maior especificidade&#44; por&#233;m o SLICC&#160;2012 era o que proporcionava a maior acur&#225;cia diagn&#243;stica global &#40;94&#44;4&#37;&#41;&#44; com desempenho similar entre os pacientes com doen&#231;a inicial&#46;<a class="elsevierStyleCrossRef" href="#bib0400"><span class="elsevierStyleSup">10</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0040" class="elsevierStylePara elsevierViewall">Foi pioneira a classifica&#231;&#227;o proposta por Gilliam &#38; Sontheimer&#44; em&#160;1981&#44; que discrimina as les&#245;es cut&#226;neas do LE entre espec&#237;ficas e inespec&#237;ficas&#46; As espec&#237;ficas&#44; definidas pela presen&#231;a da dermatite de interface dermoepid&#233;rmica&#44; s&#227;o exclusivas do LE&#44; com ou sem doen&#231;a sist&#234;mica&#46; S&#227;o subdivididas em tr&#234;s categorias&#44; com base nas caracter&#237;sticas cl&#237;nicas&#58; LECA&#44; LECS e LECC&#46; As les&#245;es inespec&#237;ficas incluem as demais manifesta&#231;&#245;es cut&#226;neas associadas ao LES&#46; Em&#160;2004&#44; a classifica&#231;&#227;o de D&#252;sseldorf acrescentou outro subtipo&#44; o LEC intermitente &#40;LECI&#41;&#44; que corresponde ao LE t&#250;mido&#44; anteriormente considerado variante de LECC&#46;<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">3</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">Algumas limita&#231;&#245;es das classifica&#231;&#245;es anteriormente citadas podem ser destacadas&#58; a&#41;&#160;nem sempre as les&#245;es de LEC podem ser classificadas como agudas&#44; subagudas ou cr&#244;nicas&#44; com base na histologia&#59; b&#41;&#160;a dermatite de interface&#44; utilizada como crit&#233;rio para definir as les&#245;es espec&#237;ficas do LEC&#44; na realidade&#44; carece de especificidade&#44; j&#225; que pode estar presente em outras condi&#231;&#245;es&#44; como dermatomiosite&#44; doen&#231;a do enxerto&#8208;<span class="elsevierStyleItalic">versus</span>&#8208;hospedeiro e rea&#231;&#245;es medicamentosas&#59; c&#41;&#160;alguns subtipos inclu&#237;dos como espec&#237;ficos&#44; como o LE t&#250;mido e a paniculite l&#250;pica&#44; nem sempre apresentam dermatite de interface&#59; d&#41;&#160;termos como agudo&#44; subagudo ou cr&#244;nico&#44; de natureza cronol&#243;gica&#44; s&#227;o utilizados para definir varia&#231;&#245;es morfol&#243;gicas&#44; al&#233;m de serem associados a graus de extens&#227;o mal definidos&#44; como localizado ou disseminado&#44; referindo&#8208;se &#224; topografia&#46; Por essas raz&#245;es&#44; em&#160;2010&#44; Lipsker prop&#244;s uma nova classifica&#231;&#227;o das les&#245;es cut&#226;neas do LE&#44; com base nas caracter&#237;sticas cl&#237;nicas e nos achados histol&#243;gicos&#46; As les&#245;es cut&#226;neas espec&#237;ficas&#44; sem a presen&#231;a obrigat&#243;ria da dermatite de interface&#44; s&#227;o subdivididas em dermoepid&#233;rmicas&#44; d&#233;rmicas e hipod&#233;rmicas&#46; As les&#245;es inespec&#237;ficas s&#227;o subdivididas em tromb&#243;ticas&#44; neutrof&#237;licas ou de natureza patogen&#233;tica incerta&#46;<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">11</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">Na falta de classifica&#231;&#227;o universalmente aceita&#44; em&#160;2013 foi constitu&#237;da uma for&#231;a&#8208;tarefa&#44; composta de especialistas no tema para propor uniformidade de crit&#233;rios diagn&#243;sticos e classifica&#231;&#227;o do LEC&#44; por meio do m&#233;todo Delphi&#46;<a class="elsevierStyleCrossRef" href="#bib0410"><span class="elsevierStyleSup">12</span></a> Recentemente&#44; foi apresentada a valida&#231;&#227;o dos crit&#233;rios de classifica&#231;&#227;o do LED&#44; forma mais comum de LEC&#44; com base exclusivamente cl&#237;nica&#46; Foram inclu&#237;dos os seguintes par&#226;metros&#44; com pontua&#231;&#245;es distintas&#44; referentes &#224;s les&#245;es cut&#226;neas&#58; cicatriz atr&#243;fica &#40;3&#160;pontos&#41;&#44; localiza&#231;&#227;o na concha auricular &#40;2&#160;pontos&#41;&#44; prefer&#234;ncia por cabe&#231;a e pesco&#231;o &#40;2&#160;pontos&#41;&#44; discromia &#40;1&#160;ponto&#41;&#44; ceratose folicular e tamp&#245;es c&#243;rneos &#40;1&#160;ponto&#41;&#44; colora&#231;&#227;o eritematosa a viol&#225;cea &#40;1&#160;ponto&#41;&#46; Escore &#8805; 5&#160;garante sensibilidade de&#160;84&#37; e especificidade de&#160;76&#37; para classifica&#231;&#227;o como LED&#44; com maior especificidade quanto maior for a pontua&#231;&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0415"><span class="elsevierStyleSup">13</span></a></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Etiopatog&#234;nese</span><p id="par0055" class="elsevierStylePara elsevierViewall">LES e LEC s&#227;o doen&#231;as multifatoriais&#44; em que est&#225; envolvida uma complexa intera&#231;&#227;o entre carga gen&#233;tica e exposi&#231;&#245;es ambientais&#44; como radia&#231;&#227;o ultravioleta &#40;RUV&#41;&#44; f&#225;rmacos&#44; defensivos agr&#237;colas e tabaco&#46;<a class="elsevierStyleCrossRefs" href="#bib0420"><span class="elsevierStyleSup">14&#44;15</span></a> Varia&#231;&#245;es epigen&#233;ticas&#44; como desregula&#231;&#227;o da express&#227;o g&#234;nica&#44; via metila&#231;&#227;o do DNA&#44; ou modifica&#231;&#245;es de histonas&#44; causadas por esses fatores externos&#44; podem ser o gatilho para a ativa&#231;&#227;o das imunidades inata e adaptativa&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">4&#44;14</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">Os estudos sobre os fatores gen&#233;ticos envolvidos no LEC ainda s&#227;o incipientes&#44; se comparados aos descritos no LES&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> Apesar disso&#44; polimorfismos gen&#233;ticos&#44; muta&#231;&#245;es e alelos de risco j&#225; foram identificados em diferentes popula&#231;&#245;es de LEC&#44; a maioria deles associados &#224;s vias das imunidades inata e adaptativa&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;14&#44;17</span></a> Genes que atuam na apoptose&#44; migra&#231;&#227;o leucocit&#225;ria&#44; via do IFN tipo&#160;I&#44; cascata do complemento&#44; apresenta&#231;&#227;o de ant&#237;genos e produ&#231;&#227;o de anticorpos est&#227;o entre os mais frequentemente afetados&#46;<a class="elsevierStyleCrossRefs" href="#bib0420"><span class="elsevierStyleSup">14&#44;17</span></a> Os genes que codificam a produ&#231;&#227;o de citocinas pr&#243;&#8208;inflamat&#243;rias s&#227;o os mais associados &#224;s vias da imunidade inata nas les&#245;es de LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> Como exemplos de associa&#231;&#245;es descritas entre genes e manifesta&#231;&#245;es cut&#226;neas&#44; podem ser citados o <span class="elsevierStyleItalic">FCGR2A</span> &#40;risco para LECA&#41;&#44; <span class="elsevierStyleItalic">TYK2</span>&#44; <span class="elsevierStyleItalic">IRF5</span>&#44; <span class="elsevierStyleItalic">TNF</span>&#8208;&#945; &#40;risco para LECS&#41; e <span class="elsevierStyleItalic">ITGAM</span> &#40;risco para LED&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0425"><span class="elsevierStyleSup">15&#44;17</span></a> Variantes de HLA tamb&#233;m j&#225; foram correlacionadas &#224; progress&#227;o da doen&#231;a cut&#226;nea&#44; dentre as quais se destacam o HLA&#8208;B8&#44; HLA&#8208;DR e HLA&#8208;DQ&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> At&#233; o presente momento&#44; apenas uma variante monogen&#233;tica de LEC foi identificada&#44; uma forma rara de LE perni&#243;tico familiar associada a muta&#231;&#245;es no gene <span class="elsevierStyleItalic">TREX1</span>&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;14&#44;17&#44;18</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">Dentre os fatores ambientais&#44; a RUV &#233; o mais bem estabelecido desencadeador do LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> A irradia&#231;&#227;o da pele altera a morfologia e a fun&#231;&#227;o dos ceratin&#243;citos&#44; induzindo diretamente a produ&#231;&#227;o de citocinas pr&#243;&#8208;inflamat&#243;rias &#40;IL&#8208;1&#945;&#44; IL&#8208;1&#946;&#44; IL&#8208;6&#44; TNF&#8208;&#945; e IFN&#8208;&#945;&#44; k e ¿&#41; e apoptose&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">4&#44;14&#44;17</span></a> O aumento de citocinas inflamat&#243;rias e a exposi&#231;&#227;o a res&#237;duos celulares&#44; liberados pela morte celular&#44; desencadeiam o recrutamento de linf&#243;citos e c&#233;lulas dendr&#237;ticas plasmocitoides &#40;CDP&#41;&#44; que acionar&#227;o a ativa&#231;&#227;o do sistema imune&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;18</span></a> As CDP s&#227;o raras na pele normal e abundantes nas les&#245;es de LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0440"><span class="elsevierStyleSup">18</span></a> Res&#237;duos celulares&#44; especialmente nucleares&#44; s&#227;o capturados pelas CDP&#44; que tamb&#233;m podem servir como reservat&#243;rio de autoant&#237;genos frente a linf&#243;citos&#160;B&#160;e&#160;T autorreativos&#46;<a class="elsevierStyleCrossRef" href="#bib0420"><span class="elsevierStyleSup">14</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">J&#225; foi demonstrado que a apoptose dos ceratin&#243;citos&#44; como a mediada pela via do Fas&#47;FasL&#44; apresenta forte correla&#231;&#227;o com a atividade da doen&#231;a&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> O papel dos ceratin&#243;citos no surgimento e desenvolvimento das les&#245;es de LEC tamb&#233;m envolve retroalimenta&#231;&#227;o positiva na produ&#231;&#227;o de IFN&#44; especialmente dos tipos&#160;I&#160;e&#160;III&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> O IFN produzido &#233; capaz de ativar tanto o sistema imune inato quanto adaptativo&#44; exercendo papel central na patog&#234;nese do LE&#46;<a class="elsevierStyleCrossRefs" href="#bib0420"><span class="elsevierStyleSup">14&#44;19</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">A ativa&#231;&#227;o do sistema imune inato promove a inflama&#231;&#227;o tecidual&#44; especialmente mediada pelas CDP e neutr&#243;filos &#40;incluindo as redes extracelulares de neutr&#243;filos &#8211; NET&#59; do ingl&#234;s&#44; <span class="elsevierStyleItalic">neutrophil extracellular traps</span>&#41;&#44; e o aumento da express&#227;o de autoant&#237;genos&#44; inclusive o Ro&#47;SS&#8208;A &#40;prote&#237;na induz&#237;vel pelo IFN&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0440"><span class="elsevierStyleSup">18&#44;19</span></a> Esse aumento estimula o sistema imune adaptativo&#44; como os linf&#243;citos&#160;T&#160;citot&#243;xicos e os plasm&#243;citos&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> O aumento do IFN tamb&#233;m perpetua a express&#227;o de citocinas e quimiocinas&#44; intimamente relacionadas &#224; produ&#231;&#227;o de anticorpos&#44; os quais se depositam preferencialmente na jun&#231;&#227;o dermoepid&#233;rmica e resultam em agress&#227;o citot&#243;xica mediada principalmente por linf&#243;citos T CD8&#43;&#46;<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">4</span></a></p><p id="par0080" class="elsevierStylePara elsevierViewall">A eleva&#231;&#227;o dos n&#237;veis de IFN&#44; especialmente do tipo&#160;I&#44; tamb&#233;m leva diretamente &#224; infiltra&#231;&#227;o de linf&#243;citos Th1&#44; acelerando a inflama&#231;&#227;o tecidual e a produ&#231;&#227;o de IFN&#8208; &#947; e IL&#8208;2&#44; dentre outras citocinas&#46;<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">4</span></a> O aumento dessas citocinas estimula as vias de sinaliza&#231;&#227;o intracelulares&#44; como a via JAK&#47;STAT&#44; e altera a transcri&#231;&#227;o g&#234;nica&#46;<a class="elsevierStyleCrossRef" href="#bib0420"><span class="elsevierStyleSup">14</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">Por fim&#44; a eleva&#231;&#227;o dos n&#237;veis de citocinas&#44; o aumento da exposi&#231;&#227;o de ant&#237;genos e a atividade das c&#233;lulas Th1 estimulam a produ&#231;&#227;o de anticorpos autorreativos&#44; que se depositam principalmente na zona da membrana basal e estimulam a agress&#227;o por c&#233;lulas&#160;T CD8&#43; e c&#233;lulas <span class="elsevierStyleItalic">natural killer</span> &#40;NK&#41;<span class="elsevierStyleItalic">&#44;</span> por meio de enzimas&#44; como a granzima&#160;B&#44; que induzem apoptose pela ativa&#231;&#227;o das caspases e d&#227;o continuidade ao ciclo inflamat&#243;rio&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">4&#44;19</span></a></p><p id="par0090" class="elsevierStylePara elsevierViewall">O papel dos autoanticorpos permanece incerto no LEC&#46; Pacientes com LECC apresentam ocorr&#234;ncia muito menor de autoanticorpos s&#233;ricos&#44; como os antinucleares&#44; anti&#8208;DNAn&#44; anti&#8208;Sm&#44; anti&#8208;Ro&#47;SS&#8208;A e anti&#8208;La&#47;SS&#8208;B&#44; se comparados aos pacientes com LES e LECS&#46;<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">19</span></a> Por outro lado&#44; as imunoglobulinas est&#227;o fortemente envolvidas na patog&#234;nese local das les&#245;es de LEC&#46; As IgM s&#227;o as primeiras a serem recrutadas para a pele&#44; atraindo&#44; em seguida&#44; o C3 e outras imunoglobulinas&#46; Diferentemente do LES&#44; em que a IgM isolada ou em combina&#231;&#227;o com C3 &#233; a forma mais frequente de forma&#231;&#227;o de imunocomplexos&#44; no LED&#44; a IgG &#233; a respons&#225;vel pela maioria dos dep&#243;sitos de imunocomplexos&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">Apesar do aumento dos n&#237;veis s&#233;ricos de IL&#8208;17 e aumento da express&#227;o cut&#226;nea da IL&#8208;17A nos pacientes com LES&#44; poucos linf&#243;citos&#160;T&#160;produtores de IL&#8208;17 s&#227;o encontrados nas les&#245;es de LED&#44; sugerindo um papel menos importante nesta manifesta&#231;&#227;o cl&#237;nica&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> Foi descrita tamb&#233;m uma redu&#231;&#227;o na porcentagem de linf&#243;citos&#160;T&#160;reguladores na pele afetada pelo LEC&#46; Outro relato recente &#233; uma rela&#231;&#227;o inversamente proporcional entre a porcentagem de linf&#243;citos Th22 nas les&#245;es e escores de gravidade cl&#237;nica&#44; indicando que a IL&#8208;22 pode ser bom indicador da repara&#231;&#227;o cut&#226;nea&#46;<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">19</span></a></p><p id="par0100" class="elsevierStylePara elsevierViewall">Os f&#225;rmacos s&#227;o descritos como outro poss&#237;vel gatilho para o LEC&#44; especialmente para o subtipo subagudo&#46;<a class="elsevierStyleCrossRef" href="#bib0435"><span class="elsevierStyleSup">17</span></a> F&#225;rmacos classicamente reconhecidos como indutores de LEC&#44; como anti&#8208;hipertensivos&#44; antif&#250;ngicos e inibidores da bomba de pr&#243;tons&#44; dentre outros mais de cem medicamentos&#44; t&#234;m dividido import&#226;ncia com novas terapias&#8208;alvo&#44; como imunobiol&#243;gicos&#44; imunoter&#225;picos e quimioter&#225;picos&#44; em decorr&#234;ncia da crescente ocorr&#234;ncia de casos relacionados a esses medicamentos&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">4&#44;17</span></a> Acredita&#8208;se que os f&#225;rmacos causadores de LEC podem ativar diretamente o sistema imune inato ou&#44; indiretamente&#44; ao reduzir a remo&#231;&#227;o de autoant&#237;genos&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> O tabagismo &#233; outro importante fator de risco associado ao LEC&#44; por estimular citocinas pr&#243;&#8208;inflamat&#243;rias&#44; a ativa&#231;&#227;o neutrof&#237;lica&#44; aumentar o estresse celular&#44; a forma&#231;&#227;o de radicais livres e a apoptose&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;14&#44;18</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">Os horm&#244;nios sexuais parecem ser pe&#231;a fundamental na patog&#234;nese do LES&#46; Por outro lado&#44; sua import&#226;ncia no LEC parece ser menor&#44; especialmente no LED&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> Apesar disso&#44; a incid&#234;ncia de LEC ainda &#233; maior no sexo feminino&#46; Como esse aumento ocorre mesmo fora da per&#237;odo f&#233;rtil&#44; postula&#8208;se que possa haver outras explica&#231;&#245;es para a maior incid&#234;ncia nas mulheres&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> A aus&#234;ncia de piora significante do LEC durante a gesta&#231;&#227;o ou o uso de anticoncepcionais orais tamb&#233;m corroboram esse achado&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> Uma poss&#237;vel hip&#243;tese alternativa &#224; influ&#234;ncia hormonal seria um efeito de dose ligado ao cromossomo&#160;X&#44; que poderia explicar&#44; por exemplo&#44; o aumento da incid&#234;ncia de LES em pacientes do sexo masculino portadores da s&#237;ndrome de Klinefelter &#40;gen&#243;tipo&#160;XXY&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> Outra hip&#243;tese seria a reativa&#231;&#227;o do cromossomo&#160;X inativado por um processo de demetila&#231;&#227;o nos linf&#243;citos&#160;T CD4&#43;&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a></p><p id="par0110" class="elsevierStylePara elsevierViewall">O papel da microbiota cut&#226;nea na patog&#234;nese do LEC ainda &#233; pouco compreendido e tem atra&#237;do maior aten&#231;&#227;o por parte dos pesquisadores&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> Aumento significante de <span class="elsevierStyleItalic">Staphylococcus</span> e <span class="elsevierStyleItalic">Corynebacterium</span>&#44; assim como redu&#231;&#227;o de <span class="elsevierStyleItalic">Cutibacterium</span>&#44; foram descritos nas les&#245;es cut&#226;neas de LES&#44; por&#233;m ainda sem evid&#234;ncias que suportem uma rela&#231;&#227;o direta&#46;<a class="elsevierStyleCrossRefs" href="#bib0430"><span class="elsevierStyleSup">16&#44;17</span></a></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Apresenta&#231;&#227;o cl&#237;nica e diagn&#243;stico diferencial</span><p id="par0115" class="elsevierStylePara elsevierViewall">A <a class="elsevierStyleCrossRef" href="#tbl0010">tabela 2</a> relaciona os subtipos cl&#237;nicos de LEC e suas variantes&#44; assim como as manifesta&#231;&#245;es cut&#226;neas inespec&#237;ficas que podem estar associadas ao LE&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">L&#250;pus eritematoso cut&#226;neo agudo</span><p id="par0120" class="elsevierStylePara elsevierViewall">Representa&#160;15&#37; dos casos de LEC e sempre est&#225; associado ao LES&#44; geralmente correlacionando com a atividade da doen&#231;a&#46;<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">3</span></a> Presente no momento do diagn&#243;stico em cerca de&#160;50&#37; dos casos de LES&#44; pode ser desencadeado ou exacerbado pela exposi&#231;&#227;o solar aguda&#46;<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">2</span></a></p><p id="par0125" class="elsevierStylePara elsevierViewall">A forma localizada &#233; a predominante &#40;90&#37;&#8208;95&#37;&#41; e corresponde &#224; t&#237;pica erup&#231;&#227;o em vespert&#237;lio ou em asa de borboleta&#44; que se manifesta como les&#227;o eritematosa e finamente escamosa&#44; acometendo de maneira sim&#233;trica as regi&#245;es malares e o dorso nasal&#44; geralmente poupando os sulcos nasolabiais &#40;<a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>A&#41;&#46; Edema facial tamb&#233;m pode estar presente&#46; O eritema costuma ser ef&#234;mero&#44; resolvendo&#8208;se em alguns dias ou semanas&#46; Eventualmente&#44; afeta a fronte&#44; o mento&#44; os pavilh&#245;es auriculares e a regi&#227;o cervical anterior&#46; Seus principais diagn&#243;sticos diferenciais s&#227;o dermatomiosite e ros&#225;cea&#44; mas ainda devem ser consideradas dermatite seborreica&#44; dermatite perioral e dermatite de contato fotoal&#233;rgica&#46; O acometimento das dobras nasolabiais e das p&#225;lpebras&#44; assim como fraqueza muscular proximal&#44; favorecem a dermatomiosite&#46;</p><p id="par0130" class="elsevierStylePara elsevierViewall">A forma disseminada&#44; menos comum &#40;5&#37;&#8208;10&#37;&#41;&#44; manifesta&#8208;se como erup&#231;&#227;o exantem&#225;tica urticariforme ou maculopapular predominante nas &#225;reas fotoexpostas &#40;<a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>B&#41;&#46; Al&#233;m de face e pesco&#231;o&#44; afeta simetricamente o V do decote e a superf&#237;cie extensora dos membros&#44; sobretudo os superiores&#44; mas pode estender&#8208;se ao tronco e at&#233; mesmo palmas e plantas&#46; Quando atinge o dorso de m&#227;os e dedos&#44; tende a poupar as articula&#231;&#245;es&#44; ao contr&#225;rio da dermatomiosite&#46; Deve ser diferenciada de rea&#231;&#245;es de hipersensibilidade a f&#225;rmacos&#44; exantemas virais e dermatites fotot&#243;xicas ou fotoal&#233;rgicas medicamentosas&#44; al&#233;m da dermatomiosite&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0135" class="elsevierStylePara elsevierViewall">O acometimento mucoso &#233; frequente em ambas as formas&#46; A mucosa oral &#233; a mais afetada&#44; em&#160;8&#37;&#8208;45&#37; dos casos&#44; atingindo principalmente as mucosas jugal&#44; palatina e labial&#44; na forma de placas enantematosas ou purp&#250;ricas&#44; vesicobolhas&#44; eros&#245;es e &#250;lceras&#46;<a class="elsevierStyleCrossRef" href="#bib0450"><span class="elsevierStyleSup">20</span></a> Ulcera&#231;&#227;o nasal &#233; menos comum e outras mucosas s&#227;o raramente afetadas&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">Uma apresenta&#231;&#227;o rara de LECA&#44; que se assemelha &#224; necr&#243;lise epid&#233;rmica t&#243;xica &#40;NET&#41;&#44; por isso conhecida como variante NET&#8208;s&#237;mile&#44; deve&#8208;se &#224; intensa dermatite de interface com necrose dos ceratin&#243;citos&#44; que resulta em descolamento epitelial de extensas &#225;reas da pele&#46; Pode haver comprometimento mucoso&#44; que costuma ser mais limitado e poupar a conjuntiva ocular&#46;<a class="elsevierStyleCrossRef" href="#bib0455"><span class="elsevierStyleSup">21</span></a></p><p id="par0145" class="elsevierStylePara elsevierViewall">Ap&#243;s resolu&#231;&#227;o&#44; as les&#245;es de LECA podem deixar hipercromia residual&#44; mas n&#227;o costumam resultar em cicatrizes&#44; exceto na forma NET&#8208;s&#237;mile&#44; ou quando complicadas por infec&#231;&#227;o secund&#225;ria&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">L&#250;pus eritematoso cut&#226;neo subagudo</span><p id="par0150" class="elsevierStylePara elsevierViewall">Responde por cerca de&#160;8&#37; de todos os casos de LEC&#44; tem dura&#231;&#227;o mais prolongada que o LECA e apresenta extrema fotossensibilidade&#46; Distribui&#8208;se de maneira sim&#233;trica&#44; preferencialmente nas &#225;reas expostas do pesco&#231;o&#44; tronco superior e membros superiores&#44; por&#233;m costuma poupar a regi&#227;o central da face&#46;<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">3</span></a> Manifesta&#8208;se sob duas formas&#44; ambas com placas eritematosas&#44; uma anular polic&#237;clica e outra papuloescamosa psoriasiforme &#40;<a class="elsevierStyleCrossRef" href="#fig0010">fig&#46; 2</a>A&#41;&#44; que eventualmente podem coexistir no mesmo paciente&#46; Atrofia e ceratose n&#227;o s&#227;o clinicamente evidentes nas les&#245;es do LECS&#46; Tamb&#233;m tendem a ser menos edematosas que as les&#245;es do LECA e menos infiltradas e discr&#244;micas que aquelas do LED&#46; Em ambas as formas&#44; surgem ocasionalmente les&#245;es vesicobolhosas e crostas na periferia das placas&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> Habitualmente&#44; resolvem sem deixar cicatrizes&#44; mas pode haver hipocromia residual&#44; geralmente tempor&#225;ria&#44; por&#233;m permanente em formas mais graves&#46; Eventualmente&#44; pode haver concomit&#226;ncia de les&#245;es de LECA ou LED com les&#245;es de LECS&#44; mas nem sempre &#233; poss&#237;vel uma distin&#231;&#227;o exata dessas les&#245;es&#46; &#201; raro o acometimento da mucosa oral&#44; com placas enantematosas circulares levemente atr&#243;ficas&#46;<a class="elsevierStyleCrossRef" href="#bib0460"><span class="elsevierStyleSup">22</span></a> Deve ser diferenciado de granuloma anular&#44; eritema anular centr&#237;fugo&#44; <span class="elsevierStyleItalic">erithema gyratum repens</span>&#44; psor&#237;ase&#44; tinha do corpo&#44; entre outros&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0155" class="elsevierStylePara elsevierViewall">Cerca de 1&#47;3 dos casos de LECS &#233; desencadeado por f&#225;rmacos&#46; Em geral&#44; o LECS medicamentoso &#233; indistingu&#237;vel do LECS idiop&#225;tico&#44; por&#233;m algumas particularidades devem levar &#224; suspei&#231;&#227;o da etiologia medicamentosa &#8211; idade mais avan&#231;ada&#44; quadros mais disseminados e presen&#231;a de les&#245;es bolhosas ou do tipo alvo&#46;<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">23</span></a> O quadro costuma ser revers&#237;vel&#44; resolvendo em alguns meses ap&#243;s a suspens&#227;o da medica&#231;&#227;o respons&#225;vel&#46; Os f&#225;rmacos mais frequentemente incriminados s&#227;o hidroclorotiazida&#44; inibidores do canal de c&#225;lcio&#44; inibidores da enzima conversora da angiotensina&#44; inibidores da bomba de pr&#243;tons&#44; terbinafina&#44; agentes anti&#8208;TNF e anticonvulsivantes&#44; por&#233;m a incid&#234;ncia tende a variar com o desenvolvimento de novos medicamentos e a mudan&#231;a na prescri&#231;&#227;o&#46;<a class="elsevierStyleCrossRefs" href="#bib0465"><span class="elsevierStyleSup">23&#8211;25</span></a> Recente revis&#227;o da literatura&#44; com foco na d&#233;cada passada &#40;2010&#8208;2020&#41;&#44; revelou que os agentes anti&#8208;TNF&#44; os inibidores da bomba de pr&#243;tons e os antineopl&#225;sicos&#44; em particular os inibidores de <span class="elsevierStyleItalic">checkpoint</span> imune&#44; destacam&#8208;se como f&#225;rmacos emergentes desencadeantes de LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0480"><span class="elsevierStyleSup">26</span></a> A lista de medicamentos respons&#225;veis &#233; extensa&#44; como pode ser observado na <a class="elsevierStyleCrossRef" href="#tbl0015">tabela 3</a>&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0160" class="elsevierStylePara elsevierViewall">O primeiro caso de LECS associado a doen&#231;a maligna foi descrito em&#160;1982&#44; como l&#250;pus eritematoso <span class="elsevierStyleItalic">gyratum repens</span> em paciente com c&#226;ncer de pulm&#227;o&#46; Desde ent&#227;o&#44; surgiram in&#250;meros relatos sugerindo uma rela&#231;&#227;o entre LECS e v&#225;rias neoplasias s&#243;lidas e n&#227;o s&#243;lidas&#44; com maior frequ&#234;ncia de carcinoma de pulm&#227;o e adenocarcinoma da mama&#46; Na maioria dos casos&#44; o paralelismo entre o desenvolvimento tumoral e a atividade da dermatose possibilitou caracterizar a associa&#231;&#227;o como s&#237;ndrome paraneopl&#225;sica&#46; Ainda que rara&#44; &#233; importante considerar essa possibilidade no LECS de in&#237;cio em idade avan&#231;ada&#44; em pacientes com maior risco de neoplasia e nos casos refrat&#225;rios ao tratamento convencional&#46;<a class="elsevierStyleCrossRef" href="#bib0485"><span class="elsevierStyleSup">27</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall">A s&#237;ndrome de <span class="elsevierStyleItalic">Rowell</span> foi originalmente descrita em&#160;1963 como uma entidade distinta&#44; pela associa&#231;&#227;o de achados cl&#237;nicos de LE e eritema multiforme&#44; al&#233;m da presen&#231;a de algumas altera&#231;&#245;es imunol&#243;gicas&#44; como FAN salpicado&#44; anticorpo anti&#8208;SjT e fator reumatoide&#46; &#192; luz dos conhecimentos cl&#237;nicos e imunol&#243;gicos modernos&#44; essa s&#237;ndrome n&#227;o deve ser vista com identidade nosol&#243;gica&#44; mas como variante rara do LECS&#44; caracterizada por les&#245;es cut&#226;neas do tipo alvo e presen&#231;a de anticorpos anti&#8208;Ro&#47;SS&#8208;A&#46;<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">28</span></a></p><p id="par0170" class="elsevierStylePara elsevierViewall">O LE neonatal tamb&#233;m &#233; considerado variante do LECS&#46; Resulta da passagem transplacent&#225;ria de autoanticorpos maternos contra ant&#237;genos Ro&#47;SS&#8208;A&#44; La&#47;SS&#8208;B e&#44; mais raramente&#44; U1&#8208;RNP&#46; Em grande parte dos casos&#44; a m&#227;e &#233; assintom&#225;tica&#44; mas pode ter s&#237;ndrome de Sj&#246;gren&#44; LECS&#44; LES ou outras doen&#231;as do tecido conjuntivo&#46; O risco &#233; pequeno na primeira gesta&#231;&#227;o ou na aus&#234;ncia da doen&#231;a em gesta&#231;&#245;es anteriores &#40;2&#37;&#41;&#44; mas aumenta substancialmente &#40;10&#160;vezes&#41; se tiver havido diagn&#243;stico em gesta&#231;&#227;o pr&#233;via&#46; As les&#245;es cut&#226;neas ocorrem em at&#233;&#160;40&#37; dos casos de LE neonatal e podem estar presentes ao nascimento&#44; mas geralmente surgem nos primeiros&#160;tr&#234;s&#160;meses de vida&#44; ap&#243;s a exposi&#231;&#227;o solar&#44; resolvendo espontaneamente em 6&#8208;12 meses&#46; S&#227;o eritematosas ou eritemato&#8208;escamosas&#44; circulares&#44; anulares ou polic&#237;clicas e afetam principalmente a face&#44; nas regi&#245;es frontal e periorbit&#225;ria &#40;<a class="elsevierStyleCrossRef" href="#fig0010">fig&#46; 2</a>B&#41;&#44; podendo estender&#8208;se ao couro cabeludo&#44; mas raramente atingem tronco e membros&#46; Dermatite seborreica e tinha da face s&#227;o os principais diagn&#243;sticos diferenciais&#46; Outras manifesta&#231;&#245;es poss&#237;veis&#44; tamb&#233;m revers&#237;veis&#44; s&#227;o as citopenias &#40;trombocitopenia&#44; anemia hemol&#237;tica&#41;&#44; doen&#231;a hepatobiliar&#44; esplenomegalia e&#44; mais raras&#44; as altera&#231;&#245;es neurol&#243;gicas e pulmonares&#46; Mais graves e irrevers&#237;veis s&#227;o as altera&#231;&#245;es card&#237;acas&#44; principalmente os dist&#250;rbios de condu&#231;&#227;o&#44; inclusive bloqueio atrioventricular total&#44; miocardiopatia e valvulopatia&#44; que podem ocorrer em 25&#37; dos casos e ser detectadas antes do nascimento&#46;<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">2&#44;29</span></a></p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">L&#250;pus eritematoso cut&#226;neo cr&#244;nico</span><p id="par0175" class="elsevierStylePara elsevierViewall">O LECC responde por mais de&#160;70&#37; dos casos de LEC e compreende diversas variantes&#44; algumas mais comuns e outras mais raras&#46;<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">3</span></a></p><p id="par0180" class="elsevierStylePara elsevierViewall">O LED &#233; a forma cl&#225;ssica e mais comum de LECC&#44; tamb&#233;m presente em&#160;20&#37;&#160;dos casos de LES&#46; Localiza&#8208;se predominantemente na cabe&#231;a e pesco&#231;o&#44; mas&#44; em cerca de&#160;30&#37;&#160;dos casos&#44; pode ser disseminado e acometer tronco e membros&#44; com prefer&#234;ncia pelas &#225;reas fotoexpostas&#44; como face&#44; pavilh&#245;es auriculares&#44; V do decote&#44; lateral do pesco&#231;o&#44; couro cabeludo e dorsal dos membros superiores&#46; As les&#245;es se iniciam como placas eritemato&#8208;infiltradas&#44; induradas &#224; palpa&#231;&#227;o&#44; evoluindo com ceratose&#44; principalmente folicular&#44; atrofia e discromia&#44; com hipocromia no centro e hipercromia na periferia&#46; Costumam ser dolorosas &#224; palpa&#231;&#227;o&#46; Podem deixar les&#245;es vitiligoides&#44; assim como resolver com cicatrizes&#44; muitas vezes mutilantes&#44; sobretudo quando acometem nariz&#44; pavilh&#245;es auriculares e p&#225;lpebras&#46; Les&#245;es em diferentes est&#225;gios costumam ser concomitantes&#46; Quando situadas nas &#225;reas pilosas&#44; como couro cabeludo&#44; barba&#44; c&#237;lios e superc&#237;lios&#44; tendem a destruir os fol&#237;culos&#44; resultando em alopecia cicatricial &#40;<a class="elsevierStyleCrossRef" href="#fig0015">fig&#46; 3</a>A&#41;&#46; Les&#245;es palmoplantares s&#227;o raras&#44; costumam ser muito dolorosas e podem ulcerar&#8208;se&#46; Excepcionalmente&#44; observam&#8208;se les&#245;es ungueais e periungueais&#46; Al&#233;m da radia&#231;&#227;o solar&#44; as les&#245;es de LED podem ser provocadas por traumatismos&#44; configurando o fen&#244;meno de Koebner&#46;<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">2&#44;3&#44;30</span></a> LED medicamentoso &#233; muito raro&#44; com relatos espor&#225;dicos associados a leflunomida&#44; 5&#8208;fluoruracil&#44; capecitabina&#44; palbociclibe&#44; pembrolizumabe e mais comumente aos agentes anti&#8208;TNF&#46;<a class="elsevierStyleCrossRef" href="#bib0505"><span class="elsevierStyleSup">31</span></a> As les&#245;es recentes de LED devem ser diferenciadas da erup&#231;&#227;o polimorfa &#224; luz&#44; sarcoidose&#44; pseudolinfomas&#44; granuloma facial e LE t&#250;mido&#46; As les&#245;es cr&#244;nicas merecem diferencia&#231;&#227;o com l&#250;pus vulgar&#44; ceratose act&#237;nica hipertr&#243;fica&#44; carcinoma espinocelular e ceratoacantoma&#46;</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0185" class="elsevierStylePara elsevierViewall">O LED mucoso &#233; relatado em&#160;3&#37;&#8208;25&#37; dos pacientes com LED e costuma ser assintom&#225;tico em 1&#47;4 dos casos&#46; Apresenta&#8208;se classicamente como placas de enantema&#44; com p&#225;pulas cerat&#243;sicas&#44; atrofia ou eros&#227;o central e ceratose radiada ou reticulada na periferia&#46; Pode ainda se manifestar como placas brancas estriadas ou homog&#234;neas&#44; eros&#245;es e ulcera&#231;&#245;es&#46; &#201; mais comum na mucosa oral&#44; principalmente jugal &#40;<a class="elsevierStyleCrossRef" href="#fig0015">fig&#46; 3</a>B&#41;&#44; palatina e labial&#44; mas pode acometer a gengiva e a l&#237;ngua&#46; As mucosas nasal&#44; genital e anal tamb&#233;m podem ser afetadas por les&#245;es discoides&#46; &#201; caracter&#237;stica a les&#227;o da conjuntiva ocular&#44; mais comum na margem palpebral inferior&#44; que pode resultar em cicatriz&#44; perda dos c&#237;lios e ectr&#243;pio&#46; H&#225; risco de transforma&#231;&#227;o maligna em carcinoma escamocelular&#44; com maior frequ&#234;ncia nos l&#225;bios&#46;<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">2&#44;22&#44;32</span></a> Seu principal diagn&#243;stico diferencial &#233; o l&#237;quen plano oral&#46;</p><p id="par0190" class="elsevierStylePara elsevierViewall">O LE hipertr&#243;fico&#44; tamb&#233;m conhecido como LE verrucoso&#44; &#233; variante bastante rara do LECC que se manifesta com les&#245;es eritematosas&#44; papulosas ou nodulares&#44; de superf&#237;cie cerat&#243;sica e algo verrucosa&#44; localizadas principalmente nas regi&#245;es extensoras dos membros superiores &#40;<a class="elsevierStyleCrossRef" href="#fig0020">fig&#46; 4</a>A&#41; e eventualmente na face e tronco superior&#46; Costuma haver coexist&#234;ncia de les&#245;es discoides t&#237;picas&#44; que facilitam o diagn&#243;stico&#46;<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">2</span></a> Deve ser diferenciado do l&#237;quen plano hipertr&#243;fico&#44; do ceratoacantoma e das verrugas vulgares&#46;</p><elsevierMultimedia ident="fig0020"></elsevierMultimedia><p id="par0195" class="elsevierStylePara elsevierViewall">O LE l&#237;quen plano&#8208;s&#237;mile ou s&#237;ndrome de superposi&#231;&#227;o l&#250;pus eritematoso&#8208;l&#237;quen plano refere&#8208;se &#224; combina&#231;&#227;o de achados cl&#237;nicos&#44; histol&#243;gicos e imunopatol&#243;gicos de ambas as dermatoses&#46; Trata&#8208;se de condi&#231;&#227;o muito rara&#44; de evolu&#231;&#227;o cr&#244;nica e predominante em mulheres&#44; que apresenta placas dolorosas vermelho&#8208;azuladas&#44; escamosas&#44; com centro atr&#243;fico&#44; localizadas nas extremidades superiores e menos frequentemente nas pernas&#44; face e tronco&#59; o acometimento palmoplantar &#233; caracter&#237;stico&#46; Les&#245;es hipertr&#243;ficas tamb&#233;m podem ocorrer&#46; H&#225; ainda relatos de acometimento mucoso&#44; distrofia ungueal e alopecia cicatricial&#44; assim como de casos desencadeados por medicamentos&#46;<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">2&#44;33&#44;34</span></a></p><p id="par0200" class="elsevierStylePara elsevierViewall">O LE profundo ou paniculite l&#250;pica responde apenas por&#160;2&#37;&#8208;3&#37; dos casos de LECC&#44; &#233; mais frequente em adultos e mulheres e se manifesta com placas e n&#243;dulos subcut&#226;neos&#44; endurecidos&#44; aderidos &#224; pele sobrejacente&#44; geralmente dolorosos&#44; que se localizam principalmente na face&#44; ombros&#44; bra&#231;os&#44; coxas&#44; gl&#250;teos e mamas &#40;<a class="elsevierStyleCrossRef" href="#fig0020">fig&#46; 4</a>B&#41;&#46; A pele da superf&#237;cie pode ou n&#227;o apresentar les&#245;es de LED&#46; Costumam causar intensa atrofia do subcut&#226;neo&#44; deixando &#225;reas deprimidas&#44; com desfigura&#231;&#227;o est&#233;tica&#44; sobretudo quando localizadas na face&#46; Eventualmente&#44; evoluem com calcifica&#231;&#227;o e ulcera&#231;&#227;o&#46; A doen&#231;a tem curso cr&#244;nico&#44; entrecortado por per&#237;odos de exacerba&#231;&#227;o e de remiss&#227;o&#46;<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">2&#44;30</span></a> Deve ser diferenciado principalmente de outros tipos de paniculite&#44; do linfoma subcut&#226;neo de c&#233;lulas&#160;T&#160;paniculite&#8208;s&#237;mile e da sarcoidose subcut&#226;nea&#46;</p><p id="par0205" class="elsevierStylePara elsevierViewall">O LE perni&#243;tico &#233; forma rara de LECC&#44; que se assemelha &#224; perniose e se manifesta por les&#245;es dolorosas&#44; papulosas&#44; nodulares ou edematosas&#44; de tonalidade eritemato&#8208;viol&#225;cea&#46; Podem evoluir com eros&#227;o ou ulcera&#231;&#227;o&#46; S&#227;o desencadeadas pela exposi&#231;&#227;o ao frio e usualmente acometem quirod&#225;tilos e dorso das m&#227;os&#46; Podod&#225;ctilos&#44; regi&#245;es plantares e calcanhares tamb&#233;m podem ser acometidos&#46; Nariz e pavilh&#245;es auriculares s&#227;o menos afetados&#46; Fen&#244;meno de Raynaud pode estar presente em alguns casos&#46; O quadro pode coexistir com les&#245;es de LED ou ocorrer no contexto de LES&#46; Estima&#8208;se que&#160;20&#37; dos pacientes com LE perni&#243;tico venham a desenvolver doen&#231;a sist&#234;mica&#46; Algumas altera&#231;&#245;es imunol&#243;gicas podem ser observadas&#44; como hipergamaglobulinemia&#44; fator reumatoide e FAN positivos&#44; assim como anticorpos antifosfol&#237;pides e antinucleares espec&#237;ficos&#44; principalmente anti&#8208;Ro&#47;SS&#8208;A&#46;<a class="elsevierStyleCrossRef" href="#bib0525"><span class="elsevierStyleSup">35</span></a> H&#225; uma forma familiar da doen&#231;a&#44; que se manifesta na inf&#226;ncia&#44; de heran&#231;a autoss&#244;mica dominante&#44; relacionada a muta&#231;&#245;es no gene TREX1 e menos frequentemente nos genes SAMHD1 ou TMEM173&#46;<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">2&#44;36</span></a> O principal diagn&#243;stico diferencial &#233; a perniose idiop&#225;tica&#44; mas ainda devem ser considerados o l&#250;pus p&#233;rnio&#44; uma forma acral de sarcoidose&#44; assim como as vasculites e vasculopatias acrais&#46;</p><p id="par0210" class="elsevierStylePara elsevierViewall">O LE comedoniano &#233; outra variante rara do LECC&#44; que se manifesta por comedos&#44; p&#225;pulas&#44; placas eritemato&#8208;infiltradas e cistos em &#225;reas seborreicas e fotoexpostas&#44; deixando cicatrizes acneiformes deprimidas&#46; Acomete preferencialmente mulheres jovens e de meia idade&#59; o tabagismo &#233; importante fator de risco&#44; como em outras formas de LECC&#46; Pode ser acompanhado de les&#245;es t&#237;picas de LED&#44; assim como associado ao LES&#46; Costuma ser confundido com acne vulgar&#44; nevo comedoniano e elastoidose nodular com cistos e comed&#245;es&#44; o que geralmente retarda o diagn&#243;stico e o tratamento&#44; resultando em cicatrizes inest&#233;ticas&#46;<a class="elsevierStyleCrossRefs" href="#bib0535"><span class="elsevierStyleSup">37&#8211;39</span></a></p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">L&#250;pus eritematoso cut&#226;neo intermitente</span><p id="par0215" class="elsevierStylePara elsevierViewall">Anteriormente categorizado entre as variantes de LECC&#44; o LE t&#250;mido foi reclassificado como LECI em raz&#227;o de seu curso cl&#237;nico&#44; em que se alternam per&#237;odos de remiss&#227;o e de recorr&#234;ncia&#46; &#201; variante rara do LEC&#44; que acomete mais as mulheres &#40;60&#37;&#160;dos casos&#41;&#44; mas a preponder&#226;ncia sobre os homens &#233; menos evidente que nas outras formas de LEC&#46; Uma caracter&#237;stica marcante do LE t&#250;mido &#233; a fotossensibilidade exacerbada&#44; talvez a mais intensa entre todas as formas de LEC&#46; Manifesta&#8208;se por placas &#250;nicas ou m&#250;ltiplas&#44; eritemato&#8208;edematosas&#44; de superf&#237;cie lisa&#44; que podem assumir configura&#231;&#227;o anular ou arciforme &#40;<a class="elsevierStyleCrossRef" href="#fig0025">fig&#46; 5</a>A&#41;&#46; Localizam&#8208;se em &#225;reas fotoexpostas&#44; principalmente na face&#44; pesco&#231;o&#44; tronco superior e membros superiores&#46; &#201; usual a resolu&#231;&#227;o espont&#226;nea das les&#245;es em algumas semanas&#44; sem deixar discromia ou cicatriz&#44; mas sobrev&#234;m epis&#243;dios com novas les&#245;es&#46; &#201; mais comum a ocorr&#234;ncia na forma isolada&#44; mas pode estar associado a outras formas de LEC&#44; principalmente LED&#44; e raramente ao LES&#46; Altera&#231;&#245;es imunol&#243;gicas tamb&#233;m s&#227;o incomuns&#44; como FAN e anticorpos antinucleares espec&#237;ficos&#46; Deve ser diferenciado da erup&#231;&#227;o polimorfa &#224; luz&#44; LED inicial&#44; mucinose reticular eritematosa e pseudolinfomas cut&#226;neos&#44; como a infiltra&#231;&#227;o linfocit&#225;ria de Jessner&#44; considerada por muitos autores como o pr&#243;prio LE t&#250;mido&#46;<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">2&#44;40&#44;41</span></a></p><elsevierMultimedia ident="fig0025"></elsevierMultimedia></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">L&#250;pus eritematoso bolhoso</span><p id="par0220" class="elsevierStylePara elsevierViewall">O LE bolhoso &#233; dermatose bolhosa autoimune&#44; subepid&#233;rmica&#44; sempre associada ao LES&#44; mediada por autoanticorpos contra o col&#225;geno&#160;VII&#46; Manifesta&#8208;se por ves&#237;culas e bolhas tensas &#40;<a class="elsevierStyleCrossRef" href="#fig0025">fig&#46; 5</a>B&#41; que surgem subitamente sobre pele s&#227; ou sobre placas eritematosas e infiltradas&#44; eventualmente assumindo configura&#231;&#227;o anular&#46; Preferem face&#44; tronco superior&#44; pesco&#231;o&#44; regi&#245;es supraclaviculares e flexuras axilares&#44; mas podem disseminar&#8208;se para outras &#225;reas n&#227;o expostas&#46; N&#227;o costumam ser acompanhadas de les&#245;es espec&#237;ficas de LEC&#44; a n&#227;o ser eritema malar&#44; que pode surgir posteriormente&#44; ao longo da evolu&#231;&#227;o da doen&#231;a&#46; As mucosas oral e genital podem ser acometidas&#59; s&#227;o t&#237;picas as les&#245;es labiais e periorais&#46;<a class="elsevierStyleCrossRef" href="#bib0560"><span class="elsevierStyleSup">42</span></a> &#201; mais comum em mulheres negras&#44; entre a segunda e quarta d&#233;cadas de vida&#46; O LE bolhoso se instala antes&#44; concomitantemente e&#44; menos frequentemente&#44; ap&#243;s o diagn&#243;stico do LES&#44; podendo ser marcador de intensa atividade sist&#234;mica&#44; com maior risco de nefrite l&#250;pica e manifesta&#231;&#245;es neuropsiqui&#225;tricas&#46;<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">43</span></a> As les&#245;es evoluem com eros&#227;o e crostas&#44; regredindo sem cicatrizes e m&#237;lios&#44; mas podem deixar discromia residual&#46; &#201; incomum a recorr&#234;ncia&#44; mesmo com a persist&#234;ncia de doen&#231;a sist&#234;mica ativa&#46;<a class="elsevierStyleCrossRef" href="#bib0570"><span class="elsevierStyleSup">44</span></a> Deve ser diferenciado da epiderm&#243;lise bolhosa adquirida&#44; dermatose bolhosa por IgA linear&#44; dermatite herpetiforme e penfigoide bolhoso&#46;</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Manifesta&#231;&#245;es cut&#226;neas inespec&#237;ficas do l&#250;pus eritematoso</span><p id="par0225" class="elsevierStylePara elsevierViewall">Exclu&#237;dos os subtipos cl&#237;nicos e respectivas variantes anteriormente expostos&#44; todas as demais manifesta&#231;&#245;es cut&#226;neas associadas ao LE devem ser consideradas inespec&#237;ficas&#46; Est&#227;o associadas ao LES e geralmente guardam rela&#231;&#227;o com a atividade da doen&#231;a&#46; No entanto&#44; n&#227;o s&#227;o exclusivas do LES&#44; podendo ocorrer em outras condi&#231;&#245;es&#44; geralmente de natureza autoimune ou autoinflamat&#243;ria&#46;<a class="elsevierStyleCrossRefs" href="#bib0575"><span class="elsevierStyleSup">45&#8211;47</span></a> O LE bolhoso&#44; embora classificado como manifesta&#231;&#227;o inespec&#237;fica&#44; neutrof&#237;lica&#44; associada ao LE&#44; deveria ser considerado subtipo cl&#237;nico espec&#237;fico de LEC&#44; pelo fato de sempre estar associado ao LES&#46;<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">11</span></a> As manifesta&#231;&#245;es inespec&#237;ficas mais comuns est&#227;o listadas na <a class="elsevierStyleCrossRef" href="#tbl0010">tabela 2</a>&#46;</p></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Diagn&#243;stico</span><p id="par0230" class="elsevierStylePara elsevierViewall">O diagn&#243;stico do LEC se fundamenta nos dados colhidos na anamnese e no exame f&#237;sico&#44; em combina&#231;&#227;o com os achados da histopatologia e&#44; eventualmente&#44; da imuno&#8208;histologia das les&#245;es cut&#226;neas&#44; para defini&#231;&#227;o do subtipo cl&#237;nico&#46;</p><p id="par0235" class="elsevierStylePara elsevierViewall">O tipo e a abrang&#234;ncia da investiga&#231;&#227;o laboratorial devem ser adequados a cada paciente&#44; individualmente&#44; a depender do subtipo de LEC definido com base nos achados cl&#237;nicos e histopatol&#243;gicos&#46;</p><p id="par0240" class="elsevierStylePara elsevierViewall">Devem ser realizados exames bioqu&#237;micos de rotina que auxiliem na identifica&#231;&#227;o de poss&#237;vel doen&#231;a sist&#234;mica&#44; al&#233;m de exames espec&#237;ficos&#44; conforme o tratamento proposto&#44; antes de iniciar a medica&#231;&#227;o e para monitorar seus potenciais efeitos adversos&#46; Exames adicionais podem ser necess&#225;rios ap&#243;s a confirma&#231;&#227;o do diagn&#243;stico e defini&#231;&#227;o do subtipo de LEC&#44; que incluem testes sorol&#243;gicos para caracterizar o perfil de autoanticorpos e testes para avaliar a atividade sist&#234;mica da doen&#231;a&#44; assim como exames complementares para investigar acometimento de &#243;rg&#227;os espec&#237;ficos&#44; que podem auxiliar na determina&#231;&#227;o do progn&#243;stico&#46; Os principais exames laboratoriais recomendados no LEC est&#227;o listados na <a class="elsevierStyleCrossRef" href="#tbl0020">tabela 4</a>&#46; Nos casos de LES&#44; faz&#8208;se necess&#225;ria a interven&#231;&#227;o do reumatologista e eventualmente de outros especialistas&#44; que devem orientar a proped&#234;utica complementar individualizada para cada paciente&#46;<a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">48</span></a></p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><p id="par0245" class="elsevierStylePara elsevierViewall">&#201; importante que a defini&#231;&#227;o de doen&#231;a sist&#234;mica n&#227;o fique estritamente condicionada aos crit&#233;rios diagn&#243;sticos inclu&#237;dos nos sistemas de classifica&#231;&#227;o&#44; como o SLICC&#160;2012 e o EULAR&#47;ACR&#160;2019&#44; que foram primordialmente desenvolvidos com objetivo de se obter uniformidade diagn&#243;stica na sele&#231;&#227;o de pacientes para ensaios cl&#237;nicos&#44; mas n&#227;o s&#227;o capazes de abranger todas as manifesta&#231;&#245;es que podem ocorrer no LES&#46;<a class="elsevierStyleCrossRef" href="#bib0500"><span class="elsevierStyleSup">30</span></a></p><p id="par0250" class="elsevierStylePara elsevierViewall">O uso de escores de atividade da doen&#231;a&#44; originalmente criados para mensura&#231;&#227;o de desfechos em ensaios cl&#237;nicos&#44; &#233; recomend&#225;vel na pr&#225;tica cl&#237;nica&#44; por permitir an&#225;lise mais objetiva da evolu&#231;&#227;o da doen&#231;a no seguimento dos pacientes com LEC&#44; podendo servir de par&#226;metro na avalia&#231;&#227;o da resposta ao tratamento indicado&#46;</p><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Histopatologia</span><p id="par0255" class="elsevierStylePara elsevierViewall">As diferentes formas de LEC&#44; com exce&#231;&#227;o do LE profundo e do LE t&#250;mido&#44; compartilham os achados histopatol&#243;gicos&#44; tornando indispens&#225;vel uma estreita correla&#231;&#227;o cl&#237;nico&#8208;patol&#243;gica para defini&#231;&#227;o do subtipo&#46; A diferencia&#231;&#227;o histopatol&#243;gica depende da evolu&#231;&#227;o e do est&#225;gio das les&#245;es&#46; Assim&#44; do ponto de vista histol&#243;gico&#44; o LE poderia ser classificado em recente &#40;LECA&#44; LECS e LED inicial&#41;&#44; completamente desenvolvido &#40;LED&#41; e tardio &#40;LED atr&#243;fico&#8208;cicatricial&#41;&#46; As altera&#231;&#245;es tendem a ser mais sutis nas les&#245;es recentes e bastante evidentes nas les&#245;es totalmente desenvolvidas&#46;<a class="elsevierStyleCrossRefs" href="#bib0445"><span class="elsevierStyleSup">19&#44;49</span></a></p><p id="par0260" class="elsevierStylePara elsevierViewall">Os principais achados s&#227;o o infiltrado inflamat&#243;rio linfoc&#237;tico perivascular e perianexial na derme superficial e profunda&#44; assim como a dermatite de interface&#44; caracterizada pela agress&#227;o de linf&#243;citos &#224; jun&#231;&#227;o dermoepid&#233;rmica&#46; Como consequ&#234;ncia&#44; outras altera&#231;&#245;es ocorrem&#44; como a degenera&#231;&#227;o vacuolar da camada basal e a necrose de ceratin&#243;citos nas camadas inferiores da epiderme&#44; seguidas por espessamento da membrana basal&#46; A epiderme torna&#8208;se atr&#243;fica e as cristas epiteliais&#44; achatadas&#46; A deposi&#231;&#227;o de mucina na derme &#233; um achado t&#237;pico do LE&#44; embora inespec&#237;fico&#44; variando em intensidade conforme o tipo de les&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0585"><span class="elsevierStyleSup">47</span></a></p><p id="par0265" class="elsevierStylePara elsevierViewall">No LED&#44; prot&#243;tipo das les&#245;es completamente desenvolvidas&#44; al&#233;m das altera&#231;&#245;es j&#225; descritas&#44; bastante proeminentes&#44; s&#227;o muito evidentes os achados de hiperceratose&#44; tamp&#245;es c&#243;rneos foliculares e atrofia epid&#233;rmica&#46; O est&#225;gio tardio e cicatricial do LED mostra incontin&#234;ncia pigmentar&#44; ectasia vascular&#44; fibrose d&#233;rmica e perda dos anexos&#46;<a class="elsevierStyleCrossRefs" href="#bib0445"><span class="elsevierStyleSup">19&#44;47</span></a></p><p id="par0270" class="elsevierStylePara elsevierViewall">No LECA&#44; as altera&#231;&#245;es costumam ser mais discretas&#44; podendo haver edema e hemorragia na derme superficial&#46; O infiltrado linfoc&#237;tico &#233; discreto&#44; apenas perivascular e superficial&#44; com presen&#231;a de neutr&#243;filos nas les&#245;es mais recentes&#46; A variante NET&#8208;s&#237;mile de LECA mostra intensa degenera&#231;&#227;o hidr&#243;pica da basal&#44; que resulta em disceratose&#44; clivagem subepid&#233;rmica e necrose completa da epiderme&#46;<a class="elsevierStyleCrossRefs" href="#bib0445"><span class="elsevierStyleSup">19&#44;47</span></a></p><p id="par0275" class="elsevierStylePara elsevierViewall">No LECS&#44; a dermatite de interface costuma ser intensa&#44; havendo muitos corpos citoides&#46; O infiltrado linfoc&#237;tico &#233; superficial e predominantemente perivascular&#46; A atrofia da epiderme&#44; a hiperceratose&#44; os tamp&#245;es foliculares&#44; a deposi&#231;&#227;o de mucina e o espessamento da membrana basal s&#227;o menos proeminentes que no LED&#46;<a class="elsevierStyleCrossRefs" href="#bib0445"><span class="elsevierStyleSup">19&#44;47</span></a></p><p id="par0280" class="elsevierStylePara elsevierViewall">O LE hipertr&#243;fico&#44; al&#233;m das altera&#231;&#245;es observadas no LED&#44; mostra acantose e acentuada hiperplasia pseudoepiteliomatosa&#44; al&#233;m de intensa hiperceratose&#46;<a class="elsevierStyleCrossRefs" href="#bib0585"><span class="elsevierStyleSup">47&#44;49</span></a></p><p id="par0285" class="elsevierStylePara elsevierViewall">O LE profundo apresenta&#8208;se como paniculite linfoc&#237;tica lobular&#44; com n&#243;dulos linfoides parasseptais e necrose hialina dos adip&#243;citos&#44; presen&#231;a de plasm&#243;citos&#44; al&#233;m de deposi&#231;&#227;o de mucina na derme reticular e ocasionalmente na hipoderme&#46; Fibrose e calcifica&#231;&#227;o podem ser observadas nos est&#225;gios finais das les&#245;es&#46; As altera&#231;&#245;es epid&#233;rmicas e d&#233;rmicas caracter&#237;sticas do LE podem estar presentes em metade dos casos&#46;<a class="elsevierStyleCrossRefs" href="#bib0585"><span class="elsevierStyleSup">47&#44;49</span></a></p><p id="par0290" class="elsevierStylePara elsevierViewall">O LE t&#250;mido caracteriza&#8208;se por intenso infiltrado linfoc&#237;tico perivascular na derme superficial e profunda&#44; al&#233;m de abundante deposi&#231;&#227;o de mucina&#44; sem a presen&#231;a das altera&#231;&#245;es epid&#233;rmicas e da dermatite de interface&#46;<a class="elsevierStyleCrossRefs" href="#bib0585"><span class="elsevierStyleSup">47&#44;49</span></a></p><p id="par0295" class="elsevierStylePara elsevierViewall">Nas les&#245;es de LE perni&#243;tico&#44; al&#233;m dos achados caracter&#237;sticos de LE&#44; em menor intensidade que no LED&#44; destacam&#8208;se a presen&#231;a de vasculite linfoc&#237;tica&#44; eventualmente com necrose fibrinoide e trombose&#44; edema da derme papilar e infiltrado linfoc&#237;tico peri&#233;crino&#46;<a class="elsevierStyleCrossRefs" href="#bib0585"><span class="elsevierStyleSup">47&#44;49</span></a></p><p id="par0300" class="elsevierStylePara elsevierViewall">O LE bolhoso mostra infiltrado inflamat&#243;rio predominante de neutr&#243;filos&#44; que costuma estar alinhado &#224; jun&#231;&#227;o dermoepid&#233;rmica e formar microabscessos nas papilas d&#233;rmicas&#44; al&#233;m de clivagem subepid&#233;rmica e bolha com neutr&#243;filos no interior&#46;<a class="elsevierStyleCrossRefs" href="#bib0585"><span class="elsevierStyleSup">47&#44;49</span></a></p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Imuno&#8208;histologia</span><p id="par0305" class="elsevierStylePara elsevierViewall">O teste da imunofluoresc&#234;ncia direta &#40;IFD&#41;&#44; realizado em cortes de tecido obtido por bi&#243;psia da les&#227;o cut&#226;nea&#44; visa identificar imunodep&#243;sitos na jun&#231;&#227;o dermoepid&#233;rmica&#44; conhecido como teste da banda l&#250;pica &#40;TBL&#41;&#46; Geralmente&#44; faz&#8208;se a pesquisa de imunodep&#243;sitos de IgG&#44; IgM&#44; IgA e C3&#46; O TBL &#233; considerado positivo quando identificada a deposi&#231;&#227;o de material granular em faixa junto &#224; zona da membrana basal&#46; &#201; recurso que pode auxiliar no diagn&#243;stico&#44; se a histologia n&#227;o &#233; decisiva frente a les&#245;es sugestivas de LE&#44; por&#233;m n&#227;o &#233; espec&#237;fico para a doen&#231;a&#44; podendo ser observado em outras condi&#231;&#245;es dermatol&#243;gicas&#44; como dermatomiosite&#44; e mesmo na pele normal ou fotodanificada&#44; principalmente da face&#46;<a class="elsevierStyleCrossRefs" href="#bib0590"><span class="elsevierStyleSup">48&#44;50</span></a> O tipo de dep&#243;sito varia conforme a cronologia e a topografia da les&#227;o&#44; assim como o local biopsiado&#44; se no centro ou periferia da les&#227;o&#46; IgM e IgG s&#227;o os imunodep&#243;sitos mais detectados&#44; em associa&#231;&#227;o ou n&#227;o com C3&#59; IgA &#233; menos comum&#46; O TBL costuma ser positivo na pele lesada de quase&#160;100&#37; dos casos de LECA&#44; em cerca de&#160;60&#37; dos casos de LECS e de&#160;90&#37; dos casos de LED&#46;<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">11&#44;19&#44;47</span></a></p><p id="par0310" class="elsevierStylePara elsevierViewall">Estudo recente que avaliou 2&#46;050 bi&#243;psias cut&#226;neas submetidas &#224; histologia e imunofluoresc&#234;ncia direta&#44; com hip&#243;teses diagn&#243;sticas de diferentes dermatoses&#44; concluiu que o valor da IFD no aux&#237;lio diagn&#243;stico do LE &#233; question&#225;vel e seu uso n&#227;o &#233; recomendado como rotina&#46;<a class="elsevierStyleCrossRef" href="#bib0600"><span class="elsevierStyleSup">50</span></a> Embora o TBL positivo na pele n&#227;o lesada e n&#227;o exposta seja altamente espec&#237;fico para LES&#44; ele acrescenta pouca informa&#231;&#227;o aos achados obtidos conjuntamente pelo exame cl&#237;nico&#44; histopatologia e sorologia&#46; Al&#233;m disso&#44; foi demonstrada sua associa&#231;&#227;o com a presen&#231;a de anticorpos anti&#8208;DNAn no soro&#44; por&#233;m com taxas de sensibilidade e especificidade similares&#44; sugerindo ser redundante a utiliza&#231;&#227;o de ambos os testes&#46;<a class="elsevierStyleCrossRef" href="#bib0600"><span class="elsevierStyleSup">50</span></a></p><p id="par0315" class="elsevierStylePara elsevierViewall">No LE bolhoso&#44; a IFD da pele perilesional demonstra dep&#243;sito cont&#237;nuo&#44; de padr&#227;o linear ou granular&#44; ao longo da zona da membrana basal&#44; principalmente de IgG&#44; al&#233;m de IgM&#44; IgA e C3&#46; A imunofluoresc&#234;ncia indireta&#44; pela t&#233;cnica de <span class="elsevierStyleItalic">salt&#8208;split skin</span>&#44; revela dep&#243;sito do lado d&#233;rmico da clivagem&#46;<a class="elsevierStyleCrossRefs" href="#bib0560"><span class="elsevierStyleSup">42&#44;47</span></a></p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Anticorpos antinucleares</span><p id="par0320" class="elsevierStylePara elsevierViewall">Os autoanticorpos antinucleares s&#227;o marcadores imunol&#243;gicos empregados tanto no diagn&#243;stico quanto na monitora&#231;&#227;o da doen&#231;a no LE&#46; O teste de triagem mais usado &#233; o fator antin&#250;cleo &#40;FAN&#41;&#44; que utiliza a t&#233;cnica da imunofluoresc&#234;ncia indireta&#44; tendo as c&#233;lulas HEp&#8208;2 como substrato&#46; O FAN tem maior relev&#226;ncia no LECA&#47;LES&#44; em que &#233; demonstrado em quase todos os pacientes &#40;94&#37;&#8208;100&#37;&#41;&#44; geralmente em t&#237;tulos elevados&#44; superiores a&#160;1&#47;160&#46; No entanto&#44; mesmo em altos t&#237;tulos&#44; n&#227;o s&#227;o espec&#237;ficos para LES&#44; j&#225; que podem ser detectados em v&#225;rias condi&#231;&#245;es&#44; como outras doen&#231;as do tecido conjuntivo&#44; doen&#231;as hematol&#243;gicas e hep&#225;ticas&#44; infec&#231;&#245;es virais&#44; uso de v&#225;rios medicamentos e at&#233; em indiv&#237;duos saud&#225;veis&#46;<a class="elsevierStyleCrossRef" href="#bib0605"><span class="elsevierStyleSup">51</span></a> O FAN &#233; demonstrado em menor propor&#231;&#227;o nas outras formas de LEC&#44; em&#160;52&#37;&#8208;80&#37; dos pacientes de LECS e em&#160;5&#37;&#8208;17&#37; dos pacientes de LED&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p><p id="par0325" class="elsevierStylePara elsevierViewall">Por n&#227;o ser um teste espec&#237;fico para LE&#44; &#233; fundamental que&#44; frente a FAN positivo&#44; a especificidade do anticorpo antinuclear seja determinada por meio de testes adicionais&#46;</p><p id="par0330" class="elsevierStylePara elsevierViewall">Os anticorpos anti&#8208;DNAn e anti&#8208;Sm s&#227;o os mais relevantes por serem espec&#237;ficos para LES&#44; embora apresentem menor sensibilidade&#44; de&#160;56&#37;&#8208;70&#37; e 19&#37;&#8208;25&#37;&#44; respectivamente&#46; Al&#233;m do valor diagn&#243;stico&#44; o anticorpo anti&#8208;DNAn pode ser usado para monitora&#231;&#227;o da doen&#231;a&#44; j&#225; que seus n&#237;veis s&#233;ricos tendem a refletir a atividade da doen&#231;a&#44; em especial a nefropatia&#44; sobretudo quando h&#225; concomit&#226;ncia com o anticorpo anti&#8208;Sm&#46;<a class="elsevierStyleCrossRefs" href="#bib0445"><span class="elsevierStyleSup">19&#44;51</span></a> &#201; baixa a preval&#234;ncia dos anticorpos anti&#8208;DNAn e anti&#8208;Sm nos pacientes de LECS&#44; e praticamente nula nos pacientes de LECC&#46;<a class="elsevierStyleCrossRefs" href="#bib0445"><span class="elsevierStyleSup">19&#44;25</span></a></p><p id="par0335" class="elsevierStylePara elsevierViewall">Os anticorpos anti&#8208;Ro&#47;SS&#8208;A e anti&#8208;La&#47;SS&#8208;B n&#227;o s&#227;o espec&#237;ficos do LE e est&#227;o frequentemente associados &#224; s&#237;ndrome de Sj&#246;gren&#46; Ocorrem&#44; respectivamente&#44; em 36&#37;&#8208;64&#37; e 8&#37;&#8208;33&#37; dos pacientes de LES e guardam rela&#231;&#227;o com as manifesta&#231;&#245;es cut&#226;neas e hematol&#243;gicas&#44; como as citopenias&#46; Os anticorpos anti&#8208;Ro&#47;SS&#8208;A e anti&#8208;La&#47;SS&#8208;B est&#227;o presentes entre 70&#37;&#8208;90&#37; e&#160;30&#37;&#8208;40&#37;&#44; respectivamente&#44; dos casos de LECS&#44; e em at&#233;&#160;25&#37;&#160;e&#160;5&#37;&#44; respectivamente&#44; dos casos de LED&#46; Particularmente&#44; os anticorpos anti&#8208;Ro&#47;SS&#8208;A s&#227;o considerados marcadores do LECS e est&#227;o relacionados com a extrema fotossensibilidade deste subtipo de LEC&#46; Al&#233;m disso&#44; quando presentes na gestante&#44; esses anticorpos atravessam a barreira placent&#225;ria e podem causar LE neonatal&#46; Os anticorpos especificamente dirigidos contra a subunidase&#160;52&#160;kD do ant&#237;geno Ro&#47;SS&#8208;A est&#227;o associados a maior risco de bloqueio card&#237;aco cong&#234;nito&#46; Adultos com esses anticorpos tamb&#233;m podem apresentar prolongamento do intervalo QT&#44; com maior risco de desenvolver arritmias ventriculares&#46;<a class="elsevierStyleCrossRef" href="#bib0605"><span class="elsevierStyleSup">51</span></a></p><p id="par0340" class="elsevierStylePara elsevierViewall">Anticorpos anti&#8208;RNP s&#227;o caracter&#237;sticos da doen&#231;a mista do tecido conjuntivo&#44; mas podem estar presentes em&#160;23&#37;&#8208;49&#37; dos pacientes de LES e n&#227;o mostram correla&#231;&#227;o com quaisquer manifesta&#231;&#245;es da doen&#231;a&#46;<a class="elsevierStyleCrossRef" href="#bib0605"><span class="elsevierStyleSup">51</span></a> Podem ocorrer entre&#160;8&#37;&#8208;10&#37; dos casos de LECS e muito raramente no LECC&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Avalia&#231;&#227;o da atividade e dano cut&#226;neos</span><p id="par0345" class="elsevierStylePara elsevierViewall">Pacientes diagnosticados com LEC devem ser submetidos a exame dermatol&#243;gico completo&#44; n&#227;o apenas durante epis&#243;dios de exacerba&#231;&#227;o da doen&#231;a&#44; mas tamb&#233;m a intervalos regulares&#44; com o objetivo de se avaliar a atividade e a progress&#227;o da doen&#231;a&#44; assim como identificar poss&#237;veis danos decorrentes do acometimento cut&#226;neo&#46;</p><p id="par0350" class="elsevierStylePara elsevierViewall">V&#225;rios escores de atividade da doen&#231;a est&#227;o bem estabelecidos na avalia&#231;&#227;o de pacientes com LES&#44; para uso em ensaios cl&#237;nicos e na pr&#225;tica cotidiana&#44; como o SLEDAI &#40;<span class="elsevierStyleItalic">Systemic Lupus Erythematosus Disease Activity Index</span>&#41;&#46; Apesar de inclu&#237;rem alguns crit&#233;rios dermatol&#243;gicos&#44; esses escores carecem de sensibilidade para avaliar a atividade cut&#226;nea nos diferentes subtipos de LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0410"><span class="elsevierStyleSup">12</span></a></p><p id="par0355" class="elsevierStylePara elsevierViewall">Por essa raz&#227;o&#44; foi criado o CLASI &#40;<span class="elsevierStyleItalic">Cutaneous Lupus Area and Severity Index</span>&#41;&#44; um instrumento desenvolvido especificamente para quantificar o acometimento cut&#226;neo no LE&#44; com escores de atividade &#40;CLASI&#8208;A&#41; e de dano &#40;CLASI&#8208;D&#41;&#46; Esse instrumento avalia a morfologia &#40;eritema&#44; descama&#231;&#227;o&#47;ceratose&#44; discromia e cicatriz&#47;atrofia&#41; e a localiza&#231;&#227;o anat&#244;mica &#40;13&#160;s&#237;tios&#41; das les&#245;es cut&#226;neas&#44; assim como o acometimento de mucosas e couro cabeludo&#46; Foi originalmente estabelecido como recurso para mensurar desfechos em ensaios cl&#237;nicos e validado por dermatologistas e reumatologistas&#46; O CLASI ainda demonstrou boa correla&#231;&#227;o com indicadores da qualidade de vida dos pacientes e revelou&#8208;se instrumento &#250;til e de f&#225;cil aplica&#231;&#227;o na pr&#225;tica cl&#237;nica&#46;<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">11&#44;12&#44;53</span></a></p><p id="par0360" class="elsevierStylePara elsevierViewall">Posteriormente&#44; surgiu o CLASI revisado &#40;RCLASI&#41;&#44; que acrescentou novos par&#226;metros &#8211; edema&#47;infiltra&#231;&#227;o e placas&#47;n&#243;dulos subcut&#226;neos &#8211; com o intuito de melhorar a acur&#225;cia na avalia&#231;&#227;o da atividade da doen&#231;a cut&#226;nea&#44; sendo capaz de abranger aspectos importantes de alguns subtipos de LEC&#44; como o LE t&#250;mido e o LE profundo&#46;<a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">48</span></a></p><p id="par0365" class="elsevierStylePara elsevierViewall">Entretanto&#44; uma recente revis&#227;o sistem&#225;tica constatou que&#44; dentre os ensaios que utilizaram o CLASI como medida de desfecho de interven&#231;&#245;es terap&#234;uticas&#44; s&#227;o poucos com alta qualidade de evid&#234;ncia&#46; Esse estudo concluiu que &#233; necess&#225;ria valida&#231;&#227;o adicional para averiguar a efetividade do CLASI na avalia&#231;&#227;o dos diferentes subtipos de LEC&#46; Os autores sugerem que o uso de medidas de desfecho padronizadas&#44; referidas por paciente e m&#233;dico&#44; poderiam reduzir a heterogeneidade e permitir compara&#231;&#245;es entre pacientes inclu&#237;dos em diferentes ensaios cl&#237;nicos&#46; Tamb&#233;m recomendam que o CLASI&#8208;50 &#40;redu&#231;&#227;o de&#160;50&#37; na pontua&#231;&#227;o do CLASI&#8208;A&#41; poderia ser mais efetivo como medida de resposta terap&#234;utica que o CLASI&#8208;20 &#40;redu&#231;&#227;o de&#160;20&#37; no CLASI&#8208;A&#41;&#44; usualmente utilizado como crit&#233;rio de boa resposta nos ensaios cl&#237;nicos&#46;<a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">54</span></a></p></span></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Progress&#227;o de l&#250;pus cut&#226;neo a l&#250;pus eritematoso sist&#234;mico</span><p id="par0370" class="elsevierStylePara elsevierViewall">De&#160;5&#37;&#8208;25&#37; dos casos de LEC isolado&#44; independentemente do subtipo&#44; podem progredir para LES durante sua evolu&#231;&#227;o&#44; com tempo m&#233;dio de&#160;oito&#160;anos entre o diagn&#243;stico da doen&#231;a cut&#226;nea e o desenvolvimento da doen&#231;a sist&#234;mica&#46; Estudo de base populacional desenvolvido na Su&#233;cia mostrou que a maior possibilidade de desenvolver LES ocorre at&#233;&#160;tr&#234;s&#160;anos ap&#243;s o diagn&#243;stico da doen&#231;a cut&#226;nea&#44; al&#233;m de ser mais prov&#225;vel nas mulheres&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p><p id="par0375" class="elsevierStylePara elsevierViewall">Por outro lado&#44; aproximadamente&#160;50&#37;&#8208;60&#37; dos pacientes de LECS experimentam transi&#231;&#227;o ou j&#225; podem ser classificados como LES quando do diagn&#243;stico da doen&#231;a cut&#226;nea&#44; geralmente preenchendo crit&#233;rios cut&#226;neos&#44; musculoesquel&#233;ticos e sorol&#243;gicos&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p><p id="par0380" class="elsevierStylePara elsevierViewall">Entretanto&#44; os pacientes de LEC que progridem para LES tendem a apresentar sintomas sist&#234;micos mais leves&#59; s&#227;o raras as manifesta&#231;&#245;es cardiopulmonares e neurol&#243;gicas&#44; assim como outras complica&#231;&#245;es graves da doen&#231;a&#46; Crit&#233;rios relacionados &#224; nefropatia s&#227;o indicadores relevantes de diferencia&#231;&#227;o entre doen&#231;a cut&#226;nea isolada e doen&#231;a sist&#234;mica&#46; Quando presente&#44; o acometimento renal tende a ser menos grave naqueles que evoluem de LEC a LES&#44; por&#233;m faltam estudos mais consistentes para permitir essa conclus&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p><p id="par0385" class="elsevierStylePara elsevierViewall">H&#225; evid&#234;ncia de que LED e LECS com les&#245;es disseminadas exibem maior probabilidade de evolu&#237;rem com manifesta&#231;&#245;es sist&#234;micas que aqueles com les&#245;es localizadas&#46; Estudo retrospectivo&#44; que comparou pacientes de LED com doen&#231;a localizada e pacientes de LED e LECS com doen&#231;a disseminada&#44; mostrou que&#160;30&#37; dos casos com les&#245;es disseminadas apresentaram manifesta&#231;&#245;es extracut&#226;neas&#44; como nefrite&#44; pleurite e poliartrite&#44; enquanto aqueles com doen&#231;a localizada n&#227;o tiveram manifesta&#231;&#245;es sist&#234;micas&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p><p id="par0390" class="elsevierStylePara elsevierViewall">As les&#245;es cut&#226;neas inespec&#237;ficas prevalecem no LES&#44; principalmente com doen&#231;a em atividade&#46; Por isso&#44; quando presentes&#44; implica maior probabilidade de doen&#231;a sist&#234;mica&#44; em particular a ocorr&#234;ncia de telangiectasias periungueais&#46; A presen&#231;a dessas les&#245;es foi verificada em&#160;76&#37; dos pacientes de LES com LED concomitante e em nenhum paciente com LED exclusivo&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p><p id="par0395" class="elsevierStylePara elsevierViewall">Pacientes de LEC com potencial de desenvolver LES t&#234;m maior probabilidade de apresentar FAN com t&#237;tulos elevados em compara&#231;&#227;o com aqueles de LEC exclusivo&#46; Al&#233;m de marcadores de acometimento sist&#234;mico importante nos pacientes de LES&#44; t&#237;tulos elevados do FAN e a presen&#231;a dos anticorpos espec&#237;ficos anti&#8208;DNAn ou anti&#8208;Sm tamb&#233;m s&#227;o indicativos de evolu&#231;&#227;o para doen&#231;a sist&#234;mica nos pacientes com LEC&#46;</p><p id="par0400" class="elsevierStylePara elsevierViewall">Outras altera&#231;&#245;es laboratoriais persistentes&#44; como anemia&#44; leucopenia&#44; trombocitopenia e eleva&#231;&#227;o da velocidade de hemossedimenta&#231;&#227;o&#44; tamb&#233;m s&#227;o consideradas importantes marcadores de progress&#227;o para LES&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p><p id="par0405" class="elsevierStylePara elsevierViewall">Tamb&#233;m &#233; mat&#233;ria de discuss&#227;o se a administra&#231;&#227;o precoce de antimal&#225;ricos em pacientes de LEC&#44; com potencial de desenvolver doen&#231;a sist&#234;mica&#44; poderia prevenir a progress&#227;o a LES ou atenuar danos a &#243;rg&#227;os vitais&#44; uma vez instalada a doen&#231;a sist&#234;mica&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p><p id="par0410" class="elsevierStylePara elsevierViewall">Recomenda&#8208;se seguimento peri&#243;dico&#44; a intervalos mais curtos&#44; de pacientes com LEC que apresentam fatores de risco para progress&#227;o a LES&#44; com exame cl&#237;nico minucioso e adequada revis&#227;o laboratorial&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Tratamento</span><p id="par0415" class="elsevierStylePara elsevierViewall">O tratamento do LEC envolve medidas farmacol&#243;gicas e n&#227;o farmacol&#243;gicas&#46; Escolher a terapia mais eficaz para cada caso pode ser desafiador e exige aten&#231;&#227;o &#224;s manifesta&#231;&#245;es cl&#237;nicas e familiaridade com as terapias dispon&#237;veis&#46; &#201; importante avaliar a ades&#227;o do paciente ao tratamento em cada consulta&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a> Embora existam apenas tr&#234;s f&#225;rmacos aprovados pela ag&#234;ncia norte&#8208;americana Food and Drug Administration &#40;FDA&#41; para uso no LES &#8211; corticosteroides&#44; hidroxicloroquina e belimumabe &#8211; e nenhuma aprovada especificamente para LEC&#44; &#233; poss&#237;vel encontrar dados na literatura que permitem racionalizar a abordagem terap&#234;utica&#46;<a class="elsevierStyleCrossRef" href="#bib0630"><span class="elsevierStyleSup">56</span></a></p><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Medidas gerais</span><p id="par0420" class="elsevierStylePara elsevierViewall">A fotoprote&#231;&#227;o &#233; pilar fundamental do tratamento do LEC&#46; Os fotoprotetores podem prevenir o surgimento de les&#245;es nos pacientes com LEC&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;55&#8211;58</span></a> Entretanto&#44; outras medidas de cuidado tamb&#233;m se somam a seu uso&#44; como mudan&#231;as comportamentais&#44; uso de chap&#233;us e vestes longas&#44; preferencialmente com tecnologia para prote&#231;&#227;o &#224; RUV&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;58&#44;59</span></a></p><p id="par0425" class="elsevierStylePara elsevierViewall">A cessa&#231;&#227;o do tabagismo deve ser averiguada e encorajada a cada consulta&#44; de prefer&#234;ncia com referenciamento do paciente a programas e terapias de apoio&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;57</span></a> A suplementa&#231;&#227;o de vitamina D nos pacientes com defici&#234;ncia pode ser ben&#233;fica para o controle da doen&#231;a&#46;<a class="elsevierStyleCrossRefs" href="#bib0630"><span class="elsevierStyleSup">56&#44;57&#44;60</span></a> Em caso de LEC induzido por f&#225;rmacos&#44; a medica&#231;&#227;o suspeita deve ser prontamente suspensa&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a></p><p id="par0430" class="elsevierStylePara elsevierViewall">Contracep&#231;&#227;o pode ser necess&#225;ria quando do uso de f&#225;rmacos teratog&#234;nicos&#46; Mulheres com LEC podem utilizar contraceptivos orais combinados&#44; se n&#227;o houver hist&#243;ria de tromboembolismo ou altos n&#237;veis de anticorpos antifosfol&#237;pides&#59; caso contr&#225;rio&#44; deve&#8208;se optar por dispositivo intrauterino ou uso de progest&#225;genos isolados&#46;<a class="elsevierStyleCrossRefs" href="#bib0575"><span class="elsevierStyleSup">45&#44;61</span></a></p><p id="par0435" class="elsevierStylePara elsevierViewall">O uso de camuflagem cosm&#233;tica e pr&#243;teses de cabelos podem ocultar cicatrizes e alopecia&#44; melhorando a qualidade de vida e a autoestima dos pacientes&#46;<a class="elsevierStyleCrossRefs" href="#bib0645"><span class="elsevierStyleSup">59&#44;62</span></a> &#201; importante que pacientes com LEC sejam orientados a evitar interven&#231;&#245;es que traumatizem a pele&#44; pelo risco de koebneriza&#231;&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0660"><span class="elsevierStyleSup">62</span></a></p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Tratamento t&#243;pico</span><p id="par0440" class="elsevierStylePara elsevierViewall">Os corticosteroides s&#227;o considerados a primeira linha de tratamento t&#243;pico&#44; por seu efeito anti&#8208;inflamat&#243;rio&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;6</span></a> Podem ser utilizados nos casos de les&#245;es localizadas ou como terapia adjuvante nos pacientes em tratamento sist&#234;mico&#46; Corticosteroides potentes&#44; como o clobetasol&#44; s&#227;o mais eficazes para o controle da doen&#231;a que os de baixa pot&#234;ncia&#46;<a class="elsevierStyleCrossRefs" href="#bib0630"><span class="elsevierStyleSup">56&#44;61</span></a> Entretanto&#44; essas medica&#231;&#245;es est&#227;o associadas a maior risco de efeitos colaterais&#44; como estrias e telangiectasias&#44; por seu efeito nos fibroblastos e vasos sangu&#237;neos&#44; respectivamente&#44; al&#233;m de dermatite perioral rosaceiforme&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;60</span></a> Por isso&#44; a terapia com corticosteroides t&#243;picos potentes deve ser usada pelo menor tempo poss&#237;vel&#46; A inje&#231;&#227;o intralesional de corticoide pode ser aplicada em les&#245;es hipertr&#243;ficas localizadas&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;55</span></a></p><p id="par0445" class="elsevierStylePara elsevierViewall">Os inibidores t&#243;picos da calcineurina &#8211; tacrolimo&#160;0&#44;03&#37;&#160;ou&#160;0&#44;1&#37; em pomada e pimecrolimo&#160;1&#37; em creme &#8211; podem ser utilizados como substitutos dos corticosteroides nos casos que exijam tratamento prolongado ou com maior risco de efeitos colaterais&#44; como les&#245;es na face de crian&#231;as&#46;<a class="elsevierStyleCrossRefs" href="#bib0625"><span class="elsevierStyleSup">55&#44;61</span></a> S&#227;o menos eficazes que os corticoides t&#243;picos potentes&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> Os efeitos colaterais relacionados ao uso dessas medica&#231;&#245;es incluem sensa&#231;&#227;o de ard&#234;ncia&#44; prurido e eritema no local da aplica&#231;&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">57</span></a> Alguns estudos mostraram bons resultados com a aplica&#231;&#227;o combinada de clobetasol&#160;0&#44;05&#37; e tacrolimo&#160;0&#44;03&#37;&#46;</p><p id="par0450" class="elsevierStylePara elsevierViewall">O R&#8208;salbutamol &#233; um agonista do receptor &#946;2&#8208;adren&#233;rgico que inibe a produ&#231;&#227;o de IL&#8208;2 e IFN&#8208;&#947;&#44; podendo melhorar les&#245;es de LEC&#44; quando utilizado a&#160;0&#44;5&#37; em creme&#46;<a class="elsevierStyleCrossRefs" href="#bib0625"><span class="elsevierStyleSup">55&#44;60</span></a> Entretanto&#44; n&#227;o &#233; comercialmente dispon&#237;vel para uso t&#243;pico&#46;<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">60</span></a> Os retinoides t&#243;picos j&#225; foram utilizados com sucesso em algumas pequenas s&#233;ries de casos&#46;<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">60</span></a></p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Tratamento sist&#234;mico</span><p id="par0455" class="elsevierStylePara elsevierViewall">Pacientes com les&#245;es localizadas refrat&#225;rias ao tratamento t&#243;pico ou com les&#245;es disseminadas geralmente necessitam de tratamento sist&#234;mico&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a> A <a class="elsevierStyleCrossRef" href="#tbl0025">tabela 5</a> mostra o n&#237;vel de evid&#234;ncia e o grau de recomenda&#231;&#227;o dos principais medicamentos de uso sist&#234;mico no tratamento do LEC&#46;</p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia></span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Antimal&#225;ricos</span><p id="par0460" class="elsevierStylePara elsevierViewall">Os antimal&#225;ricos &#40;AM&#41; constituem a primeira linha de tratamento sist&#234;mico&#59; &#233; prov&#225;vel que previnam a progress&#227;o do LEC para doen&#231;a sist&#234;mica&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;59&#44;61&#44;63</span></a> S&#227;o capazes de inibir a apresenta&#231;&#227;o de ant&#237;genos pelas CDP&#44; a forma&#231;&#227;o de complexos ant&#237;geno&#8208;anticorpo e a sinaliza&#231;&#227;o via receptores <span class="elsevierStyleItalic">Toll&#8208;like&#44;</span> reduzindo a produ&#231;&#227;o de IFN tipo&#160;I&#46;<a class="elsevierStyleCrossRefs" href="#bib0420"><span class="elsevierStyleSup">14&#44;55&#44;59</span></a> A hidroxicloroquina &#40;HCQ&#41; &#233; o AM mais utilizado pelo melhor perfil de seguran&#231;a quanto &#224; toxicidade ocular em rela&#231;&#227;o &#224; cloroquina &#40;CQ&#41;&#46; A dose recomendada de HCQ&#44; em parte da literatura&#44; &#233; de&#160;6&#44;5&#160;mg&#47;kg&#47;dia&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a> Contudo&#44; em&#160;2016&#44; a American Academy of Ophthalmology recomendou que doses maiores que&#160;5&#160;mg&#47;kg&#47;dia de HCQ e 2&#44;3&#160;mg&#47;kg&#47;dia de CQ sejam evitadas&#44; por risco aumentado de retinopatia&#46;<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">58</span></a></p><p id="par0465" class="elsevierStylePara elsevierViewall">O &#237;ndice de resposta dos AM &#233; de cerca de&#160;63&#37; dentre os diversos subtipos de LEC e pode ser um pouco maior para a CQ em rela&#231;&#227;o &#224; HCQ&#46;<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">64</span></a> A taxa m&#233;dia de resposta foi de&#160;91&#37; nos casos de LECA&#44; 57&#37;&#160;no LED e apenas&#160;31&#37; no LE perni&#243;tico&#46;<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">64</span></a> Pacientes de LECC tendem a responder mais lentamente aos AM que aqueles de LECA&#46;<a class="elsevierStyleCrossRef" href="#bib0630"><span class="elsevierStyleSup">56</span></a></p><p id="par0470" class="elsevierStylePara elsevierViewall">Em casos refrat&#225;rios&#44; um AM pode ser substitu&#237;do por outro &#8211; HCQ por CQ ou CQ por HCQ&#59; nesses casos&#44; a taxa de resposta ao segundo AM pode chegar a&#160;56&#37;&#44; mas cair para&#160;42&#37; ap&#243;s&#160;um&#160;ano e 22&#37; ap&#243;s&#160;dois&#160;anos&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">4&#44;6&#44;45&#44;60&#44;64</span></a> A adi&#231;&#227;o de quinacrina&#44; f&#225;rmaco n&#227;o dispon&#237;vel no Brasil&#44; na dose de&#160;100&#8208;200&#160;mg&#47;dia&#44; nos casos refrat&#225;rios aos AM em monoterapia&#44; pode aumentar a taxa de resposta para&#160;66&#37;&#44; sem aumentar o risco de retinopatia&#46;<a class="elsevierStyleCrossRefs" href="#bib0575"><span class="elsevierStyleSup">45&#44;57&#44;58&#44;61&#44;64</span></a> O uso de AM durante a gesta&#231;&#227;o e lacta&#231;&#227;o &#233; recomendado&#44; especialmente nas pacientes com les&#245;es cut&#226;neas e LES&#44; podendo reduzir o risco de acometimento card&#237;aco pelo LE neonatal&#46;<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">65</span></a></p><p id="par0475" class="elsevierStylePara elsevierViewall">Os efeitos colaterais dos AM incluem n&#225;useas&#44; v&#244;mitos&#44; pigmenta&#231;&#227;o cut&#226;nea&#44; tonteira&#44; cefaleia&#44; ototoxicidade e neuropatia perif&#233;rica&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> A retinopatia &#233; o efeito colateral mais relevante e ocorre em at&#233;&#160;1&#37; dos casos&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> Os pacientes devem ser avaliados no in&#237;cio do tratamento e&#44; caso n&#227;o tenham nenhum fator de risco adicional&#44; anualmente&#44; ap&#243;s o quinto ano de uso do medicamento&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a> Pacientes com doses acima de&#160;5&#44;0&#160;mg&#47;kg&#47;dia&#44; insufici&#234;ncia renal&#44; uso concomitante de tamoxifeno e maculopatia retiniana preexistente est&#227;o sob maior risco de retinopatia e devem ser monitorados com maior frequ&#234;ncia&#46;<a class="elsevierStyleCrossRef" href="#bib0630"><span class="elsevierStyleSup">56</span></a> A campimetria e o exame de fundo de olho podem n&#227;o detectar altera&#231;&#245;es iniciais&#59; a tomografia de coer&#234;ncia &#243;ptica &#233; recomendada para auxiliar no diagn&#243;stico precoce&#46;<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">65</span></a> Existem raros relatos de toxicidade card&#237;aca&#44; com prolongamento do intervalo QT&#46;<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">65</span></a></p><p id="par0480" class="elsevierStylePara elsevierViewall">Quando dispon&#237;vel&#44; a dosagem s&#233;rica de HCQ pode ser utilizada para avalia&#231;&#227;o do tratamento ap&#243;s&#160;seis&#160;meses de uso sem resposta&#46;<a class="elsevierStyleCrossRefs" href="#bib0575"><span class="elsevierStyleSup">45&#44;60</span></a> Valores inferiores a&#160;200&#160;ng&#47;mL indicam m&#225;&#8208;ades&#227;o ao tratamento&#44; enquanto valores acima de&#160;750&#160;ng&#47;mL est&#227;o correlacionados a melhores taxas de controle da atividade da doen&#231;a&#46;<a class="elsevierStyleCrossRefs" href="#bib0575"><span class="elsevierStyleSup">45&#44;56</span></a> Pacientes com contraindica&#231;&#227;o aos AM ou com dose otimizada de AM&#44; mas sem resposta ou com resposta parcial&#44; t&#234;m indica&#231;&#227;o de f&#225;rmacos de segunda linha de tratamento&#46; Tabagistas s&#227;o mais propensos a n&#227;o responderem aos AM&#46;<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">57</span></a></p></span><span id="sec0110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Metotrexato</span><p id="par0485" class="elsevierStylePara elsevierViewall">O metotrexato &#40;MTX&#41; &#233; a primeira escolha dentre os f&#225;rmacos de segunda linha para pacientes refrat&#225;rios ou com contraindica&#231;&#227;o ao uso dos AM&#46;<a class="elsevierStyleCrossRefs" href="#bib0625"><span class="elsevierStyleSup">55&#44;66</span></a> &#201; um inibidor da diidrofolato&#8208;redutase&#44; que afeta a replica&#231;&#227;o celular e suprime a produ&#231;&#227;o de anticorpos&#46;<a class="elsevierStyleCrossRef" href="#bib0645"><span class="elsevierStyleSup">59</span></a> A dose recomendada pode variar de&#160;7&#44;5&#8208;25&#160;mg&#47;semana&#44; via oral ou subcut&#226;nea&#46; Os efeitos colaterais s&#227;o n&#225;useas&#44; v&#244;mitos&#44; dor abdominal&#44; hepatotoxidade&#44; ulcera&#231;&#227;o de mucosas&#44; supress&#227;o medular&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">4&#44;55&#44;60</span></a> A aplica&#231;&#227;o subcut&#226;nea e a administra&#231;&#227;o de &#225;cido f&#243;lico nos dias posteriores ao uso da medica&#231;&#227;o podem reduzir significantemente os efeitos colaterais gastrintestinais&#46;<a class="elsevierStyleCrossRefs" href="#bib0640"><span class="elsevierStyleSup">58&#44;61</span></a> Os pacientes devem ser monitorados laboratorialmente nas primeiras semanas de uso&#44; ap&#243;s aumento das doses e&#44; trimestralmente&#44; no acompanhamento regular&#46;</p><p id="par0490" class="elsevierStylePara elsevierViewall">O uso de MTX deve ser evitado em pacientes etilistas&#44; naqueles em uso concomitante de f&#225;rmacos hepatot&#243;xicos&#44; com esteatose hep&#225;tica grave&#44; insufici&#234;ncia renal ou doen&#231;a hep&#225;tica de base&#44; incluindo hepatites virais&#44; condi&#231;&#245;es que devem ser pesquisadas antes do in&#237;cio do tratamento com MTX&#46;<a class="elsevierStyleCrossRefs" href="#bib0640"><span class="elsevierStyleSup">58&#44;61</span></a> O risco de hepatoxicidade fora dessas condi&#231;&#245;es &#233; baixo&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a> Pneumonite intersticial &#233; complica&#231;&#227;o rara e potencialmente fatal&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">4&#44;55</span></a> MTX &#233; teratog&#234;nico e deve ser recomendada contracep&#231;&#227;o adequada&#46;<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">60</span></a></p></span><span id="sec0115" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Retinoides sist&#234;micos</span><p id="par0495" class="elsevierStylePara elsevierViewall">Os retinoides s&#227;o utilizados com sucesso no tratamento de LEC refrat&#225;rio&#44; especialmente nas formas verrucosas&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;55&#44;61</span></a> Eles inibem a produ&#231;&#227;o de citocinas pr&#243;&#8208;inflamat&#243;rias&#44; como a IL&#8208;6 e o IFN&#8208;&#947;&#44; al&#233;m de regular e normalizar a diferencia&#231;&#227;o dos ceratin&#243;citos&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a> Dados da literatura n&#227;o mostram diferen&#231;a significante de efic&#225;cia entre HCQ e acitretina em pacientes com diferentes subtipos de LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">57</span></a> A isotretino&#237;na tamb&#233;m j&#225; foi utilizada em pequenas s&#233;ries de casos&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a></p><p id="par0500" class="elsevierStylePara elsevierViewall">A dose de acitretina e isotretino&#237;na &#233; de&#160;0&#44;2&#8208;1&#44;0&#160;mg&#47;kg&#47;dia&#46; A resposta&#44; em geral&#44; &#233; r&#225;pida e ocorre em duas a seis semanas&#46; A recidiva tamb&#233;m costuma sobrevir logo ap&#243;s a interrup&#231;&#227;o da medica&#231;&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a></p><p id="par0505" class="elsevierStylePara elsevierViewall">Pacientes em uso de retinoides devem ser monitorados regularmente pelo risco de hepatotoxicidade e aumento dos n&#237;veis s&#233;ricos de triglic&#233;rides&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> Outros efeitos colaterais incluem xerose mucocut&#226;nea e altera&#231;&#245;es &#243;sseas&#44; como a hiperostose&#46;<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">67</span></a> O uso de fotoprotetores deve ser intensificado&#44; pelo risco de agravamento da fotossensibilidade&#46;<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">67</span></a> Em decorr&#234;ncia do risco de teratogenicidade&#44; mulheres em idade f&#233;rtil devem ser submetidas a contracep&#231;&#227;o adequada durante e ap&#243;s o t&#233;rmino do tratamento &#40;isotretino&#237;na&#44; at&#233;&#160;um&#160;m&#234;s&#44; e acitretina&#44; at&#233;&#160;dois a tr&#234;s&#160;anos&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;55</span></a></p></span><span id="sec0120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Dapsona</span><p id="par0510" class="elsevierStylePara elsevierViewall">A dapsona &#233; agente imunomodulador e antimicrobiano que inibe a mieloperoxidase presente em neutr&#243;filos e mon&#243;citos&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;59&#44;68</span></a> Pode ser usada isoladamente ou em combina&#231;&#227;o com os AM&#46; Mais de&#160;50&#37; dos pacientes com LEC respondem favoravelmente ao uso da dapsona&#44; inclusive aqueles com LED&#44; subtipo classicamente mais resistente&#44; em que a taxa de resposta se aproxima de&#160;60&#37;&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;68</span></a> A dapsona &#233; considerada f&#225;rmaco de primeira escolha no tratamento do LE bolhoso e de outras manifesta&#231;&#245;es neutrof&#237;licas no LE&#44; como a urtic&#225;ria vasculite&#46;<a class="elsevierStyleCrossRefs" href="#bib0630"><span class="elsevierStyleSup">56&#44;61</span></a> As variantes hipercerat&#243;sicas usualmente n&#227;o respondem bem &#224; dapsona&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a></p><p id="par0515" class="elsevierStylePara elsevierViewall">A dose inicial &#233; de&#160;50&#160;mg&#47;dia e pode ser aumentada at&#233;&#160;200&#160;mg&#47;dia&#46;<a class="elsevierStyleCrossRefs" href="#bib0625"><span class="elsevierStyleSup">55&#44;61</span></a> Os pacientes devem ser avaliados quanto &#224; defici&#234;ncia de glicose&#8208;6&#8208;fosfatodesidrogenase antes do in&#237;cio do tratamento&#46;<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">58</span></a></p><p id="par0520" class="elsevierStylePara elsevierViewall">Os efeitos colaterais podem ser graves&#44; como erup&#231;&#227;o ao f&#225;rmaco com eosinofilia e sintomas sist&#234;micos&#44; a s&#237;ndrome DRESS &#40;do ingl&#234;s&#44; <span class="elsevierStyleItalic">drug reaction with eosinophilia and systemic symptoms</span>&#41;&#44; meta&#8208;hemoglobinemia e agranulocitose&#46;<a class="elsevierStyleCrossRefs" href="#bib0625"><span class="elsevierStyleSup">55&#44;57</span></a> Anemia hemol&#237;tica pode ocorrer em at&#233;&#160;50&#37; dos pacientes&#46;<a class="elsevierStyleCrossRefs" href="#bib0635"><span class="elsevierStyleSup">57&#44;68</span></a> Os n&#237;veis de hemoglobina devem ser monitorados durante o primeiro m&#234;s de tratamento e&#44; ent&#227;o&#44; a cada tr&#234;s meses&#46; Os n&#237;veis de meta&#8208;hemoglobina podem ser avaliados entre o&#160;8&#176;&#160;e&#160;14&#176;&#160;dia ap&#243;s a introdu&#231;&#227;o da medica&#231;&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">60</span></a> A dapsona &#233; o &#250;nico f&#225;rmaco de segunda linha que pode ser utilizado durante a gesta&#231;&#227;o e a amamenta&#231;&#227;o&#46;<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">60&#44;61</span></a></p></span><span id="sec0125" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Micofenolato de mofetila</span><p id="par0525" class="elsevierStylePara elsevierViewall">O micofenolato de mofetila &#40;MFM&#41; &#233; considerado agente de terceira linha para o tratamento do LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a> O MFM causa deple&#231;&#227;o do trifosfato de guanosina&#44; necess&#225;rio para ades&#227;o de linf&#243;citos e mon&#243;citos ao endot&#233;lio durante o processo de inflama&#231;&#227;o&#44; al&#233;m de induzir apoptose de linf&#243;citos&#160;T e reduzir a ativa&#231;&#227;o dos linf&#243;citos&#160;B&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a> Foi relatada uma taxa de resposta completa ou significante em&#160;62&#37; dos pacientes de LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> MFM pode ser usado isoladamente ou em combina&#231;&#227;o com AM&#46;<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">4</span></a> A dose inicial &#233; de&#160;500&#160;mg&#47;dia e pode ser aumentada at&#233;&#160;3&#160;g&#47;dia&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a></p><p id="par0530" class="elsevierStylePara elsevierViewall">Os efeitos colaterais mais frequentes s&#227;o gastrintestinais&#44; citopenias&#44; hepatotoxicidade e infec&#231;&#245;es virais e urin&#225;rias&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a> Os pacientes devem realizar revis&#245;es laboratoriais mensalmente&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a> O f&#225;rmaco &#233; da categoria&#160;X e n&#227;o pode ser utilizado durante a gesta&#231;&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a></p></span><span id="sec0130" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Azatioprina</span><p id="par0535" class="elsevierStylePara elsevierViewall">A azatioprina &#233; um an&#225;logo da purina que deprime a fun&#231;&#227;o dos linf&#243;citos&#160;T&#160;e&#160;B e reduz a apresenta&#231;&#227;o de ant&#237;genos&#46;<a class="elsevierStyleCrossRef" href="#bib0645"><span class="elsevierStyleSup">59</span></a> Pode ser indicada no LEC em caso de insucesso dos tratamentos descritos anteriormente&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> S&#233;ries de caso t&#234;m mostrado sucesso no tratamento do LEC&#44; embora n&#227;o existam grandes estudos que suportem essa recomenda&#231;&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> Pode ser usada nas gestantes com LES&#44; mas sua rela&#231;&#227;o risco&#8208;benef&#237;cio deve ser ponderada&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> A dose recomendada &#233; de&#160;1&#8208;3&#160;mg&#47;kg&#47;dia&#46; Os efeitos adversos s&#227;o gastrintestinais&#44; infec&#231;&#245;es oportunistas e citopenias&#46;<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">58</span></a></p></span><span id="sec0135" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Talidomida</span><p id="par0540" class="elsevierStylePara elsevierViewall">A talidomida &#233; um f&#225;rmaco utilizado como terapia de resgate nos casos graves&#44; refrat&#225;rios e com alto risco de forma&#231;&#227;o de cicatrizes&#46;<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">66</span></a> Atua inibindo a s&#237;ntese de TNF&#8208;&#945;&#44; a angiog&#234;nese e a apoptose de ceratin&#243;citos induzida pela RUV&#44; reduzindo a produ&#231;&#227;o de IFN&#8208;&#947; e a fagocitose por polimorfonucleares&#46;<a class="elsevierStyleCrossRefs" href="#bib0625"><span class="elsevierStyleSup">55&#44;69</span></a> A taxa de resposta &#233; superior a&#160;90&#37; nos diferentes subtipos de LEC&#44; a mais alta dentre todos os tratamentos dispon&#237;veis&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;57&#44;70</span></a> Por&#233;m&#44; com alto risco de reca&#237;das&#44; de at&#233;&#160;70&#37;&#44; ap&#243;s a suspens&#227;o da medica&#231;&#227;o&#44; especialmente no LED&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;56&#44;70</span></a> A dose inicial recomendada &#233; de&#160;100&#160;mg&#47;dia&#44; que deve ser reduzida assim que a resposta cl&#237;nica for alcan&#231;ada&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a></p><p id="par0545" class="elsevierStylePara elsevierViewall">A alta frequ&#234;ncia de eventos adversos pode limitar seu uso&#44; afetando&#160;24&#37; dos pacientes &#40;16&#37;&#160;com neuropatia perif&#233;rica e 2&#37;&#160;com eventos tromboemb&#243;licos&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0630"><span class="elsevierStyleSup">56&#44;70</span></a> A polineuropatia &#233; classicamente sim&#233;trica&#44; dolorosa e afeta m&#227;os e p&#233;s&#46; &#201; usualmente acompanhada de perda sensorial e preserva&#231;&#227;o da for&#231;a muscular&#46;<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">69</span></a> Deve ser realizada eletroneuromiografia no in&#237;cio do tratamento e&#44; como controle&#44; a cada&#160;seis&#160;meses&#46;<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">69</span></a> Outros efeitos colaterais s&#227;o seda&#231;&#227;o&#44; hipotens&#227;o ortost&#225;tica&#44; erup&#231;&#227;o maculopapular&#44; constipa&#231;&#227;o e xerostomia&#46;<a class="elsevierStyleCrossRefs" href="#bib0685"><span class="elsevierStyleSup">67&#44;69</span></a></p><p id="par0550" class="elsevierStylePara elsevierViewall">A teratogenicidade &#233; um dos efeitos colaterais mais tem&#237;veis relacionados ao uso da talidomida&#46;<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">69</span></a> Seu uso em mulheres em idade f&#233;rtil deve ser excepcional e apenas ap&#243;s falha de todos os tratamentos dispon&#237;veis&#46; Nesses casos&#44; recomenda&#8208;se a ado&#231;&#227;o de dois m&#233;todos contraceptivos&#44; um de alta efetividade e o outro de barreira&#46; Deve ser realizado teste de gravidez&#160;24&#160;horas antes do in&#237;cio do tratamento&#44; repetido semanalmente no primeiro m&#234;s e&#44; posteriormente&#44; a cada duas a quatro semanas&#46;<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">69</span></a></p><p id="par0555" class="elsevierStylePara elsevierViewall">&#193;cido acetilsalic&#237;lico&#44; em baixas doses&#44; pode ser associado &#224; talidomida em pacientes com alto risco cardiovascular ou presen&#231;a de anticorpos antifosfol&#237;pides&#46;<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">60&#44;69</span></a></p><p id="par0560" class="elsevierStylePara elsevierViewall">A lenalidomida&#44; um derivado da talidomida&#44; exibe melhor perfil de seguran&#231;a quanto ao risco de neuropatia&#44; por&#233;m ainda existem poucos dados na literatura sobre seu uso em pacientes com LEC&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;61</span></a> Alguns autores contraindicam seu uso no LEC devido ao risco de induzir LES&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a></p></span><span id="sec0140" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Corticosteroides sist&#234;micos</span><p id="par0565" class="elsevierStylePara elsevierViewall">Os corticosteroides sist&#234;micos podem ser utilizados no in&#237;cio do tratamento das formas agressivas e disseminadas de LEC&#44; at&#233; que as outras medica&#231;&#245;es iniciem sua a&#231;&#227;o terap&#234;utica&#46; Devem ser reduzidos e suspensos o mais brevemente poss&#237;vel&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;6</span></a> Apresentam maior taxa de resposta no LECA&#44; provavelmente pela associa&#231;&#227;o com LES&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a> A dose usual &#233; de&#160;0&#44;5&#8208;1&#160;mg&#47;kg&#47;dia de prednisona e deve ser reduzida&#44; logo que poss&#237;vel&#44; at&#233; atingir doses di&#225;rias inferiores a&#160;7&#44;5&#160;mg&#46; A terapia de longo prazo com corticosteroides sist&#234;micos n&#227;o &#233; indicada no LEC&#46;<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">60&#44;61</span></a></p></span><span id="sec0145" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">Outros tratamentos</span><p id="par0570" class="elsevierStylePara elsevierViewall">A clofazimina apresenta propriedades antimicrobianas&#44; anti&#8208;inflamat&#243;rias e imunossupressoras&#46;<a class="elsevierStyleCrossRef" href="#bib0645"><span class="elsevierStyleSup">59</span></a> A dose &#233; de&#160;100&#8208;200&#160;mg&#47;dia e pode ser utilizada como tratamento adjuvante&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a> Os principais efeitos colaterais s&#227;o hiperpigmenta&#231;&#227;o cinza&#8208;acastanhada&#44; xerose cut&#226;nea&#44; n&#225;useas e v&#244;mitos&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a> Os &#233;steres do &#225;cido fum&#225;rico j&#225; foram usados com sucesso no LED&#44; por&#233;m os dados ainda s&#227;o limitados na literatura&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;57</span></a></p><p id="par0575" class="elsevierStylePara elsevierViewall">O uso de antiagregantes plaquet&#225;rios &#233; recomendado nos pacientes com livedo racemoso&#44; les&#245;es do tipo papulose maligna atr&#243;fica &#40;doen&#231;a de Degos&#41;&#44; ulcera&#231;&#227;o&#44; tromboflebite e anetodermia&#46;<a class="elsevierStyleCrossRef" href="#bib0575"><span class="elsevierStyleSup">45</span></a></p><p id="par0580" class="elsevierStylePara elsevierViewall">O uso de <span class="elsevierStyleItalic">pulsed&#8208;dye&#8208;laser</span> &#40;<span class="elsevierStyleItalic">laser</span> pulsado de corante&#41; &#233; descrito como tratamento de cicatrizes&#46; Entretanto&#44; dado o risco de fotossensibilidade&#44; seu uso n&#227;o &#233; recomendado na presen&#231;a de les&#245;es cut&#226;neas ativas&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;7&#44;61</span></a></p><p id="par0585" class="elsevierStylePara elsevierViewall">Ciclosporina&#44; ciclofosfamida e imunoglobulina endovenosa n&#227;o s&#227;o indicadas no tratamento do LEC sem acometimento sist&#234;mico&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;61</span></a></p></span><span id="sec0150" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0160">Terapias&#8208;alvo</span><p id="par0590" class="elsevierStylePara elsevierViewall">Os avan&#231;os na compreens&#227;o da patog&#234;nese&#44; especialmente das vias de ativa&#231;&#227;o dos sistemas imunes inato e adaptativo&#44; abriram um novo campo de pesquisa para uma nova gera&#231;&#227;o de f&#225;rmacos&#44; os chamados imunobiol&#243;gicos&#46;<a class="elsevierStyleCrossRef" href="#bib0630"><span class="elsevierStyleSup">56</span></a> Os principais alvos terap&#234;uticos s&#227;o as vias de ativa&#231;&#227;o das c&#233;lulas&#160;B&#44; c&#233;lulas&#160;T e CDP&#44; al&#233;m das citocinas pr&#243;&#8208;inflamat&#243;rias&#44; seus receptores e vias de sinaliza&#231;&#227;o intracelular&#44; como IL&#8208;6&#44; IL&#8208;12&#44; IL&#8208;23&#44; IFN e via de sinaliza&#231;&#227;o JAK&#47;STAT&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;14&#44;60</span></a></p><p id="par0595" class="elsevierStylePara elsevierViewall">Alvo nas c&#233;lulas&#160;B&#58; o belimumabe &#233; um anticorpo monoclonal contra o fator de ativa&#231;&#227;o de c&#233;lulas&#160;B &#40;<span class="elsevierStyleItalic">Blys</span>&#41;&#44; aprovado pelo FDA para uso no LES&#46; Os estudos originais n&#227;o inclu&#237;ram an&#225;lise espec&#237;fica do desfecho das les&#245;es cut&#226;neas&#44; embora an&#225;lises posteriores tenham demonstrado melhora do quadro cut&#226;neo&#46; A efic&#225;cia no LEC est&#225; em investiga&#231;&#227;o em estudos de fase&#160;III&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> Tr&#234;s estudos observacionais&#44; com uso do rituximabe&#44; anticorpo monoclonal anti&#8208;CD20&#44; nas manifesta&#231;&#245;es mucocut&#226;neas do LE&#44; apresentaram taxas de resposta variando entre&#160;35&#37;&#160;e&#160;76&#37;&#46; Resposta mais favor&#225;vel foi verificada no LECA &#8211; no entanto&#44; sem evid&#234;ncia de efeito ben&#233;fico nos subtipos subagudo e cr&#244;nico do LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">57</span></a></p><p id="par0600" class="elsevierStylePara elsevierViewall">Alvo nas vias do interferon&#58; as tentativas de inibi&#231;&#227;o espec&#237;fica dos IFN n&#227;o apresentaram resultados satisfat&#243;rios nos ensaios cl&#237;nicos&#44; provavelmente pela grande redund&#226;ncia entre os diferentes tipos de IFN&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> O bloqueio do receptor de IFN apresenta uma perspectiva mais animadora&#46; O anifrolumabe&#44; um anticorpo monoclonal contra o receptor do IFN tipo&#160;I&#44; reduziu os escores de atividade das les&#245;es cut&#226;neas em pacientes com LES em ensaio cl&#237;nico de fase&#160;IIb&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a></p><p id="par0605" class="elsevierStylePara elsevierViewall">Alvo na via JAK&#47;STAT&#58; essa via &#233; importante para o mecanismo de retroalimenta&#231;&#227;o positiva do IFN&#46; A primeira gera&#231;&#227;o de inibidores &#8211; baricitinibe e ruxolitinibe &#8211; mostrou efic&#225;cia em pequeno n&#250;mero de pacientes com LE perni&#243;tico&#46; A segunda gera&#231;&#227;o de inibidores est&#225; sendo testada em ensaios cl&#237;nicos&#46;<a class="elsevierStyleCrossRef" href="#bib0420"><span class="elsevierStyleSup">14</span></a></p></span></span><span id="sec0155" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0165">Considera&#231;&#245;es finais</span><p id="par0610" class="elsevierStylePara elsevierViewall">LEC &#233; doen&#231;a autoimune multifatorial&#44; resultante da intera&#231;&#227;o de fatores ambientais&#44; gen&#233;ticos e imunol&#243;gicos&#44; que se apresenta com variada manifesta&#231;&#227;o dermatol&#243;gica&#46; O reconhecimento do subtipo cl&#237;nico &#233; importante na abordagem diagn&#243;stica&#44; na decis&#227;o terap&#234;utica e na determina&#231;&#227;o do progn&#243;stico&#44; tanto na doen&#231;a exclusivamente cut&#226;nea quanto no contexto do LES&#46;</p><p id="par0615" class="elsevierStylePara elsevierViewall">Crit&#233;rios diagn&#243;sticos para defini&#231;&#227;o dos diferentes subtipos de LEC ainda s&#227;o incipientes&#46; Aguardam&#8208;se crit&#233;rios mais assertivos que possam ser futuramente incorporados na pr&#225;tica cl&#237;nica e nos ensaios terap&#234;uticos&#44; auxiliando na avalia&#231;&#227;o das manifesta&#231;&#245;es cut&#226;neas do LE&#46;</p><p id="par0620" class="elsevierStylePara elsevierViewall">Fotoprote&#231;&#227;o&#44; corticosteroides t&#243;picos e antimal&#225;ricos ainda permanecem como primeira linha no tratamento do LEC&#46; Medica&#231;&#245;es alternativas de uso sist&#234;mico incluem MTX&#44; retinoides orais&#44; dapsona e talidomida&#44; entre outros&#46; Com o avan&#231;o no conhecimento da patog&#234;nese da doen&#231;a&#44; novas estrat&#233;gias terap&#234;uticas v&#234;m sendo desenvolvidas&#44; tendo como alvos as diferentes vias de ativa&#231;&#227;o imune que t&#234;m sido identificadas&#46;</p></span><span id="sec0160" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0170">Suporte financeiro</span><p id="par0625" class="elsevierStylePara elsevierViewall">Nenhum&#46;</p></span><span id="sec0165" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0175">Contribui&#231;&#227;o dos autores</span><p id="par0630" class="elsevierStylePara elsevierViewall">Everton Carlos Siviero do Vale&#58; Concep&#231;&#227;o e desenho do estudo&#59; Revis&#227;o cr&#237;tica da literatura&#59; Elabora&#231;&#227;o e reda&#231;&#227;o do manuscrito&#59; Revis&#227;o cr&#237;tica do manuscrito&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0635" class="elsevierStylePara elsevierViewall">Lucas Campos Garcia&#58; Revis&#227;o cr&#237;tica da literatura&#59; Elabora&#231;&#227;o e reda&#231;&#227;o do manuscrito&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p></span><span id="sec0170" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0180">Conflito de interesses</span><p id="par0640" class="elsevierStylePara elsevierViewall">Nenhum&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:14 [
        0 => array:3 [
          "identificador" => "xres1897469"
          "titulo" => "Resumo"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1641676"
          "titulo" => "Palavras&#8208;chave"
        ]
        2 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introdu&#231;&#227;o"
        ]
        3 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Classifica&#231;&#227;o"
        ]
        4 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Etiopatog&#234;nese"
        ]
        5 => array:3 [
          "identificador" => "sec0020"
          "titulo" => "Apresenta&#231;&#227;o cl&#237;nica e diagn&#243;stico diferencial"
          "secciones" => array:6 [
            0 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "L&#250;pus eritematoso cut&#226;neo agudo"
            ]
            1 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "L&#250;pus eritematoso cut&#226;neo subagudo"
            ]
            2 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "L&#250;pus eritematoso cut&#226;neo cr&#244;nico"
            ]
            3 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "L&#250;pus eritematoso cut&#226;neo intermitente"
            ]
            4 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "L&#250;pus eritematoso bolhoso"
            ]
            5 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Manifesta&#231;&#245;es cut&#226;neas inespec&#237;ficas do l&#250;pus eritematoso"
            ]
          ]
        ]
        6 => array:3 [
          "identificador" => "sec0055"
          "titulo" => "Diagn&#243;stico"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "sec0060"
              "titulo" => "Histopatologia"
            ]
            1 => array:2 [
              "identificador" => "sec0065"
              "titulo" => "Imuno&#8208;histologia"
            ]
            2 => array:2 [
              "identificador" => "sec0070"
              "titulo" => "Anticorpos antinucleares"
            ]
            3 => array:2 [
              "identificador" => "sec0075"
              "titulo" => "Avalia&#231;&#227;o da atividade e dano cut&#226;neos"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0080"
          "titulo" => "Progress&#227;o de l&#250;pus cut&#226;neo a l&#250;pus eritematoso sist&#234;mico"
        ]
        8 => array:3 [
          "identificador" => "sec0085"
          "titulo" => "Tratamento"
          "secciones" => array:13 [
            0 => array:2 [
              "identificador" => "sec0090"
              "titulo" => "Medidas gerais"
            ]
            1 => array:2 [
              "identificador" => "sec0095"
              "titulo" => "Tratamento t&#243;pico"
            ]
            2 => array:2 [
              "identificador" => "sec0100"
              "titulo" => "Tratamento sist&#234;mico"
            ]
            3 => array:2 [
              "identificador" => "sec0105"
              "titulo" => "Antimal&#225;ricos"
            ]
            4 => array:2 [
              "identificador" => "sec0110"
              "titulo" => "Metotrexato"
            ]
            5 => array:2 [
              "identificador" => "sec0115"
              "titulo" => "Retinoides sist&#234;micos"
            ]
            6 => array:2 [
              "identificador" => "sec0120"
              "titulo" => "Dapsona"
            ]
            7 => array:2 [
              "identificador" => "sec0125"
              "titulo" => "Micofenolato de mofetila"
            ]
            8 => array:2 [
              "identificador" => "sec0130"
              "titulo" => "Azatioprina"
            ]
            9 => array:2 [
              "identificador" => "sec0135"
              "titulo" => "Talidomida"
            ]
            10 => array:2 [
              "identificador" => "sec0140"
              "titulo" => "Corticosteroides sist&#234;micos"
            ]
            11 => array:2 [
              "identificador" => "sec0145"
              "titulo" => "Outros tratamentos"
            ]
            12 => array:2 [
              "identificador" => "sec0150"
              "titulo" => "Terapias&#8208;alvo"
            ]
          ]
        ]
        9 => array:2 [
          "identificador" => "sec0155"
          "titulo" => "Considera&#231;&#245;es finais"
        ]
        10 => array:2 [
          "identificador" => "sec0160"
          "titulo" => "Suporte financeiro"
        ]
        11 => array:2 [
          "identificador" => "sec0165"
          "titulo" => "Contribui&#231;&#227;o dos autores"
        ]
        12 => array:2 [
          "identificador" => "sec0170"
          "titulo" => "Conflito de interesses"
        ]
        13 => array:1 [
          "titulo" => "Refer&#234;ncias"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2022-06-27"
    "fechaAceptado" => "2022-09-12"
    "PalabrasClave" => array:1 [
      "pt" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palavras&#8208;chave"
          "identificador" => "xpalclavsec1641676"
          "palabras" => array:5 [
            0 => "Doen&#231;as autoimunes"
            1 => "L&#250;pus eritematoso cut&#226;neo"
            2 => "L&#250;pus eritematoso discoide"
            3 => "L&#250;pus eritematoso sist&#234;mico"
            4 => "Paniculite l&#250;pica"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:1 [
      "pt" => array:2 [
        "titulo" => "Resumo"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">O l&#250;pus eritematoso cut&#226;neo &#233; doen&#231;a autoimune de express&#227;o cl&#237;nica variada&#44; que pode apresentar&#8208;se como doen&#231;a exclusivamente cut&#226;nea ou ser uma das m&#250;ltiplas manifesta&#231;&#245;es do l&#250;pus eritematoso sist&#234;mico&#46; Sua classifica&#231;&#227;o engloba os subtipos agudo&#44; subagudo&#44; intermitente&#44; cr&#244;nico e bolhoso&#44; que s&#227;o usualmente identificados com base nas caracter&#237;sticas cl&#237;nicas e nos achados histopatol&#243;gicos e laboratoriais&#46; Outras manifesta&#231;&#245;es cut&#226;neas n&#227;o espec&#237;ficas podem estar associadas ao l&#250;pus eritematoso sist&#234;mico e geralmente guardam rela&#231;&#227;o com a atividade da doen&#231;a&#46; Fatores ambientais&#44; gen&#233;ticos e imunol&#243;gicos participam da patog&#234;nese das les&#245;es cut&#226;neas do l&#250;pus eritematoso&#46; Recentemente&#44; tem havido consider&#225;vel progresso na elucida&#231;&#227;o dos mecanismos envolvidos no seu desenvolvimento&#44; o que possibilita antever futuros alvos de tratamentos mais efetivos&#46; Esta revis&#227;o se prop&#245;e a discutir os principais aspectos etiopatog&#234;nicos&#44; cl&#237;nicos&#44; diagn&#243;sticos e terap&#234;uticos do l&#250;pus eritematoso cut&#226;neo&#44; visando &#224; atualiza&#231;&#227;o de internistas e de especialistas de diferentes &#225;reas&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:2 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Como citar este artigo&#58; Vale EC&#44; Garcia LC&#46; Cutaneous lupus erythematosus&#58; a review of etiopathogenic&#44; clinical&#44; diagnostic and therapeutic aspects&#46; An Bras Dermatol&#46; 2023&#59;98&#58;355&#8211;72&#46;</p>"
      ]
      1 => array:2 [
        "etiqueta" => "&#9734;&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0025">Trabalho realizado no Servi&#231;o de Dermatologia&#44; Hospital das Cl&#237;nicas&#44; Universidade Federal de Minas Gerais&#44; Belo Horizonte&#44; MG&#44; Brasil&#46;</p>"
      ]
    ]
    "multimedia" => array:10 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2634
            "Ancho" => 1675
            "Tamanyo" => 251439
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">L&#250;pus eritematoso cut&#226;neo agudo&#46; &#40;A&#41; Forma localizada&#58; eritema em asa de borboleta nas regi&#245;es malares&#46; &#40;B&#41; Forma disseminada&#58; erup&#231;&#227;o papuloescamosa sim&#233;trica acometendo tronco e membros superiores&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figura 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1397
            "Ancho" => 2925
            "Tamanyo" => 255607
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; L&#250;pus eritematoso cut&#226;neo subagudo&#58; placas eritemato&#8208;papuloescamosas anulares confluentes no t&#243;rax e nos membros superiores&#46; &#40;B&#41; L&#250;pus eritematoso neonatal&#58; placas eritematosas circulares e polic&#237;clicas na face&#46;</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "fig0015"
        "etiqueta" => "Figura 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 1499
            "Ancho" => 2508
            "Tamanyo" => 346263
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">L&#250;pus eritematoso cut&#226;neo cr&#244;nico&#46; &#40;A&#41; Forma discoide localizada no couro cabeludo&#44; com alopecia cicatricial&#46; &#40;B&#41; Forma discoide afetando a mucosa jugal&#46;</p>"
        ]
      ]
      3 => array:7 [
        "identificador" => "fig0020"
        "etiqueta" => "Figura 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr4.jpeg"
            "Alto" => 1973
            "Ancho" => 2508
            "Tamanyo" => 377939
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">L&#250;pus eritematoso cut&#226;neo cr&#244;nico&#46; &#40;A&#41; Variante verrucosa localizada no membro superior&#46; &#40;B&#41; Paniculite l&#250;pica acometendo o bra&#231;o e evoluindo com lipoatrofia&#46;</p>"
        ]
      ]
      4 => array:7 [
        "identificador" => "fig0025"
        "etiqueta" => "Figura 5"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr5.jpeg"
            "Alto" => 3171
            "Ancho" => 1675
            "Tamanyo" => 439940
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; L&#250;pus eritematoso t&#250;mido&#58; les&#245;es eritemato&#8208;edematosas arciformes e anulares na face e regi&#227;o cervical&#46; &#40;B&#41; L&#250;pus eritematoso bolhoso&#58; les&#245;es bolhosas&#44; ulcerocrostosas hem&#225;ticas e les&#245;es residuais hipocr&#244;micas&#44; localizadas na regi&#227;o cervical&#44; tronco&#44; axilas e membros superiores&#46;</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabela 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">ACR&#44; American College of Rheumatology&#59; EULAR&#44; European League Against Rheumatism&#59; SLICC&#44; Systemic Lupus International Collaborating Clinics&#59; FAN&#44; fator antin&#250;cleo&#59; LEC&#44; l&#250;pus eritematoso cut&#226;neo&#59; LES&#44; l&#250;pus eritematoso sist&#234;mico&#46;</p><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">ACR 1997&#58; LES &#8805; 4&#160;crit&#233;rios&#46;</p><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">SLICC 2012&#58; LES &#8805;&#160;4&#160;crit&#233;rios&#44; ao menos um cl&#237;nico e um imunol&#243;gico&#59; quadro de nefrite l&#250;pica comprovada por bi&#243;psia&#44; com FAN ou anti&#8208;DNAn&#44; tamb&#233;m pode ser classificado como LES&#46;</p><p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">EULAR&#47;ACR 2019&#58; LES &#61; escore &#8805; 10&#160;pontos&#44; ao menos um cl&#237;nico &#40;considera&#8208;se somente o crit&#233;rio com a pontua&#231;&#227;o mais alta em cada dom&#237;nio&#41;&#46;</p><p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Os crit&#233;rios dermatol&#243;gicos est&#227;o destacados em negrito nos tr&#234;s sistemas de classifica&#231;&#227;o&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">ACR 1997<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">4</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">SLICC 2012<a class="elsevierStyleCrossRef" href="#bib0390"><span class="elsevierStyleSup">8</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">EULAR&#47;ACR 2019<a class="elsevierStyleCrossRef" href="#bib0395"><span class="elsevierStyleSup">9</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Crit&#233;rio de entrada&#58;</span> nenhum&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Crit&#233;rio de entrada&#58;</span> nenhum&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Crit&#233;rio de entrada&#58;</span> FAN&#160;&#8805;&#160;1&#58;80&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Crit&#233;rios cl&#237;nicos &#40;&#61; 9&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Crit&#233;rios cl&#237;nicos &#40;&#61; 11&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Crit&#233;rios cl&#237;nicos &#40;pontos&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Erup&#231;&#227;o malar</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">LEC agudo&#44; subagudo ou LE bolhoso</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Constitucional&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Erup&#231;&#227;o discoide</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">LEC cr&#244;nico &#40;inclui LEC t&#250;mido&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Febre &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Fotossensibilidade</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">&#218;lceras orais ou nasais</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hematol&#243;gicos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">&#218;lceras orais</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Alopecia n&#227;o cicatricial</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Leucopenia &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Artrite n&#227;o erosiva &#40;&#8805; 2&#160;articula&#231;&#245;es&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Sinovite &#40;&#8805; 2&#160;articula&#231;&#245;es&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Trombocitopenia &#40;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Serosite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Serosite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Hem&#243;lise autoimune &#40;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Pleurite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Pleurite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Neuropsiqui&#225;tricos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Pericardite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Pericardite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Del&#237;rio &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Derrame pleural ou peric&#225;rdico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Derrame pleural ou peric&#225;rdico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Psicose &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Acometimento renal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Doen&#231;a renal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Convuls&#227;o &#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Protein&#250;ria<span class="elsevierStyleHsp" style=""></span>&#62; 0&#44;5 g&#47;24 horas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Protein&#250;ria<span class="elsevierStyleHsp" style=""></span>&#62; 0&#44;5 g&#47;24 horas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mucocut&#226;neos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Cilindros celulares&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Cilindros hem&#225;ticos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleBold">Alopecia n&#227;o cicatricial &#40;2&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Altera&#231;&#245;es neurol&#243;gicas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Doen&#231;a neurol&#243;gica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleBold">&#218;lceras orais &#40;2&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Convuls&#245;es&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Convuls&#245;es&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleBold">LEC subagudo ou LE &#40;4&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Psicose&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Psicose&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleBold">LEC agudo &#40;6&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Altera&#231;&#245;es hematol&#243;gicas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Mononeurite m&#250;ltipla&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Serosite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anemia hemol&#237;tica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Mielite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Derrame pleural ou peric&#225;rdico &#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Leucopenia &#40;&#60; 4&#46;000&#160;mm<span class="elsevierStyleSup">3</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Neuropatia craniana ou perif&#233;rica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Pericardite aguda &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Linfopenia &#40;&#60; 1&#46;500&#160;mm<span class="elsevierStyleSup">3</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Estado confusional agudo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Musculoesquel&#233;tico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Trombocitopenia &#40;&#60; 100&#46;000&#47;mm<span class="elsevierStyleSup">3</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Altera&#231;&#245;es hematol&#243;gicas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Acometimento articular &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anemia hemol&#237;tica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Leucopenia &#40;&#60; 4&#46;000&#160;mm<span class="elsevierStyleSup">3</span>&#41; ou linfopenia &#40;&#60; 1&#46;000 mm<span class="elsevierStyleSup">3</span>&#41;Trombocitopenia &#40;&#60; 100&#46;000&#47;mm<span class="elsevierStyleSup">3</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Renais&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Protein&#250;ria<span class="elsevierStyleHsp" style=""></span>&#62; 0&#44;5&#160;g&#47;24 horas &#40;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Bi&#243;psia renal &#8211; nefrite l&#250;pica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Classe II ou V &#40;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Bi&#243;psia renal &#8211; nefrite l&#250;pica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Classe III ou IV &#40;10&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Crit&#233;rios imunol&#243;gicos &#40;&#61; 2&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Crit&#233;rios imunol&#243;gicos &#40;&#61; 6&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Crit&#233;rios imunol&#243;gicos &#40;pontos&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">FAN&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">FAN&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anticorpos antifosfol&#237;pides&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Autoanticorpos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;DNAn&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anticardiolipina &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Anti&#8208;DNAn&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;Sm&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anti&#8208;&#946;2&#8208;glicoprote&#237;na 1 &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Anti&#8208;Sm&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anticorpo antifosfol&#237;pide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anticoagulante l&#250;pico &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Anticorpo antifosfol&#237;pide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anticoagulante l&#250;pico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complemento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Teste n&#227;o trepon&#234;mico falso&#8208;positivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>C3 ou C4 baixo &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anticardiolipina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>C3 e C4 baixos &#40;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anti&#8208;&#946;2&#8208;glicoprote&#237;na 1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anticorpos LES&#8208;espec&#237;ficos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complemento baixo &#40;C3&#44; C4 ou CH50&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anti&#8208;DNAn &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Coombs direto &#40;na aus&#234;ncia de anemia hemol&#237;tica&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anti&#8208;Sm &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3171299.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Crit&#233;rios de classifica&#231;&#227;o do l&#250;pus eritematoso sist&#234;mico &#8211; ACR 1997&#44; SLICC 2012 e EULAR&#47;ACR 2019</p>"
        ]
      ]
      6 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabela 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">LE&#44; l&#250;pus eritematoso&#59; NET&#44; necr&#243;lise epid&#233;rmica t&#243;xica&#46;</p>"
          "tablatextoimagen" => array:2 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Subtipos de LE cut&#226;neo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Variantes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE cut&#226;neo agudo</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Localizado&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Disseminado&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NET&#8208;s&#237;mile&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE cut&#226;neo subagudo</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anular polic&#237;clico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Papuloescamoso psoriasiforme&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">S&#237;ndrome de Rowell&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE neonatal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE cut&#226;neo intermitente&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE t&#250;mido&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="7" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE cut&#226;neo cr&#244;nico</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE discoide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE discoide mucoso&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE hipertr&#243;fico&#47;verrucoso&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE profundo&#47;paniculite l&#250;pica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE perni&#243;tico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE l&#237;quen plano&#8208;s&#237;mile&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE comedoniano&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE bolhoso&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3171298.png"
              ]
            ]
            1 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Natureza da altera&#231;&#227;o&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Manifesta&#231;&#245;es inespec&#237;ficas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Vascular&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fen&#244;meno de Raynaud&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Livedo reticular&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Livedo racemoso&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Vasculites&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Vasculopatia livedoide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Papulose do tipo doen&#231;a de Degos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Necrose cut&#226;nea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hemorragia em estilha&#231;o&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Tromboflebite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Neutrof&#237;lica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE bolhoso&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Urtic&#225;ria vasculite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatose urticariana neutrof&#237;lica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pustulose amicrobiana das dobras&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">S&#237;ndrome de Sweet&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pioderma gangrenoso&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#227;o definida&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alopecia n&#227;o cicatricial difusa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#218;lceras mucosas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#243;dulos reumatoides&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatite granulomatosa intersticial&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatofibroma eruptivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3171297.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Subtipos cl&#237;nicos e manifesta&#231;&#245;es cut&#226;neas inespec&#237;ficas do l&#250;pus eritematoso</p>"
        ]
      ]
      7 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Tabela 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0011" class="elsevierStyleSimplePara elsevierViewall">Adaptado de Borucki &#38; Werth&#44; 2020&#46;<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">23</span></a>&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Classe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Subclasse&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Medicamento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;hipertensivos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Diur&#233;ticos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hidroclorotiazida&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inibidores da enzima conversora da angiotensina</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Captopril&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cilazapril&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Enalapril&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Lisinopril&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ramipril&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Betabloqueadores&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Acebutolol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bloqueadores do canal de c&#225;lcio&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Diltiazem&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Nifedipina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Nitrendipina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Verapamil&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inibidores da bomba de pr&#243;tons&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Esomeprazol<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Lasanoprazol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Omeprazol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pantoprazol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Antif&#250;ngicos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Griseofulvina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Terbinafina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anticonvulsivantes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Carbamazepina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fenito&#237;na&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Estatinas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pravastatina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Sinvastatina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;histam&#237;nicos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bromofeniramina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cinarizina &#43; tietilperazina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ranitidina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Antibi&#243;ticos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Amoxicilina &#43; clavulanato&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ciprofloxacina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;inflamat&#243;rios n&#227;o esteroides&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Naproxeno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Piroxicam&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Quimioter&#225;picos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#8208;fluoruracil<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Capecitabina<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Docetaxel&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Doxorubicina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Gencitabina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Masitinibe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mitotane&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Nivolumabe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Paclitaxel&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Palbociclibe<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pembrolizumabe<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Tamoxifeno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Tegafur&#47;uracil<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Biol&#243;gicos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;TNF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Adalimumabe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Etanercepte&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Golimumabe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximabe<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;CD80&#47;86&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Abatacepte&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;CD11a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Efalizumabe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;IL12&#47;23&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ustekinumabe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;IL17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Secukinumabe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Antidepressivos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bupropiona&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Outras&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alopurinol<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anastrazol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Interferon&#8208;&#945; e &#946;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Imuglobulina intravenosa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Leflunomida<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Leuprorrelina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ticlopidina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Tiotr&#243;pio&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3171295.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Tamb&#233;m desencadeantes de l&#250;pus eritematoso cut&#226;neo cr&#244;nico&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Medicamentos referidos como desencadeantes de l&#250;pus eritematoso cut&#226;neo subagudo</p>"
        ]
      ]
      8 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Tabela 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Adaptado de Kuhn et al&#46;&#44; 2014&#46;<a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">48</span></a>&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Exames de rotina</span> &#40;suspeita de LEC&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hemograma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Velocidade de hemossedimenta&#231;&#227;o eritrocit&#225;ria&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Prote&#237;na C reativa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">FAN &#40;HEp&#8208;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Enzimas hep&#225;ticas &#40;TGO&#44; TGP&#44; FA&#44; GGT&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fun&#231;&#227;o renal &#40;ureia&#44; creatinina&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Urina &#40;EAS&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Exames especiais</span> &#40;LEC confirmado&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anticorpos espec&#237;ficos &#40;anti&#8208;DNAn&#44; &#8208;Sm&#44; &#8208;Ro&#47;SS&#8208;A&#44; &#8208;La&#47;SS&#8208;B&#44; &#8208;RNPn&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complemento s&#233;rico &#40;C3&#44; C4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anticorpos antifosfol&#237;pides &#40;anticardiolipinas IgG e IgM&#59;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">anticoagulante l&#250;pico&#59; &#946;2&#8208;glicoprote&#237;na I&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fator reumatoide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Imunoglobulinas &#40;imunoeletroforese&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">TSH&#44; T4&#44; anticorpos antitireoidianos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Prote&#237;nas urin&#225;rias 24 horas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Clearance</span> da creatinina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Glicose&#8208;6&#8208;fosfato desidrogenase&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3171300.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Avalia&#231;&#227;o laboratorial recomendada no l&#250;pus eritematoso cut&#226;neo &#40;LEC&#41;</p>"
        ]
      ]
      9 => array:8 [
        "identificador" => "tbl0025"
        "etiqueta" => "Tabela 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at5"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">Adaptado de Yan et al&#46;&#44; 2020&#46;&#91;58&#93;&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Medica&#231;&#227;o&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&#237;vel de evid&#234;ncia<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Grau de recomenda&#231;&#227;o<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hidroxicloroquina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Acitretina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Isotretino&#237;na&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Metotrexato&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dapsona&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Talidomida&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Micofenolato de mofetila&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Azatioprina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Belimumabe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3171296.png"
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">N&#237;vel de evid&#234;ncia&#58; 1 &#8211; Ensaio cl&#237;nico randomizado &#40;ECR&#41;&#44; revis&#245;es sistem&#225;ticas &#40;RS&#41;&#47;metan&#225;lise de ECR&#59; 2 &#8211; RS de estudos de coorte&#44; coortes&#59; 3 &#8211; RS de estudos caso&#8208;controle&#44; estudos de caso&#8208;controle&#59; 4 &#8211; S&#233;rie de casos&#44; coorte e caso&#8208;controle de baixa qualidade&#59; 5 &#8211; Opini&#227;o de especialistas&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Grau de recomenda&#231;&#227;o&#58; A &#8211; Estudos observacionais ou experimentais de maior consist&#234;ncia &#40;metan&#225;lises ou ECR&#41;&#59; B &#8211; Estudos observacionais de menor consist&#234;ncia &#40;outros ensaios cl&#237;nicos n&#227;o randomizados ou observacionais ou caso&#8208;controle&#41;&#59; C &#8211; Relatos ou s&#233;ries de casos &#40;estudos n&#227;o controlados&#41;&#59; D &#8211; Opini&#227;o desprovida de avalia&#231;&#227;o cr&#237;tica&#44; baseadas em consensos&#44; estudos fisiol&#243;gicos ou modelos animais&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">N&#237;vel de evid&#234;ncia e grau de recomenda&#231;&#227;o dos principais medicamentos de uso sist&#234;mico no l&#250;pus eritematoso cut&#226;neo</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Refer&#234;ncias"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:70 [
            0 => array:3 [
              "identificador" => "bib0355"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus erythematosus&#58; new insights into pathogenesis and therapeutic strategies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "J&#46; Wenzel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/s41584-019-0272-0"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nat Rev Rheumatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "15"
                        "paginaInicial" => "519"
                        "paginaFinal" => "532"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31399711"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0360"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous manifestations of &#8220;lupus&#8221;&#58; systemic lupus erythematosus and beyond"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "E&#46;E&#46; Cooper"
                            1 => "C&#46;E&#46; Pisano"
                            2 => "S&#46;C&#46; Shapiro"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Int J Rheumatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "2021"
                        "paginaInicial" => "6610509"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0365"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus erythematosus&#58; clinico&#8208;pathologic correlation"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "R&#46; Filotico"
                            1 => "V&#46; Mastrandrea"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.23736/S0392-0488.18.05929-1"
                      "Revista" => array:6 [
                        "tituloSerie" => "G Ital Dermatol Venereol&#46;"
                        "fecha" => "2018"
                        "volumen" => "153"
                        "paginaInicial" => "216"
                        "paginaFinal" => "229"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29368845"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0370"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus erythematosus&#58; progress and challenges"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46;J&#46; Petty"
                            1 => "L&#46; Floyd"
                            2 => "C&#46; Henderson"
                            3 => "M&#46;W&#46; Nicholas"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s11882-020-00906-8"
                      "Revista" => array:5 [
                        "tituloSerie" => "Curr Allergy Asthma Rep&#46;"
                        "fecha" => "2020"
                        "volumen" => "20"
                        "paginaInicial" => "12"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32248318"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0375"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A review of cutaneous lupus erythematosus&#58; improving outcomes with a multidisciplinary approach"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "P&#46; Jarrett"
                            1 => "V&#46;P&#46; Werth"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2147/JMDH.S179623"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Multidiscip Healthc&#46;"
                        "fecha" => "2019"
                        "volumen" => "12"
                        "paginaInicial" => "419"
                        "paginaFinal" => "428"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31213824"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0380"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus erythematosus&#58; a review of the literature"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "S&#46;C&#46; Blake"
                            1 => "B&#46;S&#46; Daniel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ijwd.2019.07.004"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Womens Dermatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "5"
                        "paginaInicial" => "320"
                        "paginaFinal" => "329"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31909151"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0385"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A quality&#8208;of&#8208;life study of cutaneous lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46; Batalla"
                            1 => "I&#46; Garc&#237;a-Doval"
                            2 => "G&#46; Pe&#243;n"
                            3 => "C&#46; de la Torre"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2013.04.005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr&#46;"
                        "fecha" => "2013"
                        "volumen" => "104"
                        "paginaInicial" => "800"
                        "paginaFinal" => "806"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23787361"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0390"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Petri"
                            1 => "A&#46;M&#46; Orbai"
                            2 => "G&#46;S&#46; Alarc&#243;n"
                            3 => "C&#46; Gordon"
                            4 => "J&#46;T&#46; Merrill"
                            5 => "P&#46;R&#46; Fortin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.34473"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum&#46;"
                        "fecha" => "2012"
                        "volumen" => "64"
                        "paginaInicial" => "2677"
                        "paginaFinal" => "2686"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22553077"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0395"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2019 European League Against Rheumatism&#47;American College of Rheumatology classification criteria for systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Aringer"
                            1 => "K&#46; Costenbader"
                            2 => "D&#46; Daikh"
                            3 => "R&#46; Brinks"
                            4 => "M&#46; Mosca"
                            5 => "R&#46; Ramsey-Goldman"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Arthritis Rheumatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "71"
                        "paginaInicial" => "1400"
                        "paginaFinal" => "1412"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0400"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The performance of different classification criteria for systemic lupus erythematosus in a real&#8208;world rheumatology department"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "B&#46;C&#46;H&#46; Tan"
                            1 => "I&#46; Tang"
                            2 => "J&#46; Bonin"
                            3 => "R&#46; Koelmeyer"
                            4 => "A&#46; Hoi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rheumatology &#40;Oxford&#41;&#46;"
                        "fecha" => "2022"
                        "volumen" => "00"
                        "paginaInicial" => "1"
                        "paginaFinal" => "5"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0405"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The cutaneous spectrum of lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "S&#46; Ribero"
                            1 => "S&#46; Sciascia"
                            2 => "L&#46; Borradori"
                            3 => "D&#46; Lipsker"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s12016-017-8627-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Rev Allergy Immunol&#46;"
                        "fecha" => "2017"
                        "volumen" => "53"
                        "paginaInicial" => "291"
                        "paginaFinal" => "305"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28752372"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0410"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus erythematosus&#58; an update on pathogenesis&#44; diagnosis and treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "E&#46;Z&#46; Hejazi"
                            1 => "V&#46;P&#46; Werth"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40257-016-0173-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Clin Dermatol&#46;"
                        "fecha" => "2016"
                        "volumen" => "17"
                        "paginaInicial" => "135"
                        "paginaFinal" => "146"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26872954"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0415"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Creation and validation of classification criteria for discoid lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;A&#46; Elman"
                            1 => "C&#46; Joyce"
                            2 => "K&#46; Braudis"
                            3 => "B&#46;F&#46; Chong"
                            4 => "A&#46;P&#46; Fernandez"
                            5 => "F&#46; Furukawa"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2020"
                        "volumen" => "156"
                        "paginaInicial" => "901"
                        "paginaFinal" => "906"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0420"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus erythematosus&#58; current and future pathogenesis&#8208;directed therapies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A&#46;J&#46; Little"
                            1 => "M&#46;D&#46; Vesely"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Yale J Biol Med&#46;"
                        "fecha" => "2020"
                        "volumen" => "93"
                        "paginaInicial" => "81"
                        "paginaFinal" => "95"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32226339"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0425"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus erythematosus&#58; clinical aspects and molecular pathogenesis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "V&#46; Oke"
                            1 => "M&#46; Wahren-Herlenius"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/joim.12057"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Intern Med&#46;"
                        "fecha" => "2013"
                        "volumen" => "273"
                        "paginaInicial" => "544"
                        "paginaFinal" => "554"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23464352"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0430"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "An update on the pathogenesis of skin damage in lupus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "Q&#46; Li"
                            1 => "H&#46; Wu"
                            2 => "S&#46; Zhou"
                            3 => "M&#46; Zhao"
                            4 => "Q&#46; Lu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Curr Rheumatol Rep&#46;"
                        "fecha" => "2020"
                        "volumen" => "22"
                        "paginaInicial" => "16"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0435"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Current insights in cutaneous lupus erythematosus immunopathogenesis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "C&#46;J&#46; Garelli"
                            1 => "M&#46;A&#46; Refat"
                            2 => "P&#46;P&#46; Nanaware"
                            3 => "Z&#46;G&#46; Ramirez-Ortiz"
                            4 => "M&#46; Rashighi"
                            5 => "J&#46;M&#46; Richmond"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3389/fimmu.2020.01353"
                      "Revista" => array:5 [
                        "tituloSerie" => "Front Immunol&#46;"
                        "fecha" => "2020"
                        "volumen" => "11"
                        "paginaInicial" => "1353"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32714331"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0440"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Immunopathogenesis of skin injury in systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "G&#46;A&#46; Hile"
                            1 => "J&#46;M&#46; Kahlenberg"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/BOR.0000000000000770"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Opin Rheumatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "33"
                        "paginaInicial" => "173"
                        "paginaFinal" => "180"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33315653"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0445"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A comprehensive review of immune&#8208;mediated dermatopathology in systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "Q&#46; Li"
                            1 => "H&#46; Wu"
                            2 => "W&#46; Liao"
                            3 => "M&#46; Zhao"
                            4 => "V&#46; Chan"
                            5 => "L&#46; Li"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaut.2018.07.007"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Autoimmun&#46;"
                        "fecha" => "2018"
                        "volumen" => "93"
                        "paginaInicial" => "1"
                        "paginaFinal" => "15"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30017673"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0450"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The prevalence of oral mucosal lesions and related factors in systemic lupus erythematosus patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "M&#46; Kudsi"
                            1 => "L&#46;D&#46; Nahas"
                            2 => "R&#46; Alsawah"
                            3 => "A&#46; Hamsho"
                            4 => "A&#46; Omar"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s13075-021-02614-8"
                      "Revista" => array:5 [
                        "tituloSerie" => "Arthritis Res Ther&#46;"
                        "fecha" => "2021"
                        "volumen" => "23"
                        "paginaInicial" => "229"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34479636"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0455"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Toxic epidermal necrolysis&#8208;like lupus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "E&#46;J&#46; Roberts"
                            1 => "V&#46; Melchionda"
                            2 => "G&#46; Saldanha"
                            3 => "S&#46; Shaffu"
                            4 => "J&#46; Royle"
                            5 => "K&#46;E&#46; Harman"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ced.14648"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "46"
                        "paginaInicial" => "1299"
                        "paginaFinal" => "1303"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33760256"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0460"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Oral lesions in lupus erythematosus&#58; correlation with cutaneous lesions"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "M&#46;M&#46; Nico"
                            1 => "M&#46;A&#46; Vilela"
                            2 => "E&#46;A&#46; Rivitti"
                            3 => "S&#46;V&#46; Louren&#231;o"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Eur J Dermatol&#46;"
                        "fecha" => "2008"
                        "volumen" => "18"
                        "paginaInicial" => "376"
                        "paginaFinal" => "381"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0465"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus erythematosus induced by drugs &#8208; novel insights"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "R&#46; Borucki"
                            1 => "V&#46;P&#46; Werth"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/17512433.2020.1698290"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Rev Clin Pharmacol&#46;"
                        "fecha" => "2020"
                        "volumen" => "13"
                        "paginaInicial" => "35"
                        "paginaFinal" => "42"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31774327"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0470"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Drug&#8208;induced lupus erythematosus&#58; an update on drugs and mechanisms"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "Y&#46; He"
                            1 => "A&#46;H&#46; Sawalha"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/BOR.0000000000000522"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Opin Rheumatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "30"
                        "paginaInicial" => "490"
                        "paginaFinal" => "497"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29870500"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0475"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "An update in drug&#8208;induced subacute cutaneous lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "T&#46;C&#46; Michaelis"
                            1 => "R&#46;D&#46; Sontheimer"
                            2 => "G&#46;C&#46; Lowe"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Dermatol Online J&#46;"
                        "fecha" => "2017"
                        "volumen" => "23"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0480"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous drug&#8208;induced lupus erythematosus&#58; clinical and immunological characteristics and update on new associated drugs"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Bataille"
                            1 => "F&#46; Chasset"
                            2 => "J&#46;B&#46; Monfort"
                            3 => "T&#46; De Risi-Pugliese"
                            4 => "A&#46; Soria"
                            5 => "C&#46; Franc&#232;s"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.annder.2021.02.006"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Dermatol Venereol&#46;"
                        "fecha" => "2021"
                        "volumen" => "148"
                        "paginaInicial" => "211"
                        "paginaFinal" => "220"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34711400"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0485"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Trigger factors of cutaneous lupus erythematosus&#58; a review of current literature"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "J&#46; Szcz&#281;ch"
                            1 => "D&#46; Samotij"
                            2 => "V&#46;P&#46; Werth"
                            3 => "A&#46; Reich"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/0961203317691369"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lupus&#46;"
                        "fecha" => "2017"
                        "volumen" => "26"
                        "paginaInicial" => "791"
                        "paginaFinal" => "807"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28173739"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0490"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The last word on the so&#8208;called&#8217;Rowell&#39;s syndrome&#8217;&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "E&#46; Antiga"
                            1 => "M&#46; Caproni"
                            2 => "D&#46; Bonciani"
                            3 => "V&#46; Bonciolini"
                            4 => "P&#46; Fabbri"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/0961203311430513"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lupus&#46;"
                        "fecha" => "2012"
                        "volumen" => "21"
                        "paginaInicial" => "577"
                        "paginaFinal" => "585"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22170759"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0495"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Neonatal lupus erythematosus &#8208; practical guidelines"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;M&#46; Derdulska"
                            1 => "L&#46; Rudnicka"
                            2 => "A&#46; Szykut-Badaczewska"
                            3 => "D&#46; Mehrholz"
                            4 => "R&#46;J&#46; Nowicki"
                            5 => "W&#46; Bara&#324;ska-Rybak"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1515/jpm-2020-0543"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Perinat Med&#46;"
                        "fecha" => "2021"
                        "volumen" => "49"
                        "paginaInicial" => "529"
                        "paginaFinal" => "538"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33470961"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0500"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Recognition and management of cutaneous connective tissue diseases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "K&#46;J&#46;B&#46; Kus"
                            1 => "A&#46;H&#46; LaChance"
                            2 => "R&#46;A&#46; Vleugels"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.mcna.2021.04.011"
                      "Revista" => array:6 [
                        "tituloSerie" => "Med Clin North Am&#46;"
                        "fecha" => "2021"
                        "volumen" => "105"
                        "paginaInicial" => "757"
                        "paginaFinal" => "782"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34059249"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0505"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Development of chronic cutaneous lupus erythematosus during biologic therapy&#58; a systematic review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46; Mirali"
                            1 => "A&#46; Mufti"
                            2 => "R&#46;P&#46; Lansang"
                            3 => "M&#46; Sachdeva"
                            4 => "J&#46; Yeung"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "84"
                        "paginaInicial" => "835"
                        "paginaFinal" => "838"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0510"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Oral manifestations of lupus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "S&#46; Menzies"
                            1 => "F&#46; O&#39;Shea"
                            2 => "S&#46; Galvin"
                            3 => "B&#46; Wynne"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s11845-017-1622-z"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ir J Med Sci&#46;"
                        "fecha" => "2018"
                        "volumen" => "187"
                        "paginaInicial" => "91"
                        "paginaFinal" => "93"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28470356"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0515"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lupus erythematosus&#47;lichen planus overlap syndrome&#58; successful treatment with acitretin"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "D&#46;J&#46; Lospinoso"
                            1 => "C&#46; Fernelius"
                            2 => "K&#46;D&#46; Edhegard"
                            3 => "D&#46;R&#46; Finger"
                            4 => "N&#46;S&#46; Arora"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/0961203313492243"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lupus&#46;"
                        "fecha" => "2013"
                        "volumen" => "22"
                        "paginaInicial" => "851"
                        "paginaFinal" => "854"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23761099"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0520"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Seven&#8208;year itch&#58; a perplexing case of lichen planus&#8208;lupus erythematosus overlap syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "S&#46; Schmitz"
                            1 => "M&#46; Vatanchi"
                            2 => "U&#46; Alapati"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Dermatol Online J&#46;"
                        "fecha" => "2018"
                        "volumen" => "24"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0525"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Association of chilblain lupus and anti&#8208;Ro&#47;SSA and anti&#8208;La&#47;SSB antibodies&#58; a study of 30 cases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "D&#46; Canu"
                            1 => "J&#46;F&#46; Viallard"
                            2 => "E&#46; Lazaro"
                            3 => "M&#46;S&#46; Doutre"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ijd.15553"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "60"
                        "paginaInicial" => "e509"
                        "paginaFinal" => "e511"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34021592"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0530"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Chilblains in immune mediated inflammatory diseases&#58; a review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46; Dubey"
                            1 => "N&#46; Joshi"
                            2 => "O&#46; Stevenson"
                            3 => "C&#46; Gordon"
                            4 => "J&#46;A&#46; Reynolds"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Rheumatology &#40;Oxford&#41;&#46;"
                        "fecha" => "2022"
                        "volumen" => "12"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0535"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comedonal variant of chronic cutaneous lupus erythematosus causing mutilation of the earlobe"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "E&#46; Cozzani"
                            1 => "A&#46; Herzum"
                            2 => "M&#46; Burlando"
                            3 => "A&#46; Parodi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jdcr.2020.06.009"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAAD Case Rep&#46;"
                        "fecha" => "2020"
                        "volumen" => "6"
                        "paginaInicial" => "843"
                        "paginaFinal" => "844"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32875034"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0540"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comedonic lupus&#58; an unusual presentation of cutaneous lupus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "C&#46; Chess&#233;"
                            1 => "M&#46;J&#46; Fern&#225;ndez-Tapia"
                            2 => "F&#46; Borzotta"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Actas Dermosifiliogr &#40;Engl Ed&#41;&#46;"
                        "fecha" => "2021"
                        "volumen" => "112"
                        "paginaInicial" => "370"
                        "paginaFinal" => "371"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0545"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comedogenic lupus&#58; a rare variant of chronic cutaneous lupus erythematosus &#8208; case series"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "L&#46;C&#46; Garcia"
                            1 => "I&#46;B&#46; Morato"
                            2 => "R&#46;F&#46;Q&#46; Melo"
                            3 => "E&#46;C&#46;S&#46; Vale"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "An Bras Dermatol&#46;"
                        "fecha" => "2023"
                        "volumen" => "98"
                        "paginaInicial" => "159"
                        "paginaFinal" => "167"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0550"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lupus erythematosus tumidus&#58; clinical perspectives"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "N&#46; Patsinakidis"
                            1 => "O&#46; Kautz"
                            2 => "B&#46;F&#46; Gibbs"
                            3 => "U&#46; Raap"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2147/CCID.S166723"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Cosmet Investig Dermatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "12"
                        "paginaInicial" => "707"
                        "paginaFinal" => "719"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31632119"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib0555"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "V&#46; Schmitt"
                            1 => "A&#46;M&#46; Meuth"
                            2 => "S&#46; Amler"
                            3 => "E&#46; Kuehn"
                            4 => "M&#46; Haust"
                            5 => "G&#46; Messer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2009.09401.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2010"
                        "volumen" => "162"
                        "paginaInicial" => "64"
                        "paginaFinal" => "73"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19712116"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib0560"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "L&#250;pus eritematoso sist&#234;mico bolhoso"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "V&#46; Aoki"
                            1 => "E&#46;C&#46;S&#46; Vale"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "LibroEditado" => array:5 [
                        "editores" => "V&#46;Aoki, C&#46;W&#46;Maruta, C&#46;G&#46;Santi"
                        "titulo" => "Dermatoses bolhosas autoimunes&#46;"
                        "paginaInicial" => "119"
                        "paginaFinal" => "128"
                        "serieFecha" => "2016"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib0565"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical&#44; histological&#44; immunological presentations and outcomes of bullous systemic lupus erythematosus&#58; 10 new cases and a literature review of 118 cases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; de Risi-Pugliese"
                            1 => "F&#46; Cohen-Aubart"
                            2 => "J&#46; Haroche"
                            3 => "P&#46; Moguelet"
                            4 => "S&#46; Grootenboer-Mignot"
                            5 => "A&#46; Mathian"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.semarthrit.2017.11.003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Semin Arthritis Rheum&#46;"
                        "fecha" => "2018"
                        "volumen" => "48"
                        "paginaInicial" => "83"
                        "paginaFinal" => "89"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29191376"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib0570"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Vesiculobullous diseases in relation to lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "S&#46; Rutnin"
                            1 => "K&#46; Chanprapaph"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2147/CCID.S220906"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Cosmet Investig Dermatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "12"
                        "paginaInicial" => "653"
                        "paginaFinal" => "667"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31564947"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib0575"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lupus erythematosus&#58; significance of dermatologic findings"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "C&#46; Lenormand"
                            1 => "D&#46; Lipsker"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.annder.2020.08.052"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Dermatol Venereol&#46;"
                        "fecha" => "2021"
                        "volumen" => "148"
                        "paginaInicial" => "6"
                        "paginaFinal" => "15"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33483145"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib0580"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Skin manifestations associated with systemic diseases &#8208; Part I"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46;L&#46; Sampaio"
                            1 => "A&#46;L&#46; Bressan"
                            2 => "B&#46;N&#46; Vasconcelos"
                            3 => "A&#46;C&#46; Gripp"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.abd.2021.02.008"
                      "Revista" => array:6 [
                        "tituloSerie" => "An Bras Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "96"
                        "paginaInicial" => "655"
                        "paginaFinal" => "671"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34544638"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib0585"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous manifestations of lupus erythematosus&#58; a practical clinicopathological review for pathologists"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "C&#46; Bitar"
                            1 => "T&#46;D&#46; Menge"
                            2 => "M&#46;P&#46; Chan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Histopathology&#46;"
                        "fecha" => "2022"
                        "volumen" => "80"
                        "paginaInicial" => "233"
                        "paginaFinal" => "250"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            47 => array:3 [
              "identificador" => "bib0590"
              "etiqueta" => "48"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The classification and diagnosis of cutaneous lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A&#46; Kuhn"
                            1 => "A&#46; Landmann"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "J Autoimmun&#46;"
                        "fecha" => "2014"
                        "paginaInicial" => "48"
                        "paginaFinal" => "49"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            48 => array:3 [
              "identificador" => "bib0595"
              "etiqueta" => "49"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Histologic features of cutaneous lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "M&#46; Baltaci"
                            1 => "P&#46; Fritsch"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.autrev.2008.12.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "Autoimmun Rev&#46;"
                        "fecha" => "2009"
                        "volumen" => "8"
                        "paginaInicial" => "467"
                        "paginaFinal" => "473"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19162243"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            49 => array:3 [
              "identificador" => "bib0600"
              "etiqueta" => "50"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Assessment of clinical and laboratory use of the cutaneous direct immunofluorescence assay"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J&#46;D&#46;R&#46; Reimann"
                            1 => "S&#46;P&#46; Moynihan"
                            2 => "T&#46;D&#46; Horn"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "157"
                        "paginaInicial" => "1343"
                        "paginaFinal" => "1348"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            50 => array:3 [
              "identificador" => "bib0605"
              "etiqueta" => "51"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Autoantibodies associated with connective tissue diseases&#58; what meaning for clinicians&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Didier"
                            1 => "L&#46; Bolko"
                            2 => "D&#46; Giusti"
                            3 => "S&#46; Toquet"
                            4 => "A&#46; Robbins"
                            5 => "F&#46; Antonicelli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3389/fimmu.2018.00541"
                      "Revista" => array:5 [
                        "tituloSerie" => "Front Immunol&#46;"
                        "fecha" => "2018"
                        "volumen" => "9"
                        "paginaInicial" => "541"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29632529"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            51 => array:3 [
              "identificador" => "bib0610"
              "etiqueta" => "52"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "New insights into the progression from cutaneous lupus to systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "W&#46; Zhou"
                            1 => "H&#46; Wu"
                            2 => "M&#46; Zhao"
                            3 => "Q&#46; Lu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/1744666X.2020.1805316"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Rev Clin Immunol&#46;"
                        "fecha" => "2020"
                        "volumen" => "16"
                        "paginaInicial" => "829"
                        "paginaFinal" => "837"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32746644"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            52 => array:3 [
              "identificador" => "bib0615"
              "etiqueta" => "53"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The CLASI&#44; a validated tool for the evaluation of skin disease in lupus erythematosus&#58; a narrative review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "S&#46; Chakka"
                            1 => "R&#46;L&#46; Krain"
                            2 => "J&#46;S&#46;S&#46; Concha"
                            3 => "B&#46;F&#46; Chong"
                            4 => "J&#46;F&#46; Merola"
                            5 => "V&#46;P&#46; Werth"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.21037/atm-20-5048"
                      "Revista" => array:5 [
                        "tituloSerie" => "Ann Transl Med&#46;"
                        "fecha" => "2021"
                        "volumen" => "9"
                        "paginaInicial" => "431"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33842652"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            53 => array:3 [
              "identificador" => "bib0620"
              "etiqueta" => "54"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Use of the Cutaneous Lupus Disease Area and Severity Index as an outcome measure in clinical trials&#58; a descriptive study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "E&#46; Mack"
                            1 => "L&#46;S&#46; Exton"
                            2 => "M&#46;F&#46; Mohd-Mustapa"
                            3 => "C&#46; McCourt"
                            4 => "D&#46; O&#8217;Kane"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Exp Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "46"
                        "paginaInicial" => "147"
                        "paginaFinal" => "152"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            54 => array:3 [
              "identificador" => "bib0625"
              "etiqueta" => "55"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus&#58; a brief review of old and new medical therapeutic options"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "F&#46; Nutan"
                            1 => "A&#46;G&#46; Ortega-Loayza"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jisp.2017.02.001"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Investig Dermatol Symp Proc&#46;"
                        "fecha" => "2017"
                        "volumen" => "18"
                        "paginaInicial" => "S64"
                        "paginaFinal" => "S68"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28941497"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            55 => array:3 [
              "identificador" => "bib0630"
              "etiqueta" => "56"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of cutaneous lupus erythematosus&#58; current approaches and future strategies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "H&#46; Shi"
                            1 => "J&#46;E&#46; Gudjonsson"
                            2 => "J&#46;M&#46; Kahlenberg"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/BOR.0000000000000704"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Opin Rheumatol&#46;"
                        "fecha" => "2020"
                        "volumen" => "32"
                        "paginaInicial" => "208"
                        "paginaFinal" => "214"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32141953"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            56 => array:3 [
              "identificador" => "bib0635"
              "etiqueta" => "57"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Management of cutaneous manifestations of lupus erythematosus&#58; a systematic review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "J&#46;L&#46; Fairley"
                            1 => "S&#46; Oon"
                            2 => "A&#46;M&#46; Saracino"
                            3 => "M&#46; Nikpour"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Semin Arthritis Rheum&#46;"
                        "fecha" => "2020"
                        "volumen" => "50"
                        "paginaInicial" => "95"
                        "paginaFinal" => "127"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            57 => array:3 [
              "identificador" => "bib0640"
              "etiqueta" => "58"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Candidate drug replacements for quinacrine in cutaneous lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "D&#46; Yan"
                            1 => "R&#46; Borucki"
                            2 => "R&#46;D&#46; Sontheimer"
                            3 => "V&#46;P&#46; Werth"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Lupus Sci Med&#46;"
                        "fecha" => "2020"
                        "volumen" => "7"
                        "paginaInicial" => "e000430"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            58 => array:3 [
              "identificador" => "bib0645"
              "etiqueta" => "59"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Interventions for cutaneous disease in systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "C&#46;W&#46; Hannon"
                            1 => "C&#46; McCourt"
                            2 => "H&#46;C&#46; Lima"
                            3 => "S&#46; Chen"
                            4 => "C&#46; Bennett"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/14651858.CD007478.pub2"
                      "Revista" => array:5 [
                        "tituloSerie" => "Cochrane Database Syst Rev&#46;"
                        "fecha" => "2021"
                        "volumen" => "3"
                        "paginaInicial" => "CD007478"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33687069"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            59 => array:3 [
              "identificador" => "bib0650"
              "etiqueta" => "60"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Current concepts and future approaches in the treatment of cutaneous lupus erythematosus&#58; a comprehensive review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "F&#46; Chasset"
                             …1
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40265-019-01151-8"
                      "Revista" => array:6 [
                        "tituloSerie" => "Drugs&#46;"
                        "fecha" => "2019"
                        "volumen" => "79"
                        "paginaInicial" => "1199"
                        "paginaFinal" => "1215"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            60 => array:3 [
              "identificador" => "bib0655"
              "etiqueta" => "61"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "S2k guideline for treatment of cutaneous lupus erythematosus &#8211; guided by the European Dermatology Forum &#40;EDF&#41; in cooperation with the European Academy of Dermatology and Venereology &#40;EADV&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2017"
                        "volumen" => "31"
                        "paginaInicial" => "389"
                        "paginaFinal" => "404"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            61 => array:3 [
              "identificador" => "bib0660"
              "etiqueta" => "62"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatments for disease damage in cutaneous lupus erythematosus&#58; a narrative review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Dermatol Ther&#46;"
                        "fecha" => "2021"
                        "volumen" => "34"
                        "paginaInicial" => "e15034"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            62 => array:3 [
              "identificador" => "bib0665"
              "etiqueta" => "63"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Which interventions are effective for cutaneous disease in systemic lupus erythematosus&#63;&#46; A Cochrane Review summary with commentary"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [ …1]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/1756-185X.14215"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Rheum Dis&#46;"
                        "fecha" => "2021"
                        "volumen" => "24"
                        "paginaInicial" => "1540"
                        "paginaFinal" => "1542"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            63 => array:3 [
              "identificador" => "bib0670"
              "etiqueta" => "64"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes&#58; a systematic review and meta&#8208;analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.15312"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2017"
                        "volumen" => "177"
                        "paginaInicial" => "188"
                        "paginaFinal" => "196"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            64 => array:3 [
              "identificador" => "bib0675"
              "etiqueta" => "65"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity&#8208;mediated inflammatory rheumatic diseases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s42358-020-00134-8"
                      "Revista" => array:5 [
                        "tituloSerie" => "Adv Rheumatol&#46;"
                        "fecha" => "2020"
                        "volumen" => "60"
                        "paginaInicial" => "32"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            65 => array:3 [
              "identificador" => "bib0680"
              "etiqueta" => "66"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2019 update of the EULAR recommendations for the management of systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2019-215089"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis&#46;"
                        "fecha" => "2019"
                        "volumen" => "78"
                        "paginaInicial" => "736"
                        "paginaFinal" => "745"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            66 => array:3 [
              "identificador" => "bib0685"
              "etiqueta" => "67"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lupus erythematosus&#58; considerations about clinical&#44; cutaneous and therapeutic aspects"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1590/abd1806-4841.20142146"
                      "Revista" => array:6 [
                        "tituloSerie" => "An Bras Dermatol&#46;"
                        "fecha" => "2014"
                        "volumen" => "89"
                        "paginaInicial" => "118"
                        "paginaFinal" => "125"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            67 => array:3 [
              "identificador" => "bib0690"
              "etiqueta" => "68"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Dapsone as second&#8208;line treatment for cutaneous lupus erythematosus&#63;&#46; A retrospective analysis of 34 patients and a review of the literature"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000441054"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatology&#46;"
                        "fecha" => "2016"
                        "volumen" => "232"
                        "paginaInicial" => "91"
                        "paginaFinal" => "96"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            68 => array:3 [
              "identificador" => "bib0695"
              "etiqueta" => "69"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Thalidomide and lenalidomide for refractory systemic&#47;cutaneous lupus erythematosus treatment&#58; a narrative review of literature for clinical practice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/RHU.0000000000001160"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Rheumatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "27"
                        "paginaInicial" => "248"
                        "paginaFinal" => "259"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            69 => array:3 [
              "identificador" => "bib0700"
              "etiqueta" => "70"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus&#58; a systematic review and meta&#8208;analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2017.09.059"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "78"
                        "paginaInicial" => "342"
                        "paginaFinal" => "350"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "pt"
  "url" => "/26662752/0000009800000003/v3_202305121556/S2666275223000504/v3_202305121556/pt/main.assets"
  "Apartado" => array:4 [
    "identificador" => "81730"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Revis&#227;o"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/26662752/0000009800000003/v3_202305121556/S2666275223000504/v3_202305121556/pt/main.pdf?idApp=UINPBA00008Z&text.app=https://clinics.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275223000504?idApp=UINPBA00008Z"
]
Share
Journal Information

Statistics

Follow this link to access the full text of the article

Revisão
Lúpus eritematoso cutâneo: revisão dos aspectos etiopatogênicos, clínicos, diagnósticos e terapêuticos
Everton Carlos Siviero do Valea,
Corresponding author
everton.siviero@gmail.com

Autor para correspondência.
, Lucas Campos Garciaa,b
a Serviço de Dermatologia, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil
b Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil
Read
56058
Times
was read the article
7609
Total PDF
48449
Total HTML
Share statistics
 array:23 [
  "pii" => "S2666275223000504"
  "issn" => "26662752"
  "doi" => "10.1016/j.abdp.2023.02.022"
  "estado" => "S300"
  "fechaPublicacion" => "2023-05-01"
  "aid" => "723"
  "copyright" => "Sociedade Brasileira de Dermatologia"
  "copyrightAnyo" => "2023"
  "documento" => "article"
  "crossmark" => 1
  "subdocumento" => "rev"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "en" => array:18 [
      "pii" => "S0365059623000247"
      "issn" => "03650596"
      "doi" => "10.1016/j.abd.2022.09.005"
      "estado" => "S300"
      "fechaPublicacion" => "2023-05-01"
      "aid" => "723"
      "copyright" => "Sociedade Brasileira de Dermatologia"
      "documento" => "article"
      "crossmark" => 1
      "subdocumento" => "rev"
      "abierto" => array:3 [
        "ES" => false
        "ES2" => false
        "LATM" => false
      ]
      "gratuito" => false
      "lecturas" => array:1 [
        "total" => 0
      ]
      "en" => array:12 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Review</span>"
        "titulo" => "Cutaneous lupus erythematosus&#58; a review of etiopathogenic&#44; clinical&#44; diagnostic and therapeutic aspects"
        "tienePdf" => "en"
        "tieneTextoCompleto" => "en"
        "tieneResumen" => "en"
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "355"
            "paginaFinal" => "372"
          ]
        ]
        "contieneResumen" => array:1 [
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "en" => true
        ]
        "contienePdf" => array:1 [
          "en" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 0
          "multimedia" => array:8 [
            "identificador" => "fig0010"
            "etiqueta" => "Figure 2"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => true
            "mostrarDisplay" => false
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "gr2.jpeg"
                "Alto" => 1397
                "Ancho" => 2925
                "Tamanyo" => 255607
              ]
            ]
            "detalles" => array:1 [
              0 => array:3 [
                "identificador" => "at0050"
                "detalle" => "Figure "
                "rol" => "short"
              ]
            ]
            "descripcion" => array:1 [
              "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; Subacute cutaneous lupus erythematosus&#58; annular&#44; erythematous&#44; papulosquamous plaques&#44; confluent on the chest and upper limbs&#46; &#40;B&#41; Neonatal lupus erythematosus&#58; circular and polycyclic erythematous plaques on the face&#46;</p>"
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "Everton Carlos Siviero do Vale, Lucas Campos Garcia"
            "autores" => array:2 [
              0 => array:2 [
                "nombre" => "Everton Carlos Siviero do"
                "apellidos" => "Vale"
              ]
              1 => array:2 [
                "nombre" => "Lucas Campos"
                "apellidos" => "Garcia"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "en"
      "Traduccion" => array:1 [
        "pt" => array:9 [
          "pii" => "S2666275223000504"
          "doi" => "10.1016/j.abdp.2023.02.022"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => false
            "ES2" => false
            "LATM" => false
          ]
          "gratuito" => false
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "pt"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275223000504?idApp=UINPBA00008Z"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059623000247?idApp=UINPBA00008Z"
      "url" => "/03650596/0000009800000003/v3_202305121633/S0365059623000247/v3_202305121633/en/main.assets"
    ]
  ]
  "itemSiguiente" => array:17 [
    "pii" => "S2666275223000413"
    "issn" => "26662752"
    "doi" => "10.1016/j.abdp.2023.02.014"
    "estado" => "S300"
    "fechaPublicacion" => "2023-05-01"
    "aid" => "715"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "pt" => array:9 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Carta &#8208; Investiga&#231;&#227;o</span>"
      "titulo" => "Associa&#231;&#227;o entre caracter&#237;sticas cl&#237;nicas e n&#237;veis plasm&#225;ticos de Hsp70 em adultos com vitiligo n&#227;o segmentar&#58; estudo transversal"
      "tienePdf" => "pt"
      "tieneTextoCompleto" => "pt"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "373"
          "paginaFinal" => "375"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "pt" => true
      ]
      "contienePdf" => array:1 [
        "pt" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Helena Zenedin Marchioro, Caio C&#233;sar Silva de Castro, Isabella Gizzi Jiacomini, H&#233;lio Amante Miot"
          "autores" => array:4 [
            0 => array:2 [
              "nombre" => "Helena Zenedin"
              "apellidos" => "Marchioro"
            ]
            1 => array:2 [
              "nombre" => "Caio C&#233;sar Silva de"
              "apellidos" => "Castro"
            ]
            2 => array:2 [
              "nombre" => "Isabella Gizzi"
              "apellidos" => "Jiacomini"
            ]
            3 => array:2 [
              "nombre" => "H&#233;lio Amante"
              "apellidos" => "Miot"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "pt"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S036505962300020X"
        "doi" => "10.1016/j.abd.2022.09.002"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S036505962300020X?idApp=UINPBA00008Z"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275223000413?idApp=UINPBA00008Z"
    "url" => "/26662752/0000009800000003/v3_202305121556/S2666275223000413/v3_202305121556/pt/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S2666275223000498"
    "issn" => "26662752"
    "doi" => "10.1016/j.abdp.2023.02.021"
    "estado" => "S300"
    "fechaPublicacion" => "2023-05-01"
    "aid" => "722"
    "copyright" => "Sociedade Brasileira de Dermatologia"
    "documento" => "article"
    "crossmark" => 1
    "subdocumento" => "rev"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:1 [
      "total" => 0
    ]
    "pt" => array:12 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Revis&#227;o</span>"
      "titulo" => "Infec&#231;&#227;o por COVID&#8208;19 e vacinas&#58; poss&#237;veis gatilhos de reativa&#231;&#227;o de v&#237;rus da fam&#237;lia Herpesviridae"
      "tienePdf" => "pt"
      "tieneTextoCompleto" => "pt"
      "tieneResumen" => "pt"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "347"
          "paginaFinal" => "354"
        ]
      ]
      "contieneResumen" => array:1 [
        "pt" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "pt" => true
      ]
      "contienePdf" => array:1 [
        "pt" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0005"
          "etiqueta" => "Figura 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 2092
              "Ancho" => 3341
              "Tamanyo" => 556277
            ]
          ]
          "descripcion" => array:1 [
            "pt" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Manifesta&#231;&#245;es de infec&#231;&#245;es por herpesv&#237;rus associadas &#224; COVID&#8208;19&#46; HSV&#8208;1&#44; herpesv&#237;rus simples tipo&#8208;1&#59; HSV&#8208;2&#44; herpesv&#237;rus simples tipo&#8208;2&#59; VZV&#44; v&#237;rus varicela&#8208;z&#243;ster&#59; EBV&#44; v&#237;rus Epstein&#8208;Barr&#59; CMV&#44; citomegalov&#237;rus&#59; HHV&#8208;6&#44; herpesv&#237;rus humano tipo 6&#59; HHV&#8208;7&#44; herpesv&#237;rus humano tipo 7&#59; HHV8&#44; herpesv&#237;rus humano tipo 8&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Alba Navarro&#8208;Bielsa, Tamara Gracia&#8208;Caza&#241;a, Beatriz Aldea&#8208;Manrique, Isabel Abad&#237;as&#8208;Granado, Adri&#225;n Ballano, Isabel Bernad, Yolanda Gilaberte"
          "autores" => array:7 [
            0 => array:2 [
              "nombre" => "Alba"
              "apellidos" => "Navarro&#8208;Bielsa"
            ]
            1 => array:2 [
              "nombre" => "Tamara"
              "apellidos" => "Gracia&#8208;Caza&#241;a"
            ]
            2 => array:2 [
              "nombre" => "Beatriz"
              "apellidos" => "Aldea&#8208;Manrique"
            ]
            3 => array:2 [
              "nombre" => "Isabel"
              "apellidos" => "Abad&#237;as&#8208;Granado"
            ]
            4 => array:2 [
              "nombre" => "Adri&#225;n"
              "apellidos" => "Ballano"
            ]
            5 => array:2 [
              "nombre" => "Isabel"
              "apellidos" => "Bernad"
            ]
            6 => array:2 [
              "nombre" => "Yolanda"
              "apellidos" => "Gilaberte"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "pt"
    "Traduccion" => array:1 [
      "en" => array:9 [
        "pii" => "S0365059623000235"
        "doi" => "10.1016/j.abd.2022.09.004"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => false
          "ES2" => false
          "LATM" => false
        ]
        "gratuito" => false
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "en"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0365059623000235?idApp=UINPBA00008Z"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275223000498?idApp=UINPBA00008Z"
    "url" => "/26662752/0000009800000003/v3_202305121556/S2666275223000498/v3_202305121556/pt/main.assets"
  ]
  "pt" => array:19 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Revis&#227;o</span>"
    "titulo" => "L&#250;pus eritematoso cut&#226;neo&#58; revis&#227;o dos aspectos etiopatog&#234;nicos&#44; cl&#237;nicos&#44; diagn&#243;sticos e terap&#234;uticos"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "355"
        "paginaFinal" => "372"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "Everton Carlos Siviero do Vale, Lucas Campos Garcia"
        "autores" => array:2 [
          0 => array:4 [
            "nombre" => "Everton Carlos Siviero do"
            "apellidos" => "Vale"
            "email" => array:1 [
              0 => "everton.siviero@gmail.com"
            ]
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "Lucas Campos"
            "apellidos" => "Garcia"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:2 [
          0 => array:3 [
            "entidad" => "Servi&#231;o de Dermatologia&#44; Hospital das Cl&#237;nicas&#44; Universidade Federal de Minas Gerais&#44; Belo Horizonte&#44; MG&#44; Brasil"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Departamento de Cl&#237;nica M&#233;dica&#44; Faculdade de Medicina&#44; Universidade Federal de Minas Gerais&#44; Belo Horizonte&#44; MG&#44; Brasil"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Autor para correspond&#234;ncia&#46;"
          ]
        ]
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 0
      "multimedia" => array:7 [
        "identificador" => "fig0025"
        "etiqueta" => "Figura 5"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr5.jpeg"
            "Alto" => 3171
            "Ancho" => 1675
            "Tamanyo" => 439940
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; L&#250;pus eritematoso t&#250;mido&#58; les&#245;es eritemato&#8208;edematosas arciformes e anulares na face e regi&#227;o cervical&#46; &#40;B&#41; L&#250;pus eritematoso bolhoso&#58; les&#245;es bolhosas&#44; ulcerocrostosas hem&#225;ticas e les&#245;es residuais hipocr&#244;micas&#44; localizadas na regi&#227;o cervical&#44; tronco&#44; axilas e membros superiores&#46;</p>"
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Introdu&#231;&#227;o</span><p id="par0005" class="elsevierStylePara elsevierViewall">O l&#250;pus eritematoso &#40;LE&#41; &#233; doen&#231;a autoimune com amplo espectro de express&#227;o cl&#237;nica&#44; que varia desde doen&#231;a cut&#226;nea limitada at&#233; doen&#231;a sist&#234;mica grave e potencialmente fatal&#44; por comprometimento de &#243;rg&#227;os vitais&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> O LE cut&#226;neo &#40;LEC&#41; apresenta&#8208;se como doen&#231;a cut&#226;nea exclusiva ou comp&#245;e uma das m&#250;ltiplas manifesta&#231;&#245;es do LE sist&#234;mico &#40;LES&#41;&#46; Les&#245;es cut&#226;neas est&#227;o presentes em&#160;70&#37;&#8208;80&#37; dos casos de LES&#44; em algum momento de sua evolu&#231;&#227;o&#44; e podem ser a manifesta&#231;&#227;o inicial da doen&#231;a em at&#233;&#160;25&#37; dos pacientes&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Com base em caracter&#237;sticas cl&#237;nicas&#44; achados histopatol&#243;gicos&#44; altera&#231;&#245;es laboratoriais e dura&#231;&#227;o&#44; as les&#245;es cut&#226;neas espec&#237;ficas do LE s&#227;o subdivididas em tr&#234;s subtipos principais&#58; o LEC agudo &#40;LECA&#41;&#44; o LEC subagudo &#40;LECS&#41; e o LEC cr&#244;nico &#40;LECC&#41;&#46; A identifica&#231;&#227;o desses subtipos &#233; fundamental&#44; porque eles costumam ocorrer em contextos cl&#237;nicos distintos&#44; com implica&#231;&#245;es diagn&#243;sticas&#44; progn&#243;sticas e terap&#234;uticas&#46;<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">2</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">O LEC exclusivo &#233; 2&#8208;3 vezes mais frequente que o LES&#44; com incid&#234;ncia anual de&#160;4&#44;3&#47;100&#46;000&#160;indiv&#237;duos na Europa e nos EUA&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#8211;3</span></a> H&#225; predomin&#226;ncia de LE em mulheres&#44; em que a incid&#234;ncia de LES adulto &#233;&#160;7&#8208;15&#160;vezes maior e de LES infantil&#44; 3&#8208;4&#160;vezes maior&#46; Essa preponder&#226;ncia feminina &#233; menos evidente nas formas cut&#226;neas isoladas de LE&#44; com rela&#231;&#227;o de&#160;4&#58;1&#44; e &#233; ainda menos expressiva&#44; com rela&#231;&#227;o de&#160;3&#58;1&#44; no LE discoide &#40;LED&#41;&#44; forma mais comum de LECC&#46;<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">2&#44;4</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">H&#225; ainda diferen&#231;as raciais na ocorr&#234;ncia do LEC&#44; com risco&#160;5&#44;4&#160;vezes maior de LECC nos afro&#8208;americanos em rela&#231;&#227;o aos caucasianos&#46;<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">4</span></a> Na Nova Zel&#226;ndia&#44; quando comparados &#224; popula&#231;&#227;o de origem europeia&#44; os ind&#237;genas Maori mostram risco relativo de&#160;2&#44;47&#160;para desenvolver todos os subtipos de LEC e&#160;5&#44;96&#160;para LECC&#46;<a class="elsevierStyleCrossRef" href="#bib0375"><span class="elsevierStyleSup">5</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">O pico de incid&#234;ncia do LES acontece na meia&#8208;idade adulta&#44; por&#233;m mais tardiamente nos homens&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> Ainda que tamb&#233;m acometa crian&#231;as e idosos&#44; o LEC exclusivo &#233; mais comum entre&#160;20&#160;e&#160;40&#160;anos&#44; com idade m&#233;dia de instala&#231;&#227;o aos&#160;43&#160;anos&#44; por&#233;m com varia&#231;&#227;o conforme o subtipo&#46;<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">3</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">As les&#245;es cut&#226;neas do LE constituem consider&#225;vel morbidade&#44; sobretudo devido &#224; natureza cr&#244;nica&#44; ao acometimento preferencial das partes expostas do corpo e car&#225;ter desfigurante de suas sequelas&#44; que resultam em significante preju&#237;zo da qualidade de vida dos pacientes&#46;<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">7</span></a></p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Classifica&#231;&#227;o</span><p id="par0035" class="elsevierStylePara elsevierViewall">Os crit&#233;rios diagn&#243;sticos para classifica&#231;&#227;o do LES n&#227;o s&#227;o uniformes e universalmente aceitos&#59; s&#227;o precursores aqueles propostos em&#160;1971 pelo American College of Rheumatology &#40;ACR&#41;&#44; revistos em&#160;1997 &#40;ACR 1997&#41;&#59; posteriormente&#44; surgiram mais dois sistemas de classifica&#231;&#227;o &#8211; o da Systemic Lupus International Collaborating Clinics &#40;SLICC&#160;2012&#41; e o conjunto entre a European League Against Rheumatism e o ACR &#40;EULAR&#47;ACR&#160;2019&#41;&#44; que est&#227;o discriminados e podem ser comparados na <a class="elsevierStyleCrossRef" href="#tbl0005">tabela 1</a>&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">4&#44;8&#44;9</span></a> Cada um desses tr&#234;s sistemas contempla quatro achados dermatol&#243;gicos como crit&#233;rios diagn&#243;sticos do LES&#46; Estudo australiano atual&#44; que avaliou a performance dos diferentes crit&#233;rios de classifica&#231;&#227;o do LES&#44; concluiu que o ACR&#160;1997 detinha a maior especificidade&#44; por&#233;m o SLICC&#160;2012 era o que proporcionava a maior acur&#225;cia diagn&#243;stica global &#40;94&#44;4&#37;&#41;&#44; com desempenho similar entre os pacientes com doen&#231;a inicial&#46;<a class="elsevierStyleCrossRef" href="#bib0400"><span class="elsevierStyleSup">10</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0040" class="elsevierStylePara elsevierViewall">Foi pioneira a classifica&#231;&#227;o proposta por Gilliam &#38; Sontheimer&#44; em&#160;1981&#44; que discrimina as les&#245;es cut&#226;neas do LE entre espec&#237;ficas e inespec&#237;ficas&#46; As espec&#237;ficas&#44; definidas pela presen&#231;a da dermatite de interface dermoepid&#233;rmica&#44; s&#227;o exclusivas do LE&#44; com ou sem doen&#231;a sist&#234;mica&#46; S&#227;o subdivididas em tr&#234;s categorias&#44; com base nas caracter&#237;sticas cl&#237;nicas&#58; LECA&#44; LECS e LECC&#46; As les&#245;es inespec&#237;ficas incluem as demais manifesta&#231;&#245;es cut&#226;neas associadas ao LES&#46; Em&#160;2004&#44; a classifica&#231;&#227;o de D&#252;sseldorf acrescentou outro subtipo&#44; o LEC intermitente &#40;LECI&#41;&#44; que corresponde ao LE t&#250;mido&#44; anteriormente considerado variante de LECC&#46;<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">3</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">Algumas limita&#231;&#245;es das classifica&#231;&#245;es anteriormente citadas podem ser destacadas&#58; a&#41;&#160;nem sempre as les&#245;es de LEC podem ser classificadas como agudas&#44; subagudas ou cr&#244;nicas&#44; com base na histologia&#59; b&#41;&#160;a dermatite de interface&#44; utilizada como crit&#233;rio para definir as les&#245;es espec&#237;ficas do LEC&#44; na realidade&#44; carece de especificidade&#44; j&#225; que pode estar presente em outras condi&#231;&#245;es&#44; como dermatomiosite&#44; doen&#231;a do enxerto&#8208;<span class="elsevierStyleItalic">versus</span>&#8208;hospedeiro e rea&#231;&#245;es medicamentosas&#59; c&#41;&#160;alguns subtipos inclu&#237;dos como espec&#237;ficos&#44; como o LE t&#250;mido e a paniculite l&#250;pica&#44; nem sempre apresentam dermatite de interface&#59; d&#41;&#160;termos como agudo&#44; subagudo ou cr&#244;nico&#44; de natureza cronol&#243;gica&#44; s&#227;o utilizados para definir varia&#231;&#245;es morfol&#243;gicas&#44; al&#233;m de serem associados a graus de extens&#227;o mal definidos&#44; como localizado ou disseminado&#44; referindo&#8208;se &#224; topografia&#46; Por essas raz&#245;es&#44; em&#160;2010&#44; Lipsker prop&#244;s uma nova classifica&#231;&#227;o das les&#245;es cut&#226;neas do LE&#44; com base nas caracter&#237;sticas cl&#237;nicas e nos achados histol&#243;gicos&#46; As les&#245;es cut&#226;neas espec&#237;ficas&#44; sem a presen&#231;a obrigat&#243;ria da dermatite de interface&#44; s&#227;o subdivididas em dermoepid&#233;rmicas&#44; d&#233;rmicas e hipod&#233;rmicas&#46; As les&#245;es inespec&#237;ficas s&#227;o subdivididas em tromb&#243;ticas&#44; neutrof&#237;licas ou de natureza patogen&#233;tica incerta&#46;<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">11</span></a></p><p id="par0050" class="elsevierStylePara elsevierViewall">Na falta de classifica&#231;&#227;o universalmente aceita&#44; em&#160;2013 foi constitu&#237;da uma for&#231;a&#8208;tarefa&#44; composta de especialistas no tema para propor uniformidade de crit&#233;rios diagn&#243;sticos e classifica&#231;&#227;o do LEC&#44; por meio do m&#233;todo Delphi&#46;<a class="elsevierStyleCrossRef" href="#bib0410"><span class="elsevierStyleSup">12</span></a> Recentemente&#44; foi apresentada a valida&#231;&#227;o dos crit&#233;rios de classifica&#231;&#227;o do LED&#44; forma mais comum de LEC&#44; com base exclusivamente cl&#237;nica&#46; Foram inclu&#237;dos os seguintes par&#226;metros&#44; com pontua&#231;&#245;es distintas&#44; referentes &#224;s les&#245;es cut&#226;neas&#58; cicatriz atr&#243;fica &#40;3&#160;pontos&#41;&#44; localiza&#231;&#227;o na concha auricular &#40;2&#160;pontos&#41;&#44; prefer&#234;ncia por cabe&#231;a e pesco&#231;o &#40;2&#160;pontos&#41;&#44; discromia &#40;1&#160;ponto&#41;&#44; ceratose folicular e tamp&#245;es c&#243;rneos &#40;1&#160;ponto&#41;&#44; colora&#231;&#227;o eritematosa a viol&#225;cea &#40;1&#160;ponto&#41;&#46; Escore &#8805; 5&#160;garante sensibilidade de&#160;84&#37; e especificidade de&#160;76&#37; para classifica&#231;&#227;o como LED&#44; com maior especificidade quanto maior for a pontua&#231;&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0415"><span class="elsevierStyleSup">13</span></a></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Etiopatog&#234;nese</span><p id="par0055" class="elsevierStylePara elsevierViewall">LES e LEC s&#227;o doen&#231;as multifatoriais&#44; em que est&#225; envolvida uma complexa intera&#231;&#227;o entre carga gen&#233;tica e exposi&#231;&#245;es ambientais&#44; como radia&#231;&#227;o ultravioleta &#40;RUV&#41;&#44; f&#225;rmacos&#44; defensivos agr&#237;colas e tabaco&#46;<a class="elsevierStyleCrossRefs" href="#bib0420"><span class="elsevierStyleSup">14&#44;15</span></a> Varia&#231;&#245;es epigen&#233;ticas&#44; como desregula&#231;&#227;o da express&#227;o g&#234;nica&#44; via metila&#231;&#227;o do DNA&#44; ou modifica&#231;&#245;es de histonas&#44; causadas por esses fatores externos&#44; podem ser o gatilho para a ativa&#231;&#227;o das imunidades inata e adaptativa&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">4&#44;14</span></a></p><p id="par0060" class="elsevierStylePara elsevierViewall">Os estudos sobre os fatores gen&#233;ticos envolvidos no LEC ainda s&#227;o incipientes&#44; se comparados aos descritos no LES&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> Apesar disso&#44; polimorfismos gen&#233;ticos&#44; muta&#231;&#245;es e alelos de risco j&#225; foram identificados em diferentes popula&#231;&#245;es de LEC&#44; a maioria deles associados &#224;s vias das imunidades inata e adaptativa&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;14&#44;17</span></a> Genes que atuam na apoptose&#44; migra&#231;&#227;o leucocit&#225;ria&#44; via do IFN tipo&#160;I&#44; cascata do complemento&#44; apresenta&#231;&#227;o de ant&#237;genos e produ&#231;&#227;o de anticorpos est&#227;o entre os mais frequentemente afetados&#46;<a class="elsevierStyleCrossRefs" href="#bib0420"><span class="elsevierStyleSup">14&#44;17</span></a> Os genes que codificam a produ&#231;&#227;o de citocinas pr&#243;&#8208;inflamat&#243;rias s&#227;o os mais associados &#224;s vias da imunidade inata nas les&#245;es de LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> Como exemplos de associa&#231;&#245;es descritas entre genes e manifesta&#231;&#245;es cut&#226;neas&#44; podem ser citados o <span class="elsevierStyleItalic">FCGR2A</span> &#40;risco para LECA&#41;&#44; <span class="elsevierStyleItalic">TYK2</span>&#44; <span class="elsevierStyleItalic">IRF5</span>&#44; <span class="elsevierStyleItalic">TNF</span>&#8208;&#945; &#40;risco para LECS&#41; e <span class="elsevierStyleItalic">ITGAM</span> &#40;risco para LED&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0425"><span class="elsevierStyleSup">15&#44;17</span></a> Variantes de HLA tamb&#233;m j&#225; foram correlacionadas &#224; progress&#227;o da doen&#231;a cut&#226;nea&#44; dentre as quais se destacam o HLA&#8208;B8&#44; HLA&#8208;DR e HLA&#8208;DQ&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> At&#233; o presente momento&#44; apenas uma variante monogen&#233;tica de LEC foi identificada&#44; uma forma rara de LE perni&#243;tico familiar associada a muta&#231;&#245;es no gene <span class="elsevierStyleItalic">TREX1</span>&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;14&#44;17&#44;18</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">Dentre os fatores ambientais&#44; a RUV &#233; o mais bem estabelecido desencadeador do LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> A irradia&#231;&#227;o da pele altera a morfologia e a fun&#231;&#227;o dos ceratin&#243;citos&#44; induzindo diretamente a produ&#231;&#227;o de citocinas pr&#243;&#8208;inflamat&#243;rias &#40;IL&#8208;1&#945;&#44; IL&#8208;1&#946;&#44; IL&#8208;6&#44; TNF&#8208;&#945; e IFN&#8208;&#945;&#44; k e ¿&#41; e apoptose&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">4&#44;14&#44;17</span></a> O aumento de citocinas inflamat&#243;rias e a exposi&#231;&#227;o a res&#237;duos celulares&#44; liberados pela morte celular&#44; desencadeiam o recrutamento de linf&#243;citos e c&#233;lulas dendr&#237;ticas plasmocitoides &#40;CDP&#41;&#44; que acionar&#227;o a ativa&#231;&#227;o do sistema imune&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;18</span></a> As CDP s&#227;o raras na pele normal e abundantes nas les&#245;es de LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0440"><span class="elsevierStyleSup">18</span></a> Res&#237;duos celulares&#44; especialmente nucleares&#44; s&#227;o capturados pelas CDP&#44; que tamb&#233;m podem servir como reservat&#243;rio de autoant&#237;genos frente a linf&#243;citos&#160;B&#160;e&#160;T autorreativos&#46;<a class="elsevierStyleCrossRef" href="#bib0420"><span class="elsevierStyleSup">14</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">J&#225; foi demonstrado que a apoptose dos ceratin&#243;citos&#44; como a mediada pela via do Fas&#47;FasL&#44; apresenta forte correla&#231;&#227;o com a atividade da doen&#231;a&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> O papel dos ceratin&#243;citos no surgimento e desenvolvimento das les&#245;es de LEC tamb&#233;m envolve retroalimenta&#231;&#227;o positiva na produ&#231;&#227;o de IFN&#44; especialmente dos tipos&#160;I&#160;e&#160;III&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> O IFN produzido &#233; capaz de ativar tanto o sistema imune inato quanto adaptativo&#44; exercendo papel central na patog&#234;nese do LE&#46;<a class="elsevierStyleCrossRefs" href="#bib0420"><span class="elsevierStyleSup">14&#44;19</span></a></p><p id="par0075" class="elsevierStylePara elsevierViewall">A ativa&#231;&#227;o do sistema imune inato promove a inflama&#231;&#227;o tecidual&#44; especialmente mediada pelas CDP e neutr&#243;filos &#40;incluindo as redes extracelulares de neutr&#243;filos &#8211; NET&#59; do ingl&#234;s&#44; <span class="elsevierStyleItalic">neutrophil extracellular traps</span>&#41;&#44; e o aumento da express&#227;o de autoant&#237;genos&#44; inclusive o Ro&#47;SS&#8208;A &#40;prote&#237;na induz&#237;vel pelo IFN&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0440"><span class="elsevierStyleSup">18&#44;19</span></a> Esse aumento estimula o sistema imune adaptativo&#44; como os linf&#243;citos&#160;T&#160;citot&#243;xicos e os plasm&#243;citos&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> O aumento do IFN tamb&#233;m perpetua a express&#227;o de citocinas e quimiocinas&#44; intimamente relacionadas &#224; produ&#231;&#227;o de anticorpos&#44; os quais se depositam preferencialmente na jun&#231;&#227;o dermoepid&#233;rmica e resultam em agress&#227;o citot&#243;xica mediada principalmente por linf&#243;citos T CD8&#43;&#46;<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">4</span></a></p><p id="par0080" class="elsevierStylePara elsevierViewall">A eleva&#231;&#227;o dos n&#237;veis de IFN&#44; especialmente do tipo&#160;I&#44; tamb&#233;m leva diretamente &#224; infiltra&#231;&#227;o de linf&#243;citos Th1&#44; acelerando a inflama&#231;&#227;o tecidual e a produ&#231;&#227;o de IFN&#8208; &#947; e IL&#8208;2&#44; dentre outras citocinas&#46;<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">4</span></a> O aumento dessas citocinas estimula as vias de sinaliza&#231;&#227;o intracelulares&#44; como a via JAK&#47;STAT&#44; e altera a transcri&#231;&#227;o g&#234;nica&#46;<a class="elsevierStyleCrossRef" href="#bib0420"><span class="elsevierStyleSup">14</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">Por fim&#44; a eleva&#231;&#227;o dos n&#237;veis de citocinas&#44; o aumento da exposi&#231;&#227;o de ant&#237;genos e a atividade das c&#233;lulas Th1 estimulam a produ&#231;&#227;o de anticorpos autorreativos&#44; que se depositam principalmente na zona da membrana basal e estimulam a agress&#227;o por c&#233;lulas&#160;T CD8&#43; e c&#233;lulas <span class="elsevierStyleItalic">natural killer</span> &#40;NK&#41;<span class="elsevierStyleItalic">&#44;</span> por meio de enzimas&#44; como a granzima&#160;B&#44; que induzem apoptose pela ativa&#231;&#227;o das caspases e d&#227;o continuidade ao ciclo inflamat&#243;rio&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">4&#44;19</span></a></p><p id="par0090" class="elsevierStylePara elsevierViewall">O papel dos autoanticorpos permanece incerto no LEC&#46; Pacientes com LECC apresentam ocorr&#234;ncia muito menor de autoanticorpos s&#233;ricos&#44; como os antinucleares&#44; anti&#8208;DNAn&#44; anti&#8208;Sm&#44; anti&#8208;Ro&#47;SS&#8208;A e anti&#8208;La&#47;SS&#8208;B&#44; se comparados aos pacientes com LES e LECS&#46;<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">19</span></a> Por outro lado&#44; as imunoglobulinas est&#227;o fortemente envolvidas na patog&#234;nese local das les&#245;es de LEC&#46; As IgM s&#227;o as primeiras a serem recrutadas para a pele&#44; atraindo&#44; em seguida&#44; o C3 e outras imunoglobulinas&#46; Diferentemente do LES&#44; em que a IgM isolada ou em combina&#231;&#227;o com C3 &#233; a forma mais frequente de forma&#231;&#227;o de imunocomplexos&#44; no LED&#44; a IgG &#233; a respons&#225;vel pela maioria dos dep&#243;sitos de imunocomplexos&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a></p><p id="par0095" class="elsevierStylePara elsevierViewall">Apesar do aumento dos n&#237;veis s&#233;ricos de IL&#8208;17 e aumento da express&#227;o cut&#226;nea da IL&#8208;17A nos pacientes com LES&#44; poucos linf&#243;citos&#160;T&#160;produtores de IL&#8208;17 s&#227;o encontrados nas les&#245;es de LED&#44; sugerindo um papel menos importante nesta manifesta&#231;&#227;o cl&#237;nica&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> Foi descrita tamb&#233;m uma redu&#231;&#227;o na porcentagem de linf&#243;citos&#160;T&#160;reguladores na pele afetada pelo LEC&#46; Outro relato recente &#233; uma rela&#231;&#227;o inversamente proporcional entre a porcentagem de linf&#243;citos Th22 nas les&#245;es e escores de gravidade cl&#237;nica&#44; indicando que a IL&#8208;22 pode ser bom indicador da repara&#231;&#227;o cut&#226;nea&#46;<a class="elsevierStyleCrossRef" href="#bib0445"><span class="elsevierStyleSup">19</span></a></p><p id="par0100" class="elsevierStylePara elsevierViewall">Os f&#225;rmacos s&#227;o descritos como outro poss&#237;vel gatilho para o LEC&#44; especialmente para o subtipo subagudo&#46;<a class="elsevierStyleCrossRef" href="#bib0435"><span class="elsevierStyleSup">17</span></a> F&#225;rmacos classicamente reconhecidos como indutores de LEC&#44; como anti&#8208;hipertensivos&#44; antif&#250;ngicos e inibidores da bomba de pr&#243;tons&#44; dentre outros mais de cem medicamentos&#44; t&#234;m dividido import&#226;ncia com novas terapias&#8208;alvo&#44; como imunobiol&#243;gicos&#44; imunoter&#225;picos e quimioter&#225;picos&#44; em decorr&#234;ncia da crescente ocorr&#234;ncia de casos relacionados a esses medicamentos&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">4&#44;17</span></a> Acredita&#8208;se que os f&#225;rmacos causadores de LEC podem ativar diretamente o sistema imune inato ou&#44; indiretamente&#44; ao reduzir a remo&#231;&#227;o de autoant&#237;genos&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> O tabagismo &#233; outro importante fator de risco associado ao LEC&#44; por estimular citocinas pr&#243;&#8208;inflamat&#243;rias&#44; a ativa&#231;&#227;o neutrof&#237;lica&#44; aumentar o estresse celular&#44; a forma&#231;&#227;o de radicais livres e a apoptose&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;14&#44;18</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">Os horm&#244;nios sexuais parecem ser pe&#231;a fundamental na patog&#234;nese do LES&#46; Por outro lado&#44; sua import&#226;ncia no LEC parece ser menor&#44; especialmente no LED&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> Apesar disso&#44; a incid&#234;ncia de LEC ainda &#233; maior no sexo feminino&#46; Como esse aumento ocorre mesmo fora da per&#237;odo f&#233;rtil&#44; postula&#8208;se que possa haver outras explica&#231;&#245;es para a maior incid&#234;ncia nas mulheres&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> A aus&#234;ncia de piora significante do LEC durante a gesta&#231;&#227;o ou o uso de anticoncepcionais orais tamb&#233;m corroboram esse achado&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> Uma poss&#237;vel hip&#243;tese alternativa &#224; influ&#234;ncia hormonal seria um efeito de dose ligado ao cromossomo&#160;X&#44; que poderia explicar&#44; por exemplo&#44; o aumento da incid&#234;ncia de LES em pacientes do sexo masculino portadores da s&#237;ndrome de Klinefelter &#40;gen&#243;tipo&#160;XXY&#41;&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> Outra hip&#243;tese seria a reativa&#231;&#227;o do cromossomo&#160;X inativado por um processo de demetila&#231;&#227;o nos linf&#243;citos&#160;T CD4&#43;&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a></p><p id="par0110" class="elsevierStylePara elsevierViewall">O papel da microbiota cut&#226;nea na patog&#234;nese do LEC ainda &#233; pouco compreendido e tem atra&#237;do maior aten&#231;&#227;o por parte dos pesquisadores&#46;<a class="elsevierStyleCrossRef" href="#bib0430"><span class="elsevierStyleSup">16</span></a> Aumento significante de <span class="elsevierStyleItalic">Staphylococcus</span> e <span class="elsevierStyleItalic">Corynebacterium</span>&#44; assim como redu&#231;&#227;o de <span class="elsevierStyleItalic">Cutibacterium</span>&#44; foram descritos nas les&#245;es cut&#226;neas de LES&#44; por&#233;m ainda sem evid&#234;ncias que suportem uma rela&#231;&#227;o direta&#46;<a class="elsevierStyleCrossRefs" href="#bib0430"><span class="elsevierStyleSup">16&#44;17</span></a></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Apresenta&#231;&#227;o cl&#237;nica e diagn&#243;stico diferencial</span><p id="par0115" class="elsevierStylePara elsevierViewall">A <a class="elsevierStyleCrossRef" href="#tbl0010">tabela 2</a> relaciona os subtipos cl&#237;nicos de LEC e suas variantes&#44; assim como as manifesta&#231;&#245;es cut&#226;neas inespec&#237;ficas que podem estar associadas ao LE&#46;</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">L&#250;pus eritematoso cut&#226;neo agudo</span><p id="par0120" class="elsevierStylePara elsevierViewall">Representa&#160;15&#37; dos casos de LEC e sempre est&#225; associado ao LES&#44; geralmente correlacionando com a atividade da doen&#231;a&#46;<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">3</span></a> Presente no momento do diagn&#243;stico em cerca de&#160;50&#37; dos casos de LES&#44; pode ser desencadeado ou exacerbado pela exposi&#231;&#227;o solar aguda&#46;<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">2</span></a></p><p id="par0125" class="elsevierStylePara elsevierViewall">A forma localizada &#233; a predominante &#40;90&#37;&#8208;95&#37;&#41; e corresponde &#224; t&#237;pica erup&#231;&#227;o em vespert&#237;lio ou em asa de borboleta&#44; que se manifesta como les&#227;o eritematosa e finamente escamosa&#44; acometendo de maneira sim&#233;trica as regi&#245;es malares e o dorso nasal&#44; geralmente poupando os sulcos nasolabiais &#40;<a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>A&#41;&#46; Edema facial tamb&#233;m pode estar presente&#46; O eritema costuma ser ef&#234;mero&#44; resolvendo&#8208;se em alguns dias ou semanas&#46; Eventualmente&#44; afeta a fronte&#44; o mento&#44; os pavilh&#245;es auriculares e a regi&#227;o cervical anterior&#46; Seus principais diagn&#243;sticos diferenciais s&#227;o dermatomiosite e ros&#225;cea&#44; mas ainda devem ser consideradas dermatite seborreica&#44; dermatite perioral e dermatite de contato fotoal&#233;rgica&#46; O acometimento das dobras nasolabiais e das p&#225;lpebras&#44; assim como fraqueza muscular proximal&#44; favorecem a dermatomiosite&#46;</p><p id="par0130" class="elsevierStylePara elsevierViewall">A forma disseminada&#44; menos comum &#40;5&#37;&#8208;10&#37;&#41;&#44; manifesta&#8208;se como erup&#231;&#227;o exantem&#225;tica urticariforme ou maculopapular predominante nas &#225;reas fotoexpostas &#40;<a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>B&#41;&#46; Al&#233;m de face e pesco&#231;o&#44; afeta simetricamente o V do decote e a superf&#237;cie extensora dos membros&#44; sobretudo os superiores&#44; mas pode estender&#8208;se ao tronco e at&#233; mesmo palmas e plantas&#46; Quando atinge o dorso de m&#227;os e dedos&#44; tende a poupar as articula&#231;&#245;es&#44; ao contr&#225;rio da dermatomiosite&#46; Deve ser diferenciada de rea&#231;&#245;es de hipersensibilidade a f&#225;rmacos&#44; exantemas virais e dermatites fotot&#243;xicas ou fotoal&#233;rgicas medicamentosas&#44; al&#233;m da dermatomiosite&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0135" class="elsevierStylePara elsevierViewall">O acometimento mucoso &#233; frequente em ambas as formas&#46; A mucosa oral &#233; a mais afetada&#44; em&#160;8&#37;&#8208;45&#37; dos casos&#44; atingindo principalmente as mucosas jugal&#44; palatina e labial&#44; na forma de placas enantematosas ou purp&#250;ricas&#44; vesicobolhas&#44; eros&#245;es e &#250;lceras&#46;<a class="elsevierStyleCrossRef" href="#bib0450"><span class="elsevierStyleSup">20</span></a> Ulcera&#231;&#227;o nasal &#233; menos comum e outras mucosas s&#227;o raramente afetadas&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">Uma apresenta&#231;&#227;o rara de LECA&#44; que se assemelha &#224; necr&#243;lise epid&#233;rmica t&#243;xica &#40;NET&#41;&#44; por isso conhecida como variante NET&#8208;s&#237;mile&#44; deve&#8208;se &#224; intensa dermatite de interface com necrose dos ceratin&#243;citos&#44; que resulta em descolamento epitelial de extensas &#225;reas da pele&#46; Pode haver comprometimento mucoso&#44; que costuma ser mais limitado e poupar a conjuntiva ocular&#46;<a class="elsevierStyleCrossRef" href="#bib0455"><span class="elsevierStyleSup">21</span></a></p><p id="par0145" class="elsevierStylePara elsevierViewall">Ap&#243;s resolu&#231;&#227;o&#44; as les&#245;es de LECA podem deixar hipercromia residual&#44; mas n&#227;o costumam resultar em cicatrizes&#44; exceto na forma NET&#8208;s&#237;mile&#44; ou quando complicadas por infec&#231;&#227;o secund&#225;ria&#46;</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">L&#250;pus eritematoso cut&#226;neo subagudo</span><p id="par0150" class="elsevierStylePara elsevierViewall">Responde por cerca de&#160;8&#37; de todos os casos de LEC&#44; tem dura&#231;&#227;o mais prolongada que o LECA e apresenta extrema fotossensibilidade&#46; Distribui&#8208;se de maneira sim&#233;trica&#44; preferencialmente nas &#225;reas expostas do pesco&#231;o&#44; tronco superior e membros superiores&#44; por&#233;m costuma poupar a regi&#227;o central da face&#46;<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">3</span></a> Manifesta&#8208;se sob duas formas&#44; ambas com placas eritematosas&#44; uma anular polic&#237;clica e outra papuloescamosa psoriasiforme &#40;<a class="elsevierStyleCrossRef" href="#fig0010">fig&#46; 2</a>A&#41;&#44; que eventualmente podem coexistir no mesmo paciente&#46; Atrofia e ceratose n&#227;o s&#227;o clinicamente evidentes nas les&#245;es do LECS&#46; Tamb&#233;m tendem a ser menos edematosas que as les&#245;es do LECA e menos infiltradas e discr&#244;micas que aquelas do LED&#46; Em ambas as formas&#44; surgem ocasionalmente les&#245;es vesicobolhosas e crostas na periferia das placas&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> Habitualmente&#44; resolvem sem deixar cicatrizes&#44; mas pode haver hipocromia residual&#44; geralmente tempor&#225;ria&#44; por&#233;m permanente em formas mais graves&#46; Eventualmente&#44; pode haver concomit&#226;ncia de les&#245;es de LECA ou LED com les&#245;es de LECS&#44; mas nem sempre &#233; poss&#237;vel uma distin&#231;&#227;o exata dessas les&#245;es&#46; &#201; raro o acometimento da mucosa oral&#44; com placas enantematosas circulares levemente atr&#243;ficas&#46;<a class="elsevierStyleCrossRef" href="#bib0460"><span class="elsevierStyleSup">22</span></a> Deve ser diferenciado de granuloma anular&#44; eritema anular centr&#237;fugo&#44; <span class="elsevierStyleItalic">erithema gyratum repens</span>&#44; psor&#237;ase&#44; tinha do corpo&#44; entre outros&#46;</p><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0155" class="elsevierStylePara elsevierViewall">Cerca de 1&#47;3 dos casos de LECS &#233; desencadeado por f&#225;rmacos&#46; Em geral&#44; o LECS medicamentoso &#233; indistingu&#237;vel do LECS idiop&#225;tico&#44; por&#233;m algumas particularidades devem levar &#224; suspei&#231;&#227;o da etiologia medicamentosa &#8211; idade mais avan&#231;ada&#44; quadros mais disseminados e presen&#231;a de les&#245;es bolhosas ou do tipo alvo&#46;<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">23</span></a> O quadro costuma ser revers&#237;vel&#44; resolvendo em alguns meses ap&#243;s a suspens&#227;o da medica&#231;&#227;o respons&#225;vel&#46; Os f&#225;rmacos mais frequentemente incriminados s&#227;o hidroclorotiazida&#44; inibidores do canal de c&#225;lcio&#44; inibidores da enzima conversora da angiotensina&#44; inibidores da bomba de pr&#243;tons&#44; terbinafina&#44; agentes anti&#8208;TNF e anticonvulsivantes&#44; por&#233;m a incid&#234;ncia tende a variar com o desenvolvimento de novos medicamentos e a mudan&#231;a na prescri&#231;&#227;o&#46;<a class="elsevierStyleCrossRefs" href="#bib0465"><span class="elsevierStyleSup">23&#8211;25</span></a> Recente revis&#227;o da literatura&#44; com foco na d&#233;cada passada &#40;2010&#8208;2020&#41;&#44; revelou que os agentes anti&#8208;TNF&#44; os inibidores da bomba de pr&#243;tons e os antineopl&#225;sicos&#44; em particular os inibidores de <span class="elsevierStyleItalic">checkpoint</span> imune&#44; destacam&#8208;se como f&#225;rmacos emergentes desencadeantes de LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0480"><span class="elsevierStyleSup">26</span></a> A lista de medicamentos respons&#225;veis &#233; extensa&#44; como pode ser observado na <a class="elsevierStyleCrossRef" href="#tbl0015">tabela 3</a>&#46;</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0160" class="elsevierStylePara elsevierViewall">O primeiro caso de LECS associado a doen&#231;a maligna foi descrito em&#160;1982&#44; como l&#250;pus eritematoso <span class="elsevierStyleItalic">gyratum repens</span> em paciente com c&#226;ncer de pulm&#227;o&#46; Desde ent&#227;o&#44; surgiram in&#250;meros relatos sugerindo uma rela&#231;&#227;o entre LECS e v&#225;rias neoplasias s&#243;lidas e n&#227;o s&#243;lidas&#44; com maior frequ&#234;ncia de carcinoma de pulm&#227;o e adenocarcinoma da mama&#46; Na maioria dos casos&#44; o paralelismo entre o desenvolvimento tumoral e a atividade da dermatose possibilitou caracterizar a associa&#231;&#227;o como s&#237;ndrome paraneopl&#225;sica&#46; Ainda que rara&#44; &#233; importante considerar essa possibilidade no LECS de in&#237;cio em idade avan&#231;ada&#44; em pacientes com maior risco de neoplasia e nos casos refrat&#225;rios ao tratamento convencional&#46;<a class="elsevierStyleCrossRef" href="#bib0485"><span class="elsevierStyleSup">27</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall">A s&#237;ndrome de <span class="elsevierStyleItalic">Rowell</span> foi originalmente descrita em&#160;1963 como uma entidade distinta&#44; pela associa&#231;&#227;o de achados cl&#237;nicos de LE e eritema multiforme&#44; al&#233;m da presen&#231;a de algumas altera&#231;&#245;es imunol&#243;gicas&#44; como FAN salpicado&#44; anticorpo anti&#8208;SjT e fator reumatoide&#46; &#192; luz dos conhecimentos cl&#237;nicos e imunol&#243;gicos modernos&#44; essa s&#237;ndrome n&#227;o deve ser vista com identidade nosol&#243;gica&#44; mas como variante rara do LECS&#44; caracterizada por les&#245;es cut&#226;neas do tipo alvo e presen&#231;a de anticorpos anti&#8208;Ro&#47;SS&#8208;A&#46;<a class="elsevierStyleCrossRef" href="#bib0490"><span class="elsevierStyleSup">28</span></a></p><p id="par0170" class="elsevierStylePara elsevierViewall">O LE neonatal tamb&#233;m &#233; considerado variante do LECS&#46; Resulta da passagem transplacent&#225;ria de autoanticorpos maternos contra ant&#237;genos Ro&#47;SS&#8208;A&#44; La&#47;SS&#8208;B e&#44; mais raramente&#44; U1&#8208;RNP&#46; Em grande parte dos casos&#44; a m&#227;e &#233; assintom&#225;tica&#44; mas pode ter s&#237;ndrome de Sj&#246;gren&#44; LECS&#44; LES ou outras doen&#231;as do tecido conjuntivo&#46; O risco &#233; pequeno na primeira gesta&#231;&#227;o ou na aus&#234;ncia da doen&#231;a em gesta&#231;&#245;es anteriores &#40;2&#37;&#41;&#44; mas aumenta substancialmente &#40;10&#160;vezes&#41; se tiver havido diagn&#243;stico em gesta&#231;&#227;o pr&#233;via&#46; As les&#245;es cut&#226;neas ocorrem em at&#233;&#160;40&#37; dos casos de LE neonatal e podem estar presentes ao nascimento&#44; mas geralmente surgem nos primeiros&#160;tr&#234;s&#160;meses de vida&#44; ap&#243;s a exposi&#231;&#227;o solar&#44; resolvendo espontaneamente em 6&#8208;12 meses&#46; S&#227;o eritematosas ou eritemato&#8208;escamosas&#44; circulares&#44; anulares ou polic&#237;clicas e afetam principalmente a face&#44; nas regi&#245;es frontal e periorbit&#225;ria &#40;<a class="elsevierStyleCrossRef" href="#fig0010">fig&#46; 2</a>B&#41;&#44; podendo estender&#8208;se ao couro cabeludo&#44; mas raramente atingem tronco e membros&#46; Dermatite seborreica e tinha da face s&#227;o os principais diagn&#243;sticos diferenciais&#46; Outras manifesta&#231;&#245;es poss&#237;veis&#44; tamb&#233;m revers&#237;veis&#44; s&#227;o as citopenias &#40;trombocitopenia&#44; anemia hemol&#237;tica&#41;&#44; doen&#231;a hepatobiliar&#44; esplenomegalia e&#44; mais raras&#44; as altera&#231;&#245;es neurol&#243;gicas e pulmonares&#46; Mais graves e irrevers&#237;veis s&#227;o as altera&#231;&#245;es card&#237;acas&#44; principalmente os dist&#250;rbios de condu&#231;&#227;o&#44; inclusive bloqueio atrioventricular total&#44; miocardiopatia e valvulopatia&#44; que podem ocorrer em 25&#37; dos casos e ser detectadas antes do nascimento&#46;<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">2&#44;29</span></a></p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">L&#250;pus eritematoso cut&#226;neo cr&#244;nico</span><p id="par0175" class="elsevierStylePara elsevierViewall">O LECC responde por mais de&#160;70&#37; dos casos de LEC e compreende diversas variantes&#44; algumas mais comuns e outras mais raras&#46;<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">3</span></a></p><p id="par0180" class="elsevierStylePara elsevierViewall">O LED &#233; a forma cl&#225;ssica e mais comum de LECC&#44; tamb&#233;m presente em&#160;20&#37;&#160;dos casos de LES&#46; Localiza&#8208;se predominantemente na cabe&#231;a e pesco&#231;o&#44; mas&#44; em cerca de&#160;30&#37;&#160;dos casos&#44; pode ser disseminado e acometer tronco e membros&#44; com prefer&#234;ncia pelas &#225;reas fotoexpostas&#44; como face&#44; pavilh&#245;es auriculares&#44; V do decote&#44; lateral do pesco&#231;o&#44; couro cabeludo e dorsal dos membros superiores&#46; As les&#245;es se iniciam como placas eritemato&#8208;infiltradas&#44; induradas &#224; palpa&#231;&#227;o&#44; evoluindo com ceratose&#44; principalmente folicular&#44; atrofia e discromia&#44; com hipocromia no centro e hipercromia na periferia&#46; Costumam ser dolorosas &#224; palpa&#231;&#227;o&#46; Podem deixar les&#245;es vitiligoides&#44; assim como resolver com cicatrizes&#44; muitas vezes mutilantes&#44; sobretudo quando acometem nariz&#44; pavilh&#245;es auriculares e p&#225;lpebras&#46; Les&#245;es em diferentes est&#225;gios costumam ser concomitantes&#46; Quando situadas nas &#225;reas pilosas&#44; como couro cabeludo&#44; barba&#44; c&#237;lios e superc&#237;lios&#44; tendem a destruir os fol&#237;culos&#44; resultando em alopecia cicatricial &#40;<a class="elsevierStyleCrossRef" href="#fig0015">fig&#46; 3</a>A&#41;&#46; Les&#245;es palmoplantares s&#227;o raras&#44; costumam ser muito dolorosas e podem ulcerar&#8208;se&#46; Excepcionalmente&#44; observam&#8208;se les&#245;es ungueais e periungueais&#46; Al&#233;m da radia&#231;&#227;o solar&#44; as les&#245;es de LED podem ser provocadas por traumatismos&#44; configurando o fen&#244;meno de Koebner&#46;<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">2&#44;3&#44;30</span></a> LED medicamentoso &#233; muito raro&#44; com relatos espor&#225;dicos associados a leflunomida&#44; 5&#8208;fluoruracil&#44; capecitabina&#44; palbociclibe&#44; pembrolizumabe e mais comumente aos agentes anti&#8208;TNF&#46;<a class="elsevierStyleCrossRef" href="#bib0505"><span class="elsevierStyleSup">31</span></a> As les&#245;es recentes de LED devem ser diferenciadas da erup&#231;&#227;o polimorfa &#224; luz&#44; sarcoidose&#44; pseudolinfomas&#44; granuloma facial e LE t&#250;mido&#46; As les&#245;es cr&#244;nicas merecem diferencia&#231;&#227;o com l&#250;pus vulgar&#44; ceratose act&#237;nica hipertr&#243;fica&#44; carcinoma espinocelular e ceratoacantoma&#46;</p><elsevierMultimedia ident="fig0015"></elsevierMultimedia><p id="par0185" class="elsevierStylePara elsevierViewall">O LED mucoso &#233; relatado em&#160;3&#37;&#8208;25&#37; dos pacientes com LED e costuma ser assintom&#225;tico em 1&#47;4 dos casos&#46; Apresenta&#8208;se classicamente como placas de enantema&#44; com p&#225;pulas cerat&#243;sicas&#44; atrofia ou eros&#227;o central e ceratose radiada ou reticulada na periferia&#46; Pode ainda se manifestar como placas brancas estriadas ou homog&#234;neas&#44; eros&#245;es e ulcera&#231;&#245;es&#46; &#201; mais comum na mucosa oral&#44; principalmente jugal &#40;<a class="elsevierStyleCrossRef" href="#fig0015">fig&#46; 3</a>B&#41;&#44; palatina e labial&#44; mas pode acometer a gengiva e a l&#237;ngua&#46; As mucosas nasal&#44; genital e anal tamb&#233;m podem ser afetadas por les&#245;es discoides&#46; &#201; caracter&#237;stica a les&#227;o da conjuntiva ocular&#44; mais comum na margem palpebral inferior&#44; que pode resultar em cicatriz&#44; perda dos c&#237;lios e ectr&#243;pio&#46; H&#225; risco de transforma&#231;&#227;o maligna em carcinoma escamocelular&#44; com maior frequ&#234;ncia nos l&#225;bios&#46;<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">2&#44;22&#44;32</span></a> Seu principal diagn&#243;stico diferencial &#233; o l&#237;quen plano oral&#46;</p><p id="par0190" class="elsevierStylePara elsevierViewall">O LE hipertr&#243;fico&#44; tamb&#233;m conhecido como LE verrucoso&#44; &#233; variante bastante rara do LECC que se manifesta com les&#245;es eritematosas&#44; papulosas ou nodulares&#44; de superf&#237;cie cerat&#243;sica e algo verrucosa&#44; localizadas principalmente nas regi&#245;es extensoras dos membros superiores &#40;<a class="elsevierStyleCrossRef" href="#fig0020">fig&#46; 4</a>A&#41; e eventualmente na face e tronco superior&#46; Costuma haver coexist&#234;ncia de les&#245;es discoides t&#237;picas&#44; que facilitam o diagn&#243;stico&#46;<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">2</span></a> Deve ser diferenciado do l&#237;quen plano hipertr&#243;fico&#44; do ceratoacantoma e das verrugas vulgares&#46;</p><elsevierMultimedia ident="fig0020"></elsevierMultimedia><p id="par0195" class="elsevierStylePara elsevierViewall">O LE l&#237;quen plano&#8208;s&#237;mile ou s&#237;ndrome de superposi&#231;&#227;o l&#250;pus eritematoso&#8208;l&#237;quen plano refere&#8208;se &#224; combina&#231;&#227;o de achados cl&#237;nicos&#44; histol&#243;gicos e imunopatol&#243;gicos de ambas as dermatoses&#46; Trata&#8208;se de condi&#231;&#227;o muito rara&#44; de evolu&#231;&#227;o cr&#244;nica e predominante em mulheres&#44; que apresenta placas dolorosas vermelho&#8208;azuladas&#44; escamosas&#44; com centro atr&#243;fico&#44; localizadas nas extremidades superiores e menos frequentemente nas pernas&#44; face e tronco&#59; o acometimento palmoplantar &#233; caracter&#237;stico&#46; Les&#245;es hipertr&#243;ficas tamb&#233;m podem ocorrer&#46; H&#225; ainda relatos de acometimento mucoso&#44; distrofia ungueal e alopecia cicatricial&#44; assim como de casos desencadeados por medicamentos&#46;<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">2&#44;33&#44;34</span></a></p><p id="par0200" class="elsevierStylePara elsevierViewall">O LE profundo ou paniculite l&#250;pica responde apenas por&#160;2&#37;&#8208;3&#37; dos casos de LECC&#44; &#233; mais frequente em adultos e mulheres e se manifesta com placas e n&#243;dulos subcut&#226;neos&#44; endurecidos&#44; aderidos &#224; pele sobrejacente&#44; geralmente dolorosos&#44; que se localizam principalmente na face&#44; ombros&#44; bra&#231;os&#44; coxas&#44; gl&#250;teos e mamas &#40;<a class="elsevierStyleCrossRef" href="#fig0020">fig&#46; 4</a>B&#41;&#46; A pele da superf&#237;cie pode ou n&#227;o apresentar les&#245;es de LED&#46; Costumam causar intensa atrofia do subcut&#226;neo&#44; deixando &#225;reas deprimidas&#44; com desfigura&#231;&#227;o est&#233;tica&#44; sobretudo quando localizadas na face&#46; Eventualmente&#44; evoluem com calcifica&#231;&#227;o e ulcera&#231;&#227;o&#46; A doen&#231;a tem curso cr&#244;nico&#44; entrecortado por per&#237;odos de exacerba&#231;&#227;o e de remiss&#227;o&#46;<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">2&#44;30</span></a> Deve ser diferenciado principalmente de outros tipos de paniculite&#44; do linfoma subcut&#226;neo de c&#233;lulas&#160;T&#160;paniculite&#8208;s&#237;mile e da sarcoidose subcut&#226;nea&#46;</p><p id="par0205" class="elsevierStylePara elsevierViewall">O LE perni&#243;tico &#233; forma rara de LECC&#44; que se assemelha &#224; perniose e se manifesta por les&#245;es dolorosas&#44; papulosas&#44; nodulares ou edematosas&#44; de tonalidade eritemato&#8208;viol&#225;cea&#46; Podem evoluir com eros&#227;o ou ulcera&#231;&#227;o&#46; S&#227;o desencadeadas pela exposi&#231;&#227;o ao frio e usualmente acometem quirod&#225;tilos e dorso das m&#227;os&#46; Podod&#225;ctilos&#44; regi&#245;es plantares e calcanhares tamb&#233;m podem ser acometidos&#46; Nariz e pavilh&#245;es auriculares s&#227;o menos afetados&#46; Fen&#244;meno de Raynaud pode estar presente em alguns casos&#46; O quadro pode coexistir com les&#245;es de LED ou ocorrer no contexto de LES&#46; Estima&#8208;se que&#160;20&#37; dos pacientes com LE perni&#243;tico venham a desenvolver doen&#231;a sist&#234;mica&#46; Algumas altera&#231;&#245;es imunol&#243;gicas podem ser observadas&#44; como hipergamaglobulinemia&#44; fator reumatoide e FAN positivos&#44; assim como anticorpos antifosfol&#237;pides e antinucleares espec&#237;ficos&#44; principalmente anti&#8208;Ro&#47;SS&#8208;A&#46;<a class="elsevierStyleCrossRef" href="#bib0525"><span class="elsevierStyleSup">35</span></a> H&#225; uma forma familiar da doen&#231;a&#44; que se manifesta na inf&#226;ncia&#44; de heran&#231;a autoss&#244;mica dominante&#44; relacionada a muta&#231;&#245;es no gene TREX1 e menos frequentemente nos genes SAMHD1 ou TMEM173&#46;<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">2&#44;36</span></a> O principal diagn&#243;stico diferencial &#233; a perniose idiop&#225;tica&#44; mas ainda devem ser considerados o l&#250;pus p&#233;rnio&#44; uma forma acral de sarcoidose&#44; assim como as vasculites e vasculopatias acrais&#46;</p><p id="par0210" class="elsevierStylePara elsevierViewall">O LE comedoniano &#233; outra variante rara do LECC&#44; que se manifesta por comedos&#44; p&#225;pulas&#44; placas eritemato&#8208;infiltradas e cistos em &#225;reas seborreicas e fotoexpostas&#44; deixando cicatrizes acneiformes deprimidas&#46; Acomete preferencialmente mulheres jovens e de meia idade&#59; o tabagismo &#233; importante fator de risco&#44; como em outras formas de LECC&#46; Pode ser acompanhado de les&#245;es t&#237;picas de LED&#44; assim como associado ao LES&#46; Costuma ser confundido com acne vulgar&#44; nevo comedoniano e elastoidose nodular com cistos e comed&#245;es&#44; o que geralmente retarda o diagn&#243;stico e o tratamento&#44; resultando em cicatrizes inest&#233;ticas&#46;<a class="elsevierStyleCrossRefs" href="#bib0535"><span class="elsevierStyleSup">37&#8211;39</span></a></p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">L&#250;pus eritematoso cut&#226;neo intermitente</span><p id="par0215" class="elsevierStylePara elsevierViewall">Anteriormente categorizado entre as variantes de LECC&#44; o LE t&#250;mido foi reclassificado como LECI em raz&#227;o de seu curso cl&#237;nico&#44; em que se alternam per&#237;odos de remiss&#227;o e de recorr&#234;ncia&#46; &#201; variante rara do LEC&#44; que acomete mais as mulheres &#40;60&#37;&#160;dos casos&#41;&#44; mas a preponder&#226;ncia sobre os homens &#233; menos evidente que nas outras formas de LEC&#46; Uma caracter&#237;stica marcante do LE t&#250;mido &#233; a fotossensibilidade exacerbada&#44; talvez a mais intensa entre todas as formas de LEC&#46; Manifesta&#8208;se por placas &#250;nicas ou m&#250;ltiplas&#44; eritemato&#8208;edematosas&#44; de superf&#237;cie lisa&#44; que podem assumir configura&#231;&#227;o anular ou arciforme &#40;<a class="elsevierStyleCrossRef" href="#fig0025">fig&#46; 5</a>A&#41;&#46; Localizam&#8208;se em &#225;reas fotoexpostas&#44; principalmente na face&#44; pesco&#231;o&#44; tronco superior e membros superiores&#46; &#201; usual a resolu&#231;&#227;o espont&#226;nea das les&#245;es em algumas semanas&#44; sem deixar discromia ou cicatriz&#44; mas sobrev&#234;m epis&#243;dios com novas les&#245;es&#46; &#201; mais comum a ocorr&#234;ncia na forma isolada&#44; mas pode estar associado a outras formas de LEC&#44; principalmente LED&#44; e raramente ao LES&#46; Altera&#231;&#245;es imunol&#243;gicas tamb&#233;m s&#227;o incomuns&#44; como FAN e anticorpos antinucleares espec&#237;ficos&#46; Deve ser diferenciado da erup&#231;&#227;o polimorfa &#224; luz&#44; LED inicial&#44; mucinose reticular eritematosa e pseudolinfomas cut&#226;neos&#44; como a infiltra&#231;&#227;o linfocit&#225;ria de Jessner&#44; considerada por muitos autores como o pr&#243;prio LE t&#250;mido&#46;<a class="elsevierStyleCrossRefs" href="#bib0360"><span class="elsevierStyleSup">2&#44;40&#44;41</span></a></p><elsevierMultimedia ident="fig0025"></elsevierMultimedia></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">L&#250;pus eritematoso bolhoso</span><p id="par0220" class="elsevierStylePara elsevierViewall">O LE bolhoso &#233; dermatose bolhosa autoimune&#44; subepid&#233;rmica&#44; sempre associada ao LES&#44; mediada por autoanticorpos contra o col&#225;geno&#160;VII&#46; Manifesta&#8208;se por ves&#237;culas e bolhas tensas &#40;<a class="elsevierStyleCrossRef" href="#fig0025">fig&#46; 5</a>B&#41; que surgem subitamente sobre pele s&#227; ou sobre placas eritematosas e infiltradas&#44; eventualmente assumindo configura&#231;&#227;o anular&#46; Preferem face&#44; tronco superior&#44; pesco&#231;o&#44; regi&#245;es supraclaviculares e flexuras axilares&#44; mas podem disseminar&#8208;se para outras &#225;reas n&#227;o expostas&#46; N&#227;o costumam ser acompanhadas de les&#245;es espec&#237;ficas de LEC&#44; a n&#227;o ser eritema malar&#44; que pode surgir posteriormente&#44; ao longo da evolu&#231;&#227;o da doen&#231;a&#46; As mucosas oral e genital podem ser acometidas&#59; s&#227;o t&#237;picas as les&#245;es labiais e periorais&#46;<a class="elsevierStyleCrossRef" href="#bib0560"><span class="elsevierStyleSup">42</span></a> &#201; mais comum em mulheres negras&#44; entre a segunda e quarta d&#233;cadas de vida&#46; O LE bolhoso se instala antes&#44; concomitantemente e&#44; menos frequentemente&#44; ap&#243;s o diagn&#243;stico do LES&#44; podendo ser marcador de intensa atividade sist&#234;mica&#44; com maior risco de nefrite l&#250;pica e manifesta&#231;&#245;es neuropsiqui&#225;tricas&#46;<a class="elsevierStyleCrossRef" href="#bib0565"><span class="elsevierStyleSup">43</span></a> As les&#245;es evoluem com eros&#227;o e crostas&#44; regredindo sem cicatrizes e m&#237;lios&#44; mas podem deixar discromia residual&#46; &#201; incomum a recorr&#234;ncia&#44; mesmo com a persist&#234;ncia de doen&#231;a sist&#234;mica ativa&#46;<a class="elsevierStyleCrossRef" href="#bib0570"><span class="elsevierStyleSup">44</span></a> Deve ser diferenciado da epiderm&#243;lise bolhosa adquirida&#44; dermatose bolhosa por IgA linear&#44; dermatite herpetiforme e penfigoide bolhoso&#46;</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Manifesta&#231;&#245;es cut&#226;neas inespec&#237;ficas do l&#250;pus eritematoso</span><p id="par0225" class="elsevierStylePara elsevierViewall">Exclu&#237;dos os subtipos cl&#237;nicos e respectivas variantes anteriormente expostos&#44; todas as demais manifesta&#231;&#245;es cut&#226;neas associadas ao LE devem ser consideradas inespec&#237;ficas&#46; Est&#227;o associadas ao LES e geralmente guardam rela&#231;&#227;o com a atividade da doen&#231;a&#46; No entanto&#44; n&#227;o s&#227;o exclusivas do LES&#44; podendo ocorrer em outras condi&#231;&#245;es&#44; geralmente de natureza autoimune ou autoinflamat&#243;ria&#46;<a class="elsevierStyleCrossRefs" href="#bib0575"><span class="elsevierStyleSup">45&#8211;47</span></a> O LE bolhoso&#44; embora classificado como manifesta&#231;&#227;o inespec&#237;fica&#44; neutrof&#237;lica&#44; associada ao LE&#44; deveria ser considerado subtipo cl&#237;nico espec&#237;fico de LEC&#44; pelo fato de sempre estar associado ao LES&#46;<a class="elsevierStyleCrossRef" href="#bib0405"><span class="elsevierStyleSup">11</span></a> As manifesta&#231;&#245;es inespec&#237;ficas mais comuns est&#227;o listadas na <a class="elsevierStyleCrossRef" href="#tbl0010">tabela 2</a>&#46;</p></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Diagn&#243;stico</span><p id="par0230" class="elsevierStylePara elsevierViewall">O diagn&#243;stico do LEC se fundamenta nos dados colhidos na anamnese e no exame f&#237;sico&#44; em combina&#231;&#227;o com os achados da histopatologia e&#44; eventualmente&#44; da imuno&#8208;histologia das les&#245;es cut&#226;neas&#44; para defini&#231;&#227;o do subtipo cl&#237;nico&#46;</p><p id="par0235" class="elsevierStylePara elsevierViewall">O tipo e a abrang&#234;ncia da investiga&#231;&#227;o laboratorial devem ser adequados a cada paciente&#44; individualmente&#44; a depender do subtipo de LEC definido com base nos achados cl&#237;nicos e histopatol&#243;gicos&#46;</p><p id="par0240" class="elsevierStylePara elsevierViewall">Devem ser realizados exames bioqu&#237;micos de rotina que auxiliem na identifica&#231;&#227;o de poss&#237;vel doen&#231;a sist&#234;mica&#44; al&#233;m de exames espec&#237;ficos&#44; conforme o tratamento proposto&#44; antes de iniciar a medica&#231;&#227;o e para monitorar seus potenciais efeitos adversos&#46; Exames adicionais podem ser necess&#225;rios ap&#243;s a confirma&#231;&#227;o do diagn&#243;stico e defini&#231;&#227;o do subtipo de LEC&#44; que incluem testes sorol&#243;gicos para caracterizar o perfil de autoanticorpos e testes para avaliar a atividade sist&#234;mica da doen&#231;a&#44; assim como exames complementares para investigar acometimento de &#243;rg&#227;os espec&#237;ficos&#44; que podem auxiliar na determina&#231;&#227;o do progn&#243;stico&#46; Os principais exames laboratoriais recomendados no LEC est&#227;o listados na <a class="elsevierStyleCrossRef" href="#tbl0020">tabela 4</a>&#46; Nos casos de LES&#44; faz&#8208;se necess&#225;ria a interven&#231;&#227;o do reumatologista e eventualmente de outros especialistas&#44; que devem orientar a proped&#234;utica complementar individualizada para cada paciente&#46;<a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">48</span></a></p><elsevierMultimedia ident="tbl0020"></elsevierMultimedia><p id="par0245" class="elsevierStylePara elsevierViewall">&#201; importante que a defini&#231;&#227;o de doen&#231;a sist&#234;mica n&#227;o fique estritamente condicionada aos crit&#233;rios diagn&#243;sticos inclu&#237;dos nos sistemas de classifica&#231;&#227;o&#44; como o SLICC&#160;2012 e o EULAR&#47;ACR&#160;2019&#44; que foram primordialmente desenvolvidos com objetivo de se obter uniformidade diagn&#243;stica na sele&#231;&#227;o de pacientes para ensaios cl&#237;nicos&#44; mas n&#227;o s&#227;o capazes de abranger todas as manifesta&#231;&#245;es que podem ocorrer no LES&#46;<a class="elsevierStyleCrossRef" href="#bib0500"><span class="elsevierStyleSup">30</span></a></p><p id="par0250" class="elsevierStylePara elsevierViewall">O uso de escores de atividade da doen&#231;a&#44; originalmente criados para mensura&#231;&#227;o de desfechos em ensaios cl&#237;nicos&#44; &#233; recomend&#225;vel na pr&#225;tica cl&#237;nica&#44; por permitir an&#225;lise mais objetiva da evolu&#231;&#227;o da doen&#231;a no seguimento dos pacientes com LEC&#44; podendo servir de par&#226;metro na avalia&#231;&#227;o da resposta ao tratamento indicado&#46;</p><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Histopatologia</span><p id="par0255" class="elsevierStylePara elsevierViewall">As diferentes formas de LEC&#44; com exce&#231;&#227;o do LE profundo e do LE t&#250;mido&#44; compartilham os achados histopatol&#243;gicos&#44; tornando indispens&#225;vel uma estreita correla&#231;&#227;o cl&#237;nico&#8208;patol&#243;gica para defini&#231;&#227;o do subtipo&#46; A diferencia&#231;&#227;o histopatol&#243;gica depende da evolu&#231;&#227;o e do est&#225;gio das les&#245;es&#46; Assim&#44; do ponto de vista histol&#243;gico&#44; o LE poderia ser classificado em recente &#40;LECA&#44; LECS e LED inicial&#41;&#44; completamente desenvolvido &#40;LED&#41; e tardio &#40;LED atr&#243;fico&#8208;cicatricial&#41;&#46; As altera&#231;&#245;es tendem a ser mais sutis nas les&#245;es recentes e bastante evidentes nas les&#245;es totalmente desenvolvidas&#46;<a class="elsevierStyleCrossRefs" href="#bib0445"><span class="elsevierStyleSup">19&#44;49</span></a></p><p id="par0260" class="elsevierStylePara elsevierViewall">Os principais achados s&#227;o o infiltrado inflamat&#243;rio linfoc&#237;tico perivascular e perianexial na derme superficial e profunda&#44; assim como a dermatite de interface&#44; caracterizada pela agress&#227;o de linf&#243;citos &#224; jun&#231;&#227;o dermoepid&#233;rmica&#46; Como consequ&#234;ncia&#44; outras altera&#231;&#245;es ocorrem&#44; como a degenera&#231;&#227;o vacuolar da camada basal e a necrose de ceratin&#243;citos nas camadas inferiores da epiderme&#44; seguidas por espessamento da membrana basal&#46; A epiderme torna&#8208;se atr&#243;fica e as cristas epiteliais&#44; achatadas&#46; A deposi&#231;&#227;o de mucina na derme &#233; um achado t&#237;pico do LE&#44; embora inespec&#237;fico&#44; variando em intensidade conforme o tipo de les&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0585"><span class="elsevierStyleSup">47</span></a></p><p id="par0265" class="elsevierStylePara elsevierViewall">No LED&#44; prot&#243;tipo das les&#245;es completamente desenvolvidas&#44; al&#233;m das altera&#231;&#245;es j&#225; descritas&#44; bastante proeminentes&#44; s&#227;o muito evidentes os achados de hiperceratose&#44; tamp&#245;es c&#243;rneos foliculares e atrofia epid&#233;rmica&#46; O est&#225;gio tardio e cicatricial do LED mostra incontin&#234;ncia pigmentar&#44; ectasia vascular&#44; fibrose d&#233;rmica e perda dos anexos&#46;<a class="elsevierStyleCrossRefs" href="#bib0445"><span class="elsevierStyleSup">19&#44;47</span></a></p><p id="par0270" class="elsevierStylePara elsevierViewall">No LECA&#44; as altera&#231;&#245;es costumam ser mais discretas&#44; podendo haver edema e hemorragia na derme superficial&#46; O infiltrado linfoc&#237;tico &#233; discreto&#44; apenas perivascular e superficial&#44; com presen&#231;a de neutr&#243;filos nas les&#245;es mais recentes&#46; A variante NET&#8208;s&#237;mile de LECA mostra intensa degenera&#231;&#227;o hidr&#243;pica da basal&#44; que resulta em disceratose&#44; clivagem subepid&#233;rmica e necrose completa da epiderme&#46;<a class="elsevierStyleCrossRefs" href="#bib0445"><span class="elsevierStyleSup">19&#44;47</span></a></p><p id="par0275" class="elsevierStylePara elsevierViewall">No LECS&#44; a dermatite de interface costuma ser intensa&#44; havendo muitos corpos citoides&#46; O infiltrado linfoc&#237;tico &#233; superficial e predominantemente perivascular&#46; A atrofia da epiderme&#44; a hiperceratose&#44; os tamp&#245;es foliculares&#44; a deposi&#231;&#227;o de mucina e o espessamento da membrana basal s&#227;o menos proeminentes que no LED&#46;<a class="elsevierStyleCrossRefs" href="#bib0445"><span class="elsevierStyleSup">19&#44;47</span></a></p><p id="par0280" class="elsevierStylePara elsevierViewall">O LE hipertr&#243;fico&#44; al&#233;m das altera&#231;&#245;es observadas no LED&#44; mostra acantose e acentuada hiperplasia pseudoepiteliomatosa&#44; al&#233;m de intensa hiperceratose&#46;<a class="elsevierStyleCrossRefs" href="#bib0585"><span class="elsevierStyleSup">47&#44;49</span></a></p><p id="par0285" class="elsevierStylePara elsevierViewall">O LE profundo apresenta&#8208;se como paniculite linfoc&#237;tica lobular&#44; com n&#243;dulos linfoides parasseptais e necrose hialina dos adip&#243;citos&#44; presen&#231;a de plasm&#243;citos&#44; al&#233;m de deposi&#231;&#227;o de mucina na derme reticular e ocasionalmente na hipoderme&#46; Fibrose e calcifica&#231;&#227;o podem ser observadas nos est&#225;gios finais das les&#245;es&#46; As altera&#231;&#245;es epid&#233;rmicas e d&#233;rmicas caracter&#237;sticas do LE podem estar presentes em metade dos casos&#46;<a class="elsevierStyleCrossRefs" href="#bib0585"><span class="elsevierStyleSup">47&#44;49</span></a></p><p id="par0290" class="elsevierStylePara elsevierViewall">O LE t&#250;mido caracteriza&#8208;se por intenso infiltrado linfoc&#237;tico perivascular na derme superficial e profunda&#44; al&#233;m de abundante deposi&#231;&#227;o de mucina&#44; sem a presen&#231;a das altera&#231;&#245;es epid&#233;rmicas e da dermatite de interface&#46;<a class="elsevierStyleCrossRefs" href="#bib0585"><span class="elsevierStyleSup">47&#44;49</span></a></p><p id="par0295" class="elsevierStylePara elsevierViewall">Nas les&#245;es de LE perni&#243;tico&#44; al&#233;m dos achados caracter&#237;sticos de LE&#44; em menor intensidade que no LED&#44; destacam&#8208;se a presen&#231;a de vasculite linfoc&#237;tica&#44; eventualmente com necrose fibrinoide e trombose&#44; edema da derme papilar e infiltrado linfoc&#237;tico peri&#233;crino&#46;<a class="elsevierStyleCrossRefs" href="#bib0585"><span class="elsevierStyleSup">47&#44;49</span></a></p><p id="par0300" class="elsevierStylePara elsevierViewall">O LE bolhoso mostra infiltrado inflamat&#243;rio predominante de neutr&#243;filos&#44; que costuma estar alinhado &#224; jun&#231;&#227;o dermoepid&#233;rmica e formar microabscessos nas papilas d&#233;rmicas&#44; al&#233;m de clivagem subepid&#233;rmica e bolha com neutr&#243;filos no interior&#46;<a class="elsevierStyleCrossRefs" href="#bib0585"><span class="elsevierStyleSup">47&#44;49</span></a></p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Imuno&#8208;histologia</span><p id="par0305" class="elsevierStylePara elsevierViewall">O teste da imunofluoresc&#234;ncia direta &#40;IFD&#41;&#44; realizado em cortes de tecido obtido por bi&#243;psia da les&#227;o cut&#226;nea&#44; visa identificar imunodep&#243;sitos na jun&#231;&#227;o dermoepid&#233;rmica&#44; conhecido como teste da banda l&#250;pica &#40;TBL&#41;&#46; Geralmente&#44; faz&#8208;se a pesquisa de imunodep&#243;sitos de IgG&#44; IgM&#44; IgA e C3&#46; O TBL &#233; considerado positivo quando identificada a deposi&#231;&#227;o de material granular em faixa junto &#224; zona da membrana basal&#46; &#201; recurso que pode auxiliar no diagn&#243;stico&#44; se a histologia n&#227;o &#233; decisiva frente a les&#245;es sugestivas de LE&#44; por&#233;m n&#227;o &#233; espec&#237;fico para a doen&#231;a&#44; podendo ser observado em outras condi&#231;&#245;es dermatol&#243;gicas&#44; como dermatomiosite&#44; e mesmo na pele normal ou fotodanificada&#44; principalmente da face&#46;<a class="elsevierStyleCrossRefs" href="#bib0590"><span class="elsevierStyleSup">48&#44;50</span></a> O tipo de dep&#243;sito varia conforme a cronologia e a topografia da les&#227;o&#44; assim como o local biopsiado&#44; se no centro ou periferia da les&#227;o&#46; IgM e IgG s&#227;o os imunodep&#243;sitos mais detectados&#44; em associa&#231;&#227;o ou n&#227;o com C3&#59; IgA &#233; menos comum&#46; O TBL costuma ser positivo na pele lesada de quase&#160;100&#37; dos casos de LECA&#44; em cerca de&#160;60&#37; dos casos de LECS e de&#160;90&#37; dos casos de LED&#46;<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">11&#44;19&#44;47</span></a></p><p id="par0310" class="elsevierStylePara elsevierViewall">Estudo recente que avaliou 2&#46;050 bi&#243;psias cut&#226;neas submetidas &#224; histologia e imunofluoresc&#234;ncia direta&#44; com hip&#243;teses diagn&#243;sticas de diferentes dermatoses&#44; concluiu que o valor da IFD no aux&#237;lio diagn&#243;stico do LE &#233; question&#225;vel e seu uso n&#227;o &#233; recomendado como rotina&#46;<a class="elsevierStyleCrossRef" href="#bib0600"><span class="elsevierStyleSup">50</span></a> Embora o TBL positivo na pele n&#227;o lesada e n&#227;o exposta seja altamente espec&#237;fico para LES&#44; ele acrescenta pouca informa&#231;&#227;o aos achados obtidos conjuntamente pelo exame cl&#237;nico&#44; histopatologia e sorologia&#46; Al&#233;m disso&#44; foi demonstrada sua associa&#231;&#227;o com a presen&#231;a de anticorpos anti&#8208;DNAn no soro&#44; por&#233;m com taxas de sensibilidade e especificidade similares&#44; sugerindo ser redundante a utiliza&#231;&#227;o de ambos os testes&#46;<a class="elsevierStyleCrossRef" href="#bib0600"><span class="elsevierStyleSup">50</span></a></p><p id="par0315" class="elsevierStylePara elsevierViewall">No LE bolhoso&#44; a IFD da pele perilesional demonstra dep&#243;sito cont&#237;nuo&#44; de padr&#227;o linear ou granular&#44; ao longo da zona da membrana basal&#44; principalmente de IgG&#44; al&#233;m de IgM&#44; IgA e C3&#46; A imunofluoresc&#234;ncia indireta&#44; pela t&#233;cnica de <span class="elsevierStyleItalic">salt&#8208;split skin</span>&#44; revela dep&#243;sito do lado d&#233;rmico da clivagem&#46;<a class="elsevierStyleCrossRefs" href="#bib0560"><span class="elsevierStyleSup">42&#44;47</span></a></p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Anticorpos antinucleares</span><p id="par0320" class="elsevierStylePara elsevierViewall">Os autoanticorpos antinucleares s&#227;o marcadores imunol&#243;gicos empregados tanto no diagn&#243;stico quanto na monitora&#231;&#227;o da doen&#231;a no LE&#46; O teste de triagem mais usado &#233; o fator antin&#250;cleo &#40;FAN&#41;&#44; que utiliza a t&#233;cnica da imunofluoresc&#234;ncia indireta&#44; tendo as c&#233;lulas HEp&#8208;2 como substrato&#46; O FAN tem maior relev&#226;ncia no LECA&#47;LES&#44; em que &#233; demonstrado em quase todos os pacientes &#40;94&#37;&#8208;100&#37;&#41;&#44; geralmente em t&#237;tulos elevados&#44; superiores a&#160;1&#47;160&#46; No entanto&#44; mesmo em altos t&#237;tulos&#44; n&#227;o s&#227;o espec&#237;ficos para LES&#44; j&#225; que podem ser detectados em v&#225;rias condi&#231;&#245;es&#44; como outras doen&#231;as do tecido conjuntivo&#44; doen&#231;as hematol&#243;gicas e hep&#225;ticas&#44; infec&#231;&#245;es virais&#44; uso de v&#225;rios medicamentos e at&#233; em indiv&#237;duos saud&#225;veis&#46;<a class="elsevierStyleCrossRef" href="#bib0605"><span class="elsevierStyleSup">51</span></a> O FAN &#233; demonstrado em menor propor&#231;&#227;o nas outras formas de LEC&#44; em&#160;52&#37;&#8208;80&#37; dos pacientes de LECS e em&#160;5&#37;&#8208;17&#37; dos pacientes de LED&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p><p id="par0325" class="elsevierStylePara elsevierViewall">Por n&#227;o ser um teste espec&#237;fico para LE&#44; &#233; fundamental que&#44; frente a FAN positivo&#44; a especificidade do anticorpo antinuclear seja determinada por meio de testes adicionais&#46;</p><p id="par0330" class="elsevierStylePara elsevierViewall">Os anticorpos anti&#8208;DNAn e anti&#8208;Sm s&#227;o os mais relevantes por serem espec&#237;ficos para LES&#44; embora apresentem menor sensibilidade&#44; de&#160;56&#37;&#8208;70&#37; e 19&#37;&#8208;25&#37;&#44; respectivamente&#46; Al&#233;m do valor diagn&#243;stico&#44; o anticorpo anti&#8208;DNAn pode ser usado para monitora&#231;&#227;o da doen&#231;a&#44; j&#225; que seus n&#237;veis s&#233;ricos tendem a refletir a atividade da doen&#231;a&#44; em especial a nefropatia&#44; sobretudo quando h&#225; concomit&#226;ncia com o anticorpo anti&#8208;Sm&#46;<a class="elsevierStyleCrossRefs" href="#bib0445"><span class="elsevierStyleSup">19&#44;51</span></a> &#201; baixa a preval&#234;ncia dos anticorpos anti&#8208;DNAn e anti&#8208;Sm nos pacientes de LECS&#44; e praticamente nula nos pacientes de LECC&#46;<a class="elsevierStyleCrossRefs" href="#bib0445"><span class="elsevierStyleSup">19&#44;25</span></a></p><p id="par0335" class="elsevierStylePara elsevierViewall">Os anticorpos anti&#8208;Ro&#47;SS&#8208;A e anti&#8208;La&#47;SS&#8208;B n&#227;o s&#227;o espec&#237;ficos do LE e est&#227;o frequentemente associados &#224; s&#237;ndrome de Sj&#246;gren&#46; Ocorrem&#44; respectivamente&#44; em 36&#37;&#8208;64&#37; e 8&#37;&#8208;33&#37; dos pacientes de LES e guardam rela&#231;&#227;o com as manifesta&#231;&#245;es cut&#226;neas e hematol&#243;gicas&#44; como as citopenias&#46; Os anticorpos anti&#8208;Ro&#47;SS&#8208;A e anti&#8208;La&#47;SS&#8208;B est&#227;o presentes entre 70&#37;&#8208;90&#37; e&#160;30&#37;&#8208;40&#37;&#44; respectivamente&#44; dos casos de LECS&#44; e em at&#233;&#160;25&#37;&#160;e&#160;5&#37;&#44; respectivamente&#44; dos casos de LED&#46; Particularmente&#44; os anticorpos anti&#8208;Ro&#47;SS&#8208;A s&#227;o considerados marcadores do LECS e est&#227;o relacionados com a extrema fotossensibilidade deste subtipo de LEC&#46; Al&#233;m disso&#44; quando presentes na gestante&#44; esses anticorpos atravessam a barreira placent&#225;ria e podem causar LE neonatal&#46; Os anticorpos especificamente dirigidos contra a subunidase&#160;52&#160;kD do ant&#237;geno Ro&#47;SS&#8208;A est&#227;o associados a maior risco de bloqueio card&#237;aco cong&#234;nito&#46; Adultos com esses anticorpos tamb&#233;m podem apresentar prolongamento do intervalo QT&#44; com maior risco de desenvolver arritmias ventriculares&#46;<a class="elsevierStyleCrossRef" href="#bib0605"><span class="elsevierStyleSup">51</span></a></p><p id="par0340" class="elsevierStylePara elsevierViewall">Anticorpos anti&#8208;RNP s&#227;o caracter&#237;sticos da doen&#231;a mista do tecido conjuntivo&#44; mas podem estar presentes em&#160;23&#37;&#8208;49&#37; dos pacientes de LES e n&#227;o mostram correla&#231;&#227;o com quaisquer manifesta&#231;&#245;es da doen&#231;a&#46;<a class="elsevierStyleCrossRef" href="#bib0605"><span class="elsevierStyleSup">51</span></a> Podem ocorrer entre&#160;8&#37;&#8208;10&#37; dos casos de LECS e muito raramente no LECC&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Avalia&#231;&#227;o da atividade e dano cut&#226;neos</span><p id="par0345" class="elsevierStylePara elsevierViewall">Pacientes diagnosticados com LEC devem ser submetidos a exame dermatol&#243;gico completo&#44; n&#227;o apenas durante epis&#243;dios de exacerba&#231;&#227;o da doen&#231;a&#44; mas tamb&#233;m a intervalos regulares&#44; com o objetivo de se avaliar a atividade e a progress&#227;o da doen&#231;a&#44; assim como identificar poss&#237;veis danos decorrentes do acometimento cut&#226;neo&#46;</p><p id="par0350" class="elsevierStylePara elsevierViewall">V&#225;rios escores de atividade da doen&#231;a est&#227;o bem estabelecidos na avalia&#231;&#227;o de pacientes com LES&#44; para uso em ensaios cl&#237;nicos e na pr&#225;tica cotidiana&#44; como o SLEDAI &#40;<span class="elsevierStyleItalic">Systemic Lupus Erythematosus Disease Activity Index</span>&#41;&#46; Apesar de inclu&#237;rem alguns crit&#233;rios dermatol&#243;gicos&#44; esses escores carecem de sensibilidade para avaliar a atividade cut&#226;nea nos diferentes subtipos de LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0410"><span class="elsevierStyleSup">12</span></a></p><p id="par0355" class="elsevierStylePara elsevierViewall">Por essa raz&#227;o&#44; foi criado o CLASI &#40;<span class="elsevierStyleItalic">Cutaneous Lupus Area and Severity Index</span>&#41;&#44; um instrumento desenvolvido especificamente para quantificar o acometimento cut&#226;neo no LE&#44; com escores de atividade &#40;CLASI&#8208;A&#41; e de dano &#40;CLASI&#8208;D&#41;&#46; Esse instrumento avalia a morfologia &#40;eritema&#44; descama&#231;&#227;o&#47;ceratose&#44; discromia e cicatriz&#47;atrofia&#41; e a localiza&#231;&#227;o anat&#244;mica &#40;13&#160;s&#237;tios&#41; das les&#245;es cut&#226;neas&#44; assim como o acometimento de mucosas e couro cabeludo&#46; Foi originalmente estabelecido como recurso para mensurar desfechos em ensaios cl&#237;nicos e validado por dermatologistas e reumatologistas&#46; O CLASI ainda demonstrou boa correla&#231;&#227;o com indicadores da qualidade de vida dos pacientes e revelou&#8208;se instrumento &#250;til e de f&#225;cil aplica&#231;&#227;o na pr&#225;tica cl&#237;nica&#46;<a class="elsevierStyleCrossRefs" href="#bib0405"><span class="elsevierStyleSup">11&#44;12&#44;53</span></a></p><p id="par0360" class="elsevierStylePara elsevierViewall">Posteriormente&#44; surgiu o CLASI revisado &#40;RCLASI&#41;&#44; que acrescentou novos par&#226;metros &#8211; edema&#47;infiltra&#231;&#227;o e placas&#47;n&#243;dulos subcut&#226;neos &#8211; com o intuito de melhorar a acur&#225;cia na avalia&#231;&#227;o da atividade da doen&#231;a cut&#226;nea&#44; sendo capaz de abranger aspectos importantes de alguns subtipos de LEC&#44; como o LE t&#250;mido e o LE profundo&#46;<a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">48</span></a></p><p id="par0365" class="elsevierStylePara elsevierViewall">Entretanto&#44; uma recente revis&#227;o sistem&#225;tica constatou que&#44; dentre os ensaios que utilizaram o CLASI como medida de desfecho de interven&#231;&#245;es terap&#234;uticas&#44; s&#227;o poucos com alta qualidade de evid&#234;ncia&#46; Esse estudo concluiu que &#233; necess&#225;ria valida&#231;&#227;o adicional para averiguar a efetividade do CLASI na avalia&#231;&#227;o dos diferentes subtipos de LEC&#46; Os autores sugerem que o uso de medidas de desfecho padronizadas&#44; referidas por paciente e m&#233;dico&#44; poderiam reduzir a heterogeneidade e permitir compara&#231;&#245;es entre pacientes inclu&#237;dos em diferentes ensaios cl&#237;nicos&#46; Tamb&#233;m recomendam que o CLASI&#8208;50 &#40;redu&#231;&#227;o de&#160;50&#37; na pontua&#231;&#227;o do CLASI&#8208;A&#41; poderia ser mais efetivo como medida de resposta terap&#234;utica que o CLASI&#8208;20 &#40;redu&#231;&#227;o de&#160;20&#37; no CLASI&#8208;A&#41;&#44; usualmente utilizado como crit&#233;rio de boa resposta nos ensaios cl&#237;nicos&#46;<a class="elsevierStyleCrossRef" href="#bib0620"><span class="elsevierStyleSup">54</span></a></p></span></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Progress&#227;o de l&#250;pus cut&#226;neo a l&#250;pus eritematoso sist&#234;mico</span><p id="par0370" class="elsevierStylePara elsevierViewall">De&#160;5&#37;&#8208;25&#37; dos casos de LEC isolado&#44; independentemente do subtipo&#44; podem progredir para LES durante sua evolu&#231;&#227;o&#44; com tempo m&#233;dio de&#160;oito&#160;anos entre o diagn&#243;stico da doen&#231;a cut&#226;nea e o desenvolvimento da doen&#231;a sist&#234;mica&#46; Estudo de base populacional desenvolvido na Su&#233;cia mostrou que a maior possibilidade de desenvolver LES ocorre at&#233;&#160;tr&#234;s&#160;anos ap&#243;s o diagn&#243;stico da doen&#231;a cut&#226;nea&#44; al&#233;m de ser mais prov&#225;vel nas mulheres&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p><p id="par0375" class="elsevierStylePara elsevierViewall">Por outro lado&#44; aproximadamente&#160;50&#37;&#8208;60&#37; dos pacientes de LECS experimentam transi&#231;&#227;o ou j&#225; podem ser classificados como LES quando do diagn&#243;stico da doen&#231;a cut&#226;nea&#44; geralmente preenchendo crit&#233;rios cut&#226;neos&#44; musculoesquel&#233;ticos e sorol&#243;gicos&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p><p id="par0380" class="elsevierStylePara elsevierViewall">Entretanto&#44; os pacientes de LEC que progridem para LES tendem a apresentar sintomas sist&#234;micos mais leves&#59; s&#227;o raras as manifesta&#231;&#245;es cardiopulmonares e neurol&#243;gicas&#44; assim como outras complica&#231;&#245;es graves da doen&#231;a&#46; Crit&#233;rios relacionados &#224; nefropatia s&#227;o indicadores relevantes de diferencia&#231;&#227;o entre doen&#231;a cut&#226;nea isolada e doen&#231;a sist&#234;mica&#46; Quando presente&#44; o acometimento renal tende a ser menos grave naqueles que evoluem de LEC a LES&#44; por&#233;m faltam estudos mais consistentes para permitir essa conclus&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p><p id="par0385" class="elsevierStylePara elsevierViewall">H&#225; evid&#234;ncia de que LED e LECS com les&#245;es disseminadas exibem maior probabilidade de evolu&#237;rem com manifesta&#231;&#245;es sist&#234;micas que aqueles com les&#245;es localizadas&#46; Estudo retrospectivo&#44; que comparou pacientes de LED com doen&#231;a localizada e pacientes de LED e LECS com doen&#231;a disseminada&#44; mostrou que&#160;30&#37; dos casos com les&#245;es disseminadas apresentaram manifesta&#231;&#245;es extracut&#226;neas&#44; como nefrite&#44; pleurite e poliartrite&#44; enquanto aqueles com doen&#231;a localizada n&#227;o tiveram manifesta&#231;&#245;es sist&#234;micas&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p><p id="par0390" class="elsevierStylePara elsevierViewall">As les&#245;es cut&#226;neas inespec&#237;ficas prevalecem no LES&#44; principalmente com doen&#231;a em atividade&#46; Por isso&#44; quando presentes&#44; implica maior probabilidade de doen&#231;a sist&#234;mica&#44; em particular a ocorr&#234;ncia de telangiectasias periungueais&#46; A presen&#231;a dessas les&#245;es foi verificada em&#160;76&#37; dos pacientes de LES com LED concomitante e em nenhum paciente com LED exclusivo&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p><p id="par0395" class="elsevierStylePara elsevierViewall">Pacientes de LEC com potencial de desenvolver LES t&#234;m maior probabilidade de apresentar FAN com t&#237;tulos elevados em compara&#231;&#227;o com aqueles de LEC exclusivo&#46; Al&#233;m de marcadores de acometimento sist&#234;mico importante nos pacientes de LES&#44; t&#237;tulos elevados do FAN e a presen&#231;a dos anticorpos espec&#237;ficos anti&#8208;DNAn ou anti&#8208;Sm tamb&#233;m s&#227;o indicativos de evolu&#231;&#227;o para doen&#231;a sist&#234;mica nos pacientes com LEC&#46;</p><p id="par0400" class="elsevierStylePara elsevierViewall">Outras altera&#231;&#245;es laboratoriais persistentes&#44; como anemia&#44; leucopenia&#44; trombocitopenia e eleva&#231;&#227;o da velocidade de hemossedimenta&#231;&#227;o&#44; tamb&#233;m s&#227;o consideradas importantes marcadores de progress&#227;o para LES&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p><p id="par0405" class="elsevierStylePara elsevierViewall">Tamb&#233;m &#233; mat&#233;ria de discuss&#227;o se a administra&#231;&#227;o precoce de antimal&#225;ricos em pacientes de LEC&#44; com potencial de desenvolver doen&#231;a sist&#234;mica&#44; poderia prevenir a progress&#227;o a LES ou atenuar danos a &#243;rg&#227;os vitais&#44; uma vez instalada a doen&#231;a sist&#234;mica&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p><p id="par0410" class="elsevierStylePara elsevierViewall">Recomenda&#8208;se seguimento peri&#243;dico&#44; a intervalos mais curtos&#44; de pacientes com LEC que apresentam fatores de risco para progress&#227;o a LES&#44; com exame cl&#237;nico minucioso e adequada revis&#227;o laboratorial&#46;<a class="elsevierStyleCrossRef" href="#bib0610"><span class="elsevierStyleSup">52</span></a></p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Tratamento</span><p id="par0415" class="elsevierStylePara elsevierViewall">O tratamento do LEC envolve medidas farmacol&#243;gicas e n&#227;o farmacol&#243;gicas&#46; Escolher a terapia mais eficaz para cada caso pode ser desafiador e exige aten&#231;&#227;o &#224;s manifesta&#231;&#245;es cl&#237;nicas e familiaridade com as terapias dispon&#237;veis&#46; &#201; importante avaliar a ades&#227;o do paciente ao tratamento em cada consulta&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a> Embora existam apenas tr&#234;s f&#225;rmacos aprovados pela ag&#234;ncia norte&#8208;americana Food and Drug Administration &#40;FDA&#41; para uso no LES &#8211; corticosteroides&#44; hidroxicloroquina e belimumabe &#8211; e nenhuma aprovada especificamente para LEC&#44; &#233; poss&#237;vel encontrar dados na literatura que permitem racionalizar a abordagem terap&#234;utica&#46;<a class="elsevierStyleCrossRef" href="#bib0630"><span class="elsevierStyleSup">56</span></a></p><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Medidas gerais</span><p id="par0420" class="elsevierStylePara elsevierViewall">A fotoprote&#231;&#227;o &#233; pilar fundamental do tratamento do LEC&#46; Os fotoprotetores podem prevenir o surgimento de les&#245;es nos pacientes com LEC&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;55&#8211;58</span></a> Entretanto&#44; outras medidas de cuidado tamb&#233;m se somam a seu uso&#44; como mudan&#231;as comportamentais&#44; uso de chap&#233;us e vestes longas&#44; preferencialmente com tecnologia para prote&#231;&#227;o &#224; RUV&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;58&#44;59</span></a></p><p id="par0425" class="elsevierStylePara elsevierViewall">A cessa&#231;&#227;o do tabagismo deve ser averiguada e encorajada a cada consulta&#44; de prefer&#234;ncia com referenciamento do paciente a programas e terapias de apoio&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;57</span></a> A suplementa&#231;&#227;o de vitamina D nos pacientes com defici&#234;ncia pode ser ben&#233;fica para o controle da doen&#231;a&#46;<a class="elsevierStyleCrossRefs" href="#bib0630"><span class="elsevierStyleSup">56&#44;57&#44;60</span></a> Em caso de LEC induzido por f&#225;rmacos&#44; a medica&#231;&#227;o suspeita deve ser prontamente suspensa&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a></p><p id="par0430" class="elsevierStylePara elsevierViewall">Contracep&#231;&#227;o pode ser necess&#225;ria quando do uso de f&#225;rmacos teratog&#234;nicos&#46; Mulheres com LEC podem utilizar contraceptivos orais combinados&#44; se n&#227;o houver hist&#243;ria de tromboembolismo ou altos n&#237;veis de anticorpos antifosfol&#237;pides&#59; caso contr&#225;rio&#44; deve&#8208;se optar por dispositivo intrauterino ou uso de progest&#225;genos isolados&#46;<a class="elsevierStyleCrossRefs" href="#bib0575"><span class="elsevierStyleSup">45&#44;61</span></a></p><p id="par0435" class="elsevierStylePara elsevierViewall">O uso de camuflagem cosm&#233;tica e pr&#243;teses de cabelos podem ocultar cicatrizes e alopecia&#44; melhorando a qualidade de vida e a autoestima dos pacientes&#46;<a class="elsevierStyleCrossRefs" href="#bib0645"><span class="elsevierStyleSup">59&#44;62</span></a> &#201; importante que pacientes com LEC sejam orientados a evitar interven&#231;&#245;es que traumatizem a pele&#44; pelo risco de koebneriza&#231;&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0660"><span class="elsevierStyleSup">62</span></a></p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Tratamento t&#243;pico</span><p id="par0440" class="elsevierStylePara elsevierViewall">Os corticosteroides s&#227;o considerados a primeira linha de tratamento t&#243;pico&#44; por seu efeito anti&#8208;inflamat&#243;rio&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;6</span></a> Podem ser utilizados nos casos de les&#245;es localizadas ou como terapia adjuvante nos pacientes em tratamento sist&#234;mico&#46; Corticosteroides potentes&#44; como o clobetasol&#44; s&#227;o mais eficazes para o controle da doen&#231;a que os de baixa pot&#234;ncia&#46;<a class="elsevierStyleCrossRefs" href="#bib0630"><span class="elsevierStyleSup">56&#44;61</span></a> Entretanto&#44; essas medica&#231;&#245;es est&#227;o associadas a maior risco de efeitos colaterais&#44; como estrias e telangiectasias&#44; por seu efeito nos fibroblastos e vasos sangu&#237;neos&#44; respectivamente&#44; al&#233;m de dermatite perioral rosaceiforme&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;60</span></a> Por isso&#44; a terapia com corticosteroides t&#243;picos potentes deve ser usada pelo menor tempo poss&#237;vel&#46; A inje&#231;&#227;o intralesional de corticoide pode ser aplicada em les&#245;es hipertr&#243;ficas localizadas&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;55</span></a></p><p id="par0445" class="elsevierStylePara elsevierViewall">Os inibidores t&#243;picos da calcineurina &#8211; tacrolimo&#160;0&#44;03&#37;&#160;ou&#160;0&#44;1&#37; em pomada e pimecrolimo&#160;1&#37; em creme &#8211; podem ser utilizados como substitutos dos corticosteroides nos casos que exijam tratamento prolongado ou com maior risco de efeitos colaterais&#44; como les&#245;es na face de crian&#231;as&#46;<a class="elsevierStyleCrossRefs" href="#bib0625"><span class="elsevierStyleSup">55&#44;61</span></a> S&#227;o menos eficazes que os corticoides t&#243;picos potentes&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> Os efeitos colaterais relacionados ao uso dessas medica&#231;&#245;es incluem sensa&#231;&#227;o de ard&#234;ncia&#44; prurido e eritema no local da aplica&#231;&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">57</span></a> Alguns estudos mostraram bons resultados com a aplica&#231;&#227;o combinada de clobetasol&#160;0&#44;05&#37; e tacrolimo&#160;0&#44;03&#37;&#46;</p><p id="par0450" class="elsevierStylePara elsevierViewall">O R&#8208;salbutamol &#233; um agonista do receptor &#946;2&#8208;adren&#233;rgico que inibe a produ&#231;&#227;o de IL&#8208;2 e IFN&#8208;&#947;&#44; podendo melhorar les&#245;es de LEC&#44; quando utilizado a&#160;0&#44;5&#37; em creme&#46;<a class="elsevierStyleCrossRefs" href="#bib0625"><span class="elsevierStyleSup">55&#44;60</span></a> Entretanto&#44; n&#227;o &#233; comercialmente dispon&#237;vel para uso t&#243;pico&#46;<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">60</span></a> Os retinoides t&#243;picos j&#225; foram utilizados com sucesso em algumas pequenas s&#233;ries de casos&#46;<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">60</span></a></p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Tratamento sist&#234;mico</span><p id="par0455" class="elsevierStylePara elsevierViewall">Pacientes com les&#245;es localizadas refrat&#225;rias ao tratamento t&#243;pico ou com les&#245;es disseminadas geralmente necessitam de tratamento sist&#234;mico&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a> A <a class="elsevierStyleCrossRef" href="#tbl0025">tabela 5</a> mostra o n&#237;vel de evid&#234;ncia e o grau de recomenda&#231;&#227;o dos principais medicamentos de uso sist&#234;mico no tratamento do LEC&#46;</p><elsevierMultimedia ident="tbl0025"></elsevierMultimedia></span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Antimal&#225;ricos</span><p id="par0460" class="elsevierStylePara elsevierViewall">Os antimal&#225;ricos &#40;AM&#41; constituem a primeira linha de tratamento sist&#234;mico&#59; &#233; prov&#225;vel que previnam a progress&#227;o do LEC para doen&#231;a sist&#234;mica&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;59&#44;61&#44;63</span></a> S&#227;o capazes de inibir a apresenta&#231;&#227;o de ant&#237;genos pelas CDP&#44; a forma&#231;&#227;o de complexos ant&#237;geno&#8208;anticorpo e a sinaliza&#231;&#227;o via receptores <span class="elsevierStyleItalic">Toll&#8208;like&#44;</span> reduzindo a produ&#231;&#227;o de IFN tipo&#160;I&#46;<a class="elsevierStyleCrossRefs" href="#bib0420"><span class="elsevierStyleSup">14&#44;55&#44;59</span></a> A hidroxicloroquina &#40;HCQ&#41; &#233; o AM mais utilizado pelo melhor perfil de seguran&#231;a quanto &#224; toxicidade ocular em rela&#231;&#227;o &#224; cloroquina &#40;CQ&#41;&#46; A dose recomendada de HCQ&#44; em parte da literatura&#44; &#233; de&#160;6&#44;5&#160;mg&#47;kg&#47;dia&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a> Contudo&#44; em&#160;2016&#44; a American Academy of Ophthalmology recomendou que doses maiores que&#160;5&#160;mg&#47;kg&#47;dia de HCQ e 2&#44;3&#160;mg&#47;kg&#47;dia de CQ sejam evitadas&#44; por risco aumentado de retinopatia&#46;<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">58</span></a></p><p id="par0465" class="elsevierStylePara elsevierViewall">O &#237;ndice de resposta dos AM &#233; de cerca de&#160;63&#37; dentre os diversos subtipos de LEC e pode ser um pouco maior para a CQ em rela&#231;&#227;o &#224; HCQ&#46;<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">64</span></a> A taxa m&#233;dia de resposta foi de&#160;91&#37; nos casos de LECA&#44; 57&#37;&#160;no LED e apenas&#160;31&#37; no LE perni&#243;tico&#46;<a class="elsevierStyleCrossRef" href="#bib0670"><span class="elsevierStyleSup">64</span></a> Pacientes de LECC tendem a responder mais lentamente aos AM que aqueles de LECA&#46;<a class="elsevierStyleCrossRef" href="#bib0630"><span class="elsevierStyleSup">56</span></a></p><p id="par0470" class="elsevierStylePara elsevierViewall">Em casos refrat&#225;rios&#44; um AM pode ser substitu&#237;do por outro &#8211; HCQ por CQ ou CQ por HCQ&#59; nesses casos&#44; a taxa de resposta ao segundo AM pode chegar a&#160;56&#37;&#44; mas cair para&#160;42&#37; ap&#243;s&#160;um&#160;ano e 22&#37; ap&#243;s&#160;dois&#160;anos&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">4&#44;6&#44;45&#44;60&#44;64</span></a> A adi&#231;&#227;o de quinacrina&#44; f&#225;rmaco n&#227;o dispon&#237;vel no Brasil&#44; na dose de&#160;100&#8208;200&#160;mg&#47;dia&#44; nos casos refrat&#225;rios aos AM em monoterapia&#44; pode aumentar a taxa de resposta para&#160;66&#37;&#44; sem aumentar o risco de retinopatia&#46;<a class="elsevierStyleCrossRefs" href="#bib0575"><span class="elsevierStyleSup">45&#44;57&#44;58&#44;61&#44;64</span></a> O uso de AM durante a gesta&#231;&#227;o e lacta&#231;&#227;o &#233; recomendado&#44; especialmente nas pacientes com les&#245;es cut&#226;neas e LES&#44; podendo reduzir o risco de acometimento card&#237;aco pelo LE neonatal&#46;<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">65</span></a></p><p id="par0475" class="elsevierStylePara elsevierViewall">Os efeitos colaterais dos AM incluem n&#225;useas&#44; v&#244;mitos&#44; pigmenta&#231;&#227;o cut&#226;nea&#44; tonteira&#44; cefaleia&#44; ototoxicidade e neuropatia perif&#233;rica&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> A retinopatia &#233; o efeito colateral mais relevante e ocorre em at&#233;&#160;1&#37; dos casos&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> Os pacientes devem ser avaliados no in&#237;cio do tratamento e&#44; caso n&#227;o tenham nenhum fator de risco adicional&#44; anualmente&#44; ap&#243;s o quinto ano de uso do medicamento&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a> Pacientes com doses acima de&#160;5&#44;0&#160;mg&#47;kg&#47;dia&#44; insufici&#234;ncia renal&#44; uso concomitante de tamoxifeno e maculopatia retiniana preexistente est&#227;o sob maior risco de retinopatia e devem ser monitorados com maior frequ&#234;ncia&#46;<a class="elsevierStyleCrossRef" href="#bib0630"><span class="elsevierStyleSup">56</span></a> A campimetria e o exame de fundo de olho podem n&#227;o detectar altera&#231;&#245;es iniciais&#59; a tomografia de coer&#234;ncia &#243;ptica &#233; recomendada para auxiliar no diagn&#243;stico precoce&#46;<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">65</span></a> Existem raros relatos de toxicidade card&#237;aca&#44; com prolongamento do intervalo QT&#46;<a class="elsevierStyleCrossRef" href="#bib0675"><span class="elsevierStyleSup">65</span></a></p><p id="par0480" class="elsevierStylePara elsevierViewall">Quando dispon&#237;vel&#44; a dosagem s&#233;rica de HCQ pode ser utilizada para avalia&#231;&#227;o do tratamento ap&#243;s&#160;seis&#160;meses de uso sem resposta&#46;<a class="elsevierStyleCrossRefs" href="#bib0575"><span class="elsevierStyleSup">45&#44;60</span></a> Valores inferiores a&#160;200&#160;ng&#47;mL indicam m&#225;&#8208;ades&#227;o ao tratamento&#44; enquanto valores acima de&#160;750&#160;ng&#47;mL est&#227;o correlacionados a melhores taxas de controle da atividade da doen&#231;a&#46;<a class="elsevierStyleCrossRefs" href="#bib0575"><span class="elsevierStyleSup">45&#44;56</span></a> Pacientes com contraindica&#231;&#227;o aos AM ou com dose otimizada de AM&#44; mas sem resposta ou com resposta parcial&#44; t&#234;m indica&#231;&#227;o de f&#225;rmacos de segunda linha de tratamento&#46; Tabagistas s&#227;o mais propensos a n&#227;o responderem aos AM&#46;<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">57</span></a></p></span><span id="sec0110" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Metotrexato</span><p id="par0485" class="elsevierStylePara elsevierViewall">O metotrexato &#40;MTX&#41; &#233; a primeira escolha dentre os f&#225;rmacos de segunda linha para pacientes refrat&#225;rios ou com contraindica&#231;&#227;o ao uso dos AM&#46;<a class="elsevierStyleCrossRefs" href="#bib0625"><span class="elsevierStyleSup">55&#44;66</span></a> &#201; um inibidor da diidrofolato&#8208;redutase&#44; que afeta a replica&#231;&#227;o celular e suprime a produ&#231;&#227;o de anticorpos&#46;<a class="elsevierStyleCrossRef" href="#bib0645"><span class="elsevierStyleSup">59</span></a> A dose recomendada pode variar de&#160;7&#44;5&#8208;25&#160;mg&#47;semana&#44; via oral ou subcut&#226;nea&#46; Os efeitos colaterais s&#227;o n&#225;useas&#44; v&#244;mitos&#44; dor abdominal&#44; hepatotoxidade&#44; ulcera&#231;&#227;o de mucosas&#44; supress&#227;o medular&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">4&#44;55&#44;60</span></a> A aplica&#231;&#227;o subcut&#226;nea e a administra&#231;&#227;o de &#225;cido f&#243;lico nos dias posteriores ao uso da medica&#231;&#227;o podem reduzir significantemente os efeitos colaterais gastrintestinais&#46;<a class="elsevierStyleCrossRefs" href="#bib0640"><span class="elsevierStyleSup">58&#44;61</span></a> Os pacientes devem ser monitorados laboratorialmente nas primeiras semanas de uso&#44; ap&#243;s aumento das doses e&#44; trimestralmente&#44; no acompanhamento regular&#46;</p><p id="par0490" class="elsevierStylePara elsevierViewall">O uso de MTX deve ser evitado em pacientes etilistas&#44; naqueles em uso concomitante de f&#225;rmacos hepatot&#243;xicos&#44; com esteatose hep&#225;tica grave&#44; insufici&#234;ncia renal ou doen&#231;a hep&#225;tica de base&#44; incluindo hepatites virais&#44; condi&#231;&#245;es que devem ser pesquisadas antes do in&#237;cio do tratamento com MTX&#46;<a class="elsevierStyleCrossRefs" href="#bib0640"><span class="elsevierStyleSup">58&#44;61</span></a> O risco de hepatoxicidade fora dessas condi&#231;&#245;es &#233; baixo&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a> Pneumonite intersticial &#233; complica&#231;&#227;o rara e potencialmente fatal&#46;<a class="elsevierStyleCrossRefs" href="#bib0370"><span class="elsevierStyleSup">4&#44;55</span></a> MTX &#233; teratog&#234;nico e deve ser recomendada contracep&#231;&#227;o adequada&#46;<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">60</span></a></p></span><span id="sec0115" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Retinoides sist&#234;micos</span><p id="par0495" class="elsevierStylePara elsevierViewall">Os retinoides s&#227;o utilizados com sucesso no tratamento de LEC refrat&#225;rio&#44; especialmente nas formas verrucosas&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;55&#44;61</span></a> Eles inibem a produ&#231;&#227;o de citocinas pr&#243;&#8208;inflamat&#243;rias&#44; como a IL&#8208;6 e o IFN&#8208;&#947;&#44; al&#233;m de regular e normalizar a diferencia&#231;&#227;o dos ceratin&#243;citos&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a> Dados da literatura n&#227;o mostram diferen&#231;a significante de efic&#225;cia entre HCQ e acitretina em pacientes com diferentes subtipos de LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">57</span></a> A isotretino&#237;na tamb&#233;m j&#225; foi utilizada em pequenas s&#233;ries de casos&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a></p><p id="par0500" class="elsevierStylePara elsevierViewall">A dose de acitretina e isotretino&#237;na &#233; de&#160;0&#44;2&#8208;1&#44;0&#160;mg&#47;kg&#47;dia&#46; A resposta&#44; em geral&#44; &#233; r&#225;pida e ocorre em duas a seis semanas&#46; A recidiva tamb&#233;m costuma sobrevir logo ap&#243;s a interrup&#231;&#227;o da medica&#231;&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a></p><p id="par0505" class="elsevierStylePara elsevierViewall">Pacientes em uso de retinoides devem ser monitorados regularmente pelo risco de hepatotoxicidade e aumento dos n&#237;veis s&#233;ricos de triglic&#233;rides&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> Outros efeitos colaterais incluem xerose mucocut&#226;nea e altera&#231;&#245;es &#243;sseas&#44; como a hiperostose&#46;<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">67</span></a> O uso de fotoprotetores deve ser intensificado&#44; pelo risco de agravamento da fotossensibilidade&#46;<a class="elsevierStyleCrossRef" href="#bib0685"><span class="elsevierStyleSup">67</span></a> Em decorr&#234;ncia do risco de teratogenicidade&#44; mulheres em idade f&#233;rtil devem ser submetidas a contracep&#231;&#227;o adequada durante e ap&#243;s o t&#233;rmino do tratamento &#40;isotretino&#237;na&#44; at&#233;&#160;um&#160;m&#234;s&#44; e acitretina&#44; at&#233;&#160;dois a tr&#234;s&#160;anos&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;55</span></a></p></span><span id="sec0120" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Dapsona</span><p id="par0510" class="elsevierStylePara elsevierViewall">A dapsona &#233; agente imunomodulador e antimicrobiano que inibe a mieloperoxidase presente em neutr&#243;filos e mon&#243;citos&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;59&#44;68</span></a> Pode ser usada isoladamente ou em combina&#231;&#227;o com os AM&#46; Mais de&#160;50&#37; dos pacientes com LEC respondem favoravelmente ao uso da dapsona&#44; inclusive aqueles com LED&#44; subtipo classicamente mais resistente&#44; em que a taxa de resposta se aproxima de&#160;60&#37;&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;68</span></a> A dapsona &#233; considerada f&#225;rmaco de primeira escolha no tratamento do LE bolhoso e de outras manifesta&#231;&#245;es neutrof&#237;licas no LE&#44; como a urtic&#225;ria vasculite&#46;<a class="elsevierStyleCrossRefs" href="#bib0630"><span class="elsevierStyleSup">56&#44;61</span></a> As variantes hipercerat&#243;sicas usualmente n&#227;o respondem bem &#224; dapsona&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a></p><p id="par0515" class="elsevierStylePara elsevierViewall">A dose inicial &#233; de&#160;50&#160;mg&#47;dia e pode ser aumentada at&#233;&#160;200&#160;mg&#47;dia&#46;<a class="elsevierStyleCrossRefs" href="#bib0625"><span class="elsevierStyleSup">55&#44;61</span></a> Os pacientes devem ser avaliados quanto &#224; defici&#234;ncia de glicose&#8208;6&#8208;fosfatodesidrogenase antes do in&#237;cio do tratamento&#46;<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">58</span></a></p><p id="par0520" class="elsevierStylePara elsevierViewall">Os efeitos colaterais podem ser graves&#44; como erup&#231;&#227;o ao f&#225;rmaco com eosinofilia e sintomas sist&#234;micos&#44; a s&#237;ndrome DRESS &#40;do ingl&#234;s&#44; <span class="elsevierStyleItalic">drug reaction with eosinophilia and systemic symptoms</span>&#41;&#44; meta&#8208;hemoglobinemia e agranulocitose&#46;<a class="elsevierStyleCrossRefs" href="#bib0625"><span class="elsevierStyleSup">55&#44;57</span></a> Anemia hemol&#237;tica pode ocorrer em at&#233;&#160;50&#37; dos pacientes&#46;<a class="elsevierStyleCrossRefs" href="#bib0635"><span class="elsevierStyleSup">57&#44;68</span></a> Os n&#237;veis de hemoglobina devem ser monitorados durante o primeiro m&#234;s de tratamento e&#44; ent&#227;o&#44; a cada tr&#234;s meses&#46; Os n&#237;veis de meta&#8208;hemoglobina podem ser avaliados entre o&#160;8&#176;&#160;e&#160;14&#176;&#160;dia ap&#243;s a introdu&#231;&#227;o da medica&#231;&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0650"><span class="elsevierStyleSup">60</span></a> A dapsona &#233; o &#250;nico f&#225;rmaco de segunda linha que pode ser utilizado durante a gesta&#231;&#227;o e a amamenta&#231;&#227;o&#46;<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">60&#44;61</span></a></p></span><span id="sec0125" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Micofenolato de mofetila</span><p id="par0525" class="elsevierStylePara elsevierViewall">O micofenolato de mofetila &#40;MFM&#41; &#233; considerado agente de terceira linha para o tratamento do LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a> O MFM causa deple&#231;&#227;o do trifosfato de guanosina&#44; necess&#225;rio para ades&#227;o de linf&#243;citos e mon&#243;citos ao endot&#233;lio durante o processo de inflama&#231;&#227;o&#44; al&#233;m de induzir apoptose de linf&#243;citos&#160;T e reduzir a ativa&#231;&#227;o dos linf&#243;citos&#160;B&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a> Foi relatada uma taxa de resposta completa ou significante em&#160;62&#37; dos pacientes de LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> MFM pode ser usado isoladamente ou em combina&#231;&#227;o com AM&#46;<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">4</span></a> A dose inicial &#233; de&#160;500&#160;mg&#47;dia e pode ser aumentada at&#233;&#160;3&#160;g&#47;dia&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a></p><p id="par0530" class="elsevierStylePara elsevierViewall">Os efeitos colaterais mais frequentes s&#227;o gastrintestinais&#44; citopenias&#44; hepatotoxicidade e infec&#231;&#245;es virais e urin&#225;rias&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a> Os pacientes devem realizar revis&#245;es laboratoriais mensalmente&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a> O f&#225;rmaco &#233; da categoria&#160;X e n&#227;o pode ser utilizado durante a gesta&#231;&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a></p></span><span id="sec0130" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Azatioprina</span><p id="par0535" class="elsevierStylePara elsevierViewall">A azatioprina &#233; um an&#225;logo da purina que deprime a fun&#231;&#227;o dos linf&#243;citos&#160;T&#160;e&#160;B e reduz a apresenta&#231;&#227;o de ant&#237;genos&#46;<a class="elsevierStyleCrossRef" href="#bib0645"><span class="elsevierStyleSup">59</span></a> Pode ser indicada no LEC em caso de insucesso dos tratamentos descritos anteriormente&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> S&#233;ries de caso t&#234;m mostrado sucesso no tratamento do LEC&#44; embora n&#227;o existam grandes estudos que suportem essa recomenda&#231;&#227;o&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> Pode ser usada nas gestantes com LES&#44; mas sua rela&#231;&#227;o risco&#8208;benef&#237;cio deve ser ponderada&#46;<a class="elsevierStyleCrossRef" href="#bib0380"><span class="elsevierStyleSup">6</span></a> A dose recomendada &#233; de&#160;1&#8208;3&#160;mg&#47;kg&#47;dia&#46; Os efeitos adversos s&#227;o gastrintestinais&#44; infec&#231;&#245;es oportunistas e citopenias&#46;<a class="elsevierStyleCrossRef" href="#bib0640"><span class="elsevierStyleSup">58</span></a></p></span><span id="sec0135" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Talidomida</span><p id="par0540" class="elsevierStylePara elsevierViewall">A talidomida &#233; um f&#225;rmaco utilizado como terapia de resgate nos casos graves&#44; refrat&#225;rios e com alto risco de forma&#231;&#227;o de cicatrizes&#46;<a class="elsevierStyleCrossRef" href="#bib0680"><span class="elsevierStyleSup">66</span></a> Atua inibindo a s&#237;ntese de TNF&#8208;&#945;&#44; a angiog&#234;nese e a apoptose de ceratin&#243;citos induzida pela RUV&#44; reduzindo a produ&#231;&#227;o de IFN&#8208;&#947; e a fagocitose por polimorfonucleares&#46;<a class="elsevierStyleCrossRefs" href="#bib0625"><span class="elsevierStyleSup">55&#44;69</span></a> A taxa de resposta &#233; superior a&#160;90&#37; nos diferentes subtipos de LEC&#44; a mais alta dentre todos os tratamentos dispon&#237;veis&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;57&#44;70</span></a> Por&#233;m&#44; com alto risco de reca&#237;das&#44; de at&#233;&#160;70&#37;&#44; ap&#243;s a suspens&#227;o da medica&#231;&#227;o&#44; especialmente no LED&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;56&#44;70</span></a> A dose inicial recomendada &#233; de&#160;100&#160;mg&#47;dia&#44; que deve ser reduzida assim que a resposta cl&#237;nica for alcan&#231;ada&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a></p><p id="par0545" class="elsevierStylePara elsevierViewall">A alta frequ&#234;ncia de eventos adversos pode limitar seu uso&#44; afetando&#160;24&#37; dos pacientes &#40;16&#37;&#160;com neuropatia perif&#233;rica e 2&#37;&#160;com eventos tromboemb&#243;licos&#41;&#46;<a class="elsevierStyleCrossRefs" href="#bib0630"><span class="elsevierStyleSup">56&#44;70</span></a> A polineuropatia &#233; classicamente sim&#233;trica&#44; dolorosa e afeta m&#227;os e p&#233;s&#46; &#201; usualmente acompanhada de perda sensorial e preserva&#231;&#227;o da for&#231;a muscular&#46;<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">69</span></a> Deve ser realizada eletroneuromiografia no in&#237;cio do tratamento e&#44; como controle&#44; a cada&#160;seis&#160;meses&#46;<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">69</span></a> Outros efeitos colaterais s&#227;o seda&#231;&#227;o&#44; hipotens&#227;o ortost&#225;tica&#44; erup&#231;&#227;o maculopapular&#44; constipa&#231;&#227;o e xerostomia&#46;<a class="elsevierStyleCrossRefs" href="#bib0685"><span class="elsevierStyleSup">67&#44;69</span></a></p><p id="par0550" class="elsevierStylePara elsevierViewall">A teratogenicidade &#233; um dos efeitos colaterais mais tem&#237;veis relacionados ao uso da talidomida&#46;<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">69</span></a> Seu uso em mulheres em idade f&#233;rtil deve ser excepcional e apenas ap&#243;s falha de todos os tratamentos dispon&#237;veis&#46; Nesses casos&#44; recomenda&#8208;se a ado&#231;&#227;o de dois m&#233;todos contraceptivos&#44; um de alta efetividade e o outro de barreira&#46; Deve ser realizado teste de gravidez&#160;24&#160;horas antes do in&#237;cio do tratamento&#44; repetido semanalmente no primeiro m&#234;s e&#44; posteriormente&#44; a cada duas a quatro semanas&#46;<a class="elsevierStyleCrossRef" href="#bib0695"><span class="elsevierStyleSup">69</span></a></p><p id="par0555" class="elsevierStylePara elsevierViewall">&#193;cido acetilsalic&#237;lico&#44; em baixas doses&#44; pode ser associado &#224; talidomida em pacientes com alto risco cardiovascular ou presen&#231;a de anticorpos antifosfol&#237;pides&#46;<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">60&#44;69</span></a></p><p id="par0560" class="elsevierStylePara elsevierViewall">A lenalidomida&#44; um derivado da talidomida&#44; exibe melhor perfil de seguran&#231;a quanto ao risco de neuropatia&#44; por&#233;m ainda existem poucos dados na literatura sobre seu uso em pacientes com LEC&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;61</span></a> Alguns autores contraindicam seu uso no LEC devido ao risco de induzir LES&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a></p></span><span id="sec0140" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Corticosteroides sist&#234;micos</span><p id="par0565" class="elsevierStylePara elsevierViewall">Os corticosteroides sist&#234;micos podem ser utilizados no in&#237;cio do tratamento das formas agressivas e disseminadas de LEC&#44; at&#233; que as outras medica&#231;&#245;es iniciem sua a&#231;&#227;o terap&#234;utica&#46; Devem ser reduzidos e suspensos o mais brevemente poss&#237;vel&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;6</span></a> Apresentam maior taxa de resposta no LECA&#44; provavelmente pela associa&#231;&#227;o com LES&#46;<a class="elsevierStyleCrossRef" href="#bib0655"><span class="elsevierStyleSup">61</span></a> A dose usual &#233; de&#160;0&#44;5&#8208;1&#160;mg&#47;kg&#47;dia de prednisona e deve ser reduzida&#44; logo que poss&#237;vel&#44; at&#233; atingir doses di&#225;rias inferiores a&#160;7&#44;5&#160;mg&#46; A terapia de longo prazo com corticosteroides sist&#234;micos n&#227;o &#233; indicada no LEC&#46;<a class="elsevierStyleCrossRefs" href="#bib0650"><span class="elsevierStyleSup">60&#44;61</span></a></p></span><span id="sec0145" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">Outros tratamentos</span><p id="par0570" class="elsevierStylePara elsevierViewall">A clofazimina apresenta propriedades antimicrobianas&#44; anti&#8208;inflamat&#243;rias e imunossupressoras&#46;<a class="elsevierStyleCrossRef" href="#bib0645"><span class="elsevierStyleSup">59</span></a> A dose &#233; de&#160;100&#8208;200&#160;mg&#47;dia e pode ser utilizada como tratamento adjuvante&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a> Os principais efeitos colaterais s&#227;o hiperpigmenta&#231;&#227;o cinza&#8208;acastanhada&#44; xerose cut&#226;nea&#44; n&#225;useas e v&#244;mitos&#46;<a class="elsevierStyleCrossRef" href="#bib0625"><span class="elsevierStyleSup">55</span></a> Os &#233;steres do &#225;cido fum&#225;rico j&#225; foram usados com sucesso no LED&#44; por&#233;m os dados ainda s&#227;o limitados na literatura&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;57</span></a></p><p id="par0575" class="elsevierStylePara elsevierViewall">O uso de antiagregantes plaquet&#225;rios &#233; recomendado nos pacientes com livedo racemoso&#44; les&#245;es do tipo papulose maligna atr&#243;fica &#40;doen&#231;a de Degos&#41;&#44; ulcera&#231;&#227;o&#44; tromboflebite e anetodermia&#46;<a class="elsevierStyleCrossRef" href="#bib0575"><span class="elsevierStyleSup">45</span></a></p><p id="par0580" class="elsevierStylePara elsevierViewall">O uso de <span class="elsevierStyleItalic">pulsed&#8208;dye&#8208;laser</span> &#40;<span class="elsevierStyleItalic">laser</span> pulsado de corante&#41; &#233; descrito como tratamento de cicatrizes&#46; Entretanto&#44; dado o risco de fotossensibilidade&#44; seu uso n&#227;o &#233; recomendado na presen&#231;a de les&#245;es cut&#226;neas ativas&#46;<a class="elsevierStyleCrossRefs" href="#bib0380"><span class="elsevierStyleSup">6&#44;7&#44;61</span></a></p><p id="par0585" class="elsevierStylePara elsevierViewall">Ciclosporina&#44; ciclofosfamida e imunoglobulina endovenosa n&#227;o s&#227;o indicadas no tratamento do LEC sem acometimento sist&#234;mico&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;61</span></a></p></span><span id="sec0150" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0160">Terapias&#8208;alvo</span><p id="par0590" class="elsevierStylePara elsevierViewall">Os avan&#231;os na compreens&#227;o da patog&#234;nese&#44; especialmente das vias de ativa&#231;&#227;o dos sistemas imunes inato e adaptativo&#44; abriram um novo campo de pesquisa para uma nova gera&#231;&#227;o de f&#225;rmacos&#44; os chamados imunobiol&#243;gicos&#46;<a class="elsevierStyleCrossRef" href="#bib0630"><span class="elsevierStyleSup">56</span></a> Os principais alvos terap&#234;uticos s&#227;o as vias de ativa&#231;&#227;o das c&#233;lulas&#160;B&#44; c&#233;lulas&#160;T e CDP&#44; al&#233;m das citocinas pr&#243;&#8208;inflamat&#243;rias&#44; seus receptores e vias de sinaliza&#231;&#227;o intracelular&#44; como IL&#8208;6&#44; IL&#8208;12&#44; IL&#8208;23&#44; IFN e via de sinaliza&#231;&#227;o JAK&#47;STAT&#46;<a class="elsevierStyleCrossRefs" href="#bib0355"><span class="elsevierStyleSup">1&#44;14&#44;60</span></a></p><p id="par0595" class="elsevierStylePara elsevierViewall">Alvo nas c&#233;lulas&#160;B&#58; o belimumabe &#233; um anticorpo monoclonal contra o fator de ativa&#231;&#227;o de c&#233;lulas&#160;B &#40;<span class="elsevierStyleItalic">Blys</span>&#41;&#44; aprovado pelo FDA para uso no LES&#46; Os estudos originais n&#227;o inclu&#237;ram an&#225;lise espec&#237;fica do desfecho das les&#245;es cut&#226;neas&#44; embora an&#225;lises posteriores tenham demonstrado melhora do quadro cut&#226;neo&#46; A efic&#225;cia no LEC est&#225; em investiga&#231;&#227;o em estudos de fase&#160;III&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> Tr&#234;s estudos observacionais&#44; com uso do rituximabe&#44; anticorpo monoclonal anti&#8208;CD20&#44; nas manifesta&#231;&#245;es mucocut&#226;neas do LE&#44; apresentaram taxas de resposta variando entre&#160;35&#37;&#160;e&#160;76&#37;&#46; Resposta mais favor&#225;vel foi verificada no LECA &#8211; no entanto&#44; sem evid&#234;ncia de efeito ben&#233;fico nos subtipos subagudo e cr&#244;nico do LEC&#46;<a class="elsevierStyleCrossRef" href="#bib0635"><span class="elsevierStyleSup">57</span></a></p><p id="par0600" class="elsevierStylePara elsevierViewall">Alvo nas vias do interferon&#58; as tentativas de inibi&#231;&#227;o espec&#237;fica dos IFN n&#227;o apresentaram resultados satisfat&#243;rios nos ensaios cl&#237;nicos&#44; provavelmente pela grande redund&#226;ncia entre os diferentes tipos de IFN&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a> O bloqueio do receptor de IFN apresenta uma perspectiva mais animadora&#46; O anifrolumabe&#44; um anticorpo monoclonal contra o receptor do IFN tipo&#160;I&#44; reduziu os escores de atividade das les&#245;es cut&#226;neas em pacientes com LES em ensaio cl&#237;nico de fase&#160;IIb&#46;<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">1</span></a></p><p id="par0605" class="elsevierStylePara elsevierViewall">Alvo na via JAK&#47;STAT&#58; essa via &#233; importante para o mecanismo de retroalimenta&#231;&#227;o positiva do IFN&#46; A primeira gera&#231;&#227;o de inibidores &#8211; baricitinibe e ruxolitinibe &#8211; mostrou efic&#225;cia em pequeno n&#250;mero de pacientes com LE perni&#243;tico&#46; A segunda gera&#231;&#227;o de inibidores est&#225; sendo testada em ensaios cl&#237;nicos&#46;<a class="elsevierStyleCrossRef" href="#bib0420"><span class="elsevierStyleSup">14</span></a></p></span></span><span id="sec0155" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0165">Considera&#231;&#245;es finais</span><p id="par0610" class="elsevierStylePara elsevierViewall">LEC &#233; doen&#231;a autoimune multifatorial&#44; resultante da intera&#231;&#227;o de fatores ambientais&#44; gen&#233;ticos e imunol&#243;gicos&#44; que se apresenta com variada manifesta&#231;&#227;o dermatol&#243;gica&#46; O reconhecimento do subtipo cl&#237;nico &#233; importante na abordagem diagn&#243;stica&#44; na decis&#227;o terap&#234;utica e na determina&#231;&#227;o do progn&#243;stico&#44; tanto na doen&#231;a exclusivamente cut&#226;nea quanto no contexto do LES&#46;</p><p id="par0615" class="elsevierStylePara elsevierViewall">Crit&#233;rios diagn&#243;sticos para defini&#231;&#227;o dos diferentes subtipos de LEC ainda s&#227;o incipientes&#46; Aguardam&#8208;se crit&#233;rios mais assertivos que possam ser futuramente incorporados na pr&#225;tica cl&#237;nica e nos ensaios terap&#234;uticos&#44; auxiliando na avalia&#231;&#227;o das manifesta&#231;&#245;es cut&#226;neas do LE&#46;</p><p id="par0620" class="elsevierStylePara elsevierViewall">Fotoprote&#231;&#227;o&#44; corticosteroides t&#243;picos e antimal&#225;ricos ainda permanecem como primeira linha no tratamento do LEC&#46; Medica&#231;&#245;es alternativas de uso sist&#234;mico incluem MTX&#44; retinoides orais&#44; dapsona e talidomida&#44; entre outros&#46; Com o avan&#231;o no conhecimento da patog&#234;nese da doen&#231;a&#44; novas estrat&#233;gias terap&#234;uticas v&#234;m sendo desenvolvidas&#44; tendo como alvos as diferentes vias de ativa&#231;&#227;o imune que t&#234;m sido identificadas&#46;</p></span><span id="sec0160" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0170">Suporte financeiro</span><p id="par0625" class="elsevierStylePara elsevierViewall">Nenhum&#46;</p></span><span id="sec0165" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0175">Contribui&#231;&#227;o dos autores</span><p id="par0630" class="elsevierStylePara elsevierViewall">Everton Carlos Siviero do Vale&#58; Concep&#231;&#227;o e desenho do estudo&#59; Revis&#227;o cr&#237;tica da literatura&#59; Elabora&#231;&#227;o e reda&#231;&#227;o do manuscrito&#59; Revis&#227;o cr&#237;tica do manuscrito&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p><p id="par0635" class="elsevierStylePara elsevierViewall">Lucas Campos Garcia&#58; Revis&#227;o cr&#237;tica da literatura&#59; Elabora&#231;&#227;o e reda&#231;&#227;o do manuscrito&#59; Aprova&#231;&#227;o da vers&#227;o final do manuscrito&#46;</p></span><span id="sec0170" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0180">Conflito de interesses</span><p id="par0640" class="elsevierStylePara elsevierViewall">Nenhum&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:14 [
        0 => array:3 [
          "identificador" => "xres1897469"
          "titulo" => "Resumo"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1641676"
          "titulo" => "Palavras&#8208;chave"
        ]
        2 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introdu&#231;&#227;o"
        ]
        3 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Classifica&#231;&#227;o"
        ]
        4 => array:2 [
          "identificador" => "sec0015"
          "titulo" => "Etiopatog&#234;nese"
        ]
        5 => array:3 [
          "identificador" => "sec0020"
          "titulo" => "Apresenta&#231;&#227;o cl&#237;nica e diagn&#243;stico diferencial"
          "secciones" => array:6 [
            0 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "L&#250;pus eritematoso cut&#226;neo agudo"
            ]
            1 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "L&#250;pus eritematoso cut&#226;neo subagudo"
            ]
            2 => array:2 [
              "identificador" => "sec0035"
              "titulo" => "L&#250;pus eritematoso cut&#226;neo cr&#244;nico"
            ]
            3 => array:2 [
              "identificador" => "sec0040"
              "titulo" => "L&#250;pus eritematoso cut&#226;neo intermitente"
            ]
            4 => array:2 [
              "identificador" => "sec0045"
              "titulo" => "L&#250;pus eritematoso bolhoso"
            ]
            5 => array:2 [
              "identificador" => "sec0050"
              "titulo" => "Manifesta&#231;&#245;es cut&#226;neas inespec&#237;ficas do l&#250;pus eritematoso"
            ]
          ]
        ]
        6 => array:3 [
          "identificador" => "sec0055"
          "titulo" => "Diagn&#243;stico"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "sec0060"
              "titulo" => "Histopatologia"
            ]
            1 => array:2 [
              "identificador" => "sec0065"
              "titulo" => "Imuno&#8208;histologia"
            ]
            2 => array:2 [
              "identificador" => "sec0070"
              "titulo" => "Anticorpos antinucleares"
            ]
            3 => array:2 [
              "identificador" => "sec0075"
              "titulo" => "Avalia&#231;&#227;o da atividade e dano cut&#226;neos"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0080"
          "titulo" => "Progress&#227;o de l&#250;pus cut&#226;neo a l&#250;pus eritematoso sist&#234;mico"
        ]
        8 => array:3 [
          "identificador" => "sec0085"
          "titulo" => "Tratamento"
          "secciones" => array:13 [
            0 => array:2 [
              "identificador" => "sec0090"
              "titulo" => "Medidas gerais"
            ]
            1 => array:2 [
              "identificador" => "sec0095"
              "titulo" => "Tratamento t&#243;pico"
            ]
            2 => array:2 [
              "identificador" => "sec0100"
              "titulo" => "Tratamento sist&#234;mico"
            ]
            3 => array:2 [
              "identificador" => "sec0105"
              "titulo" => "Antimal&#225;ricos"
            ]
            4 => array:2 [
              "identificador" => "sec0110"
              "titulo" => "Metotrexato"
            ]
            5 => array:2 [
              "identificador" => "sec0115"
              "titulo" => "Retinoides sist&#234;micos"
            ]
            6 => array:2 [
              "identificador" => "sec0120"
              "titulo" => "Dapsona"
            ]
            7 => array:2 [
              "identificador" => "sec0125"
              "titulo" => "Micofenolato de mofetila"
            ]
            8 => array:2 [
              "identificador" => "sec0130"
              "titulo" => "Azatioprina"
            ]
            9 => array:2 [
              "identificador" => "sec0135"
              "titulo" => "Talidomida"
            ]
            10 => array:2 [
              "identificador" => "sec0140"
              "titulo" => "Corticosteroides sist&#234;micos"
            ]
            11 => array:2 [
              "identificador" => "sec0145"
              "titulo" => "Outros tratamentos"
            ]
            12 => array:2 [
              "identificador" => "sec0150"
              "titulo" => "Terapias&#8208;alvo"
            ]
          ]
        ]
        9 => array:2 [
          "identificador" => "sec0155"
          "titulo" => "Considera&#231;&#245;es finais"
        ]
        10 => array:2 [
          "identificador" => "sec0160"
          "titulo" => "Suporte financeiro"
        ]
        11 => array:2 [
          "identificador" => "sec0165"
          "titulo" => "Contribui&#231;&#227;o dos autores"
        ]
        12 => array:2 [
          "identificador" => "sec0170"
          "titulo" => "Conflito de interesses"
        ]
        13 => array:1 [
          "titulo" => "Refer&#234;ncias"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2022-06-27"
    "fechaAceptado" => "2022-09-12"
    "PalabrasClave" => array:1 [
      "pt" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palavras&#8208;chave"
          "identificador" => "xpalclavsec1641676"
          "palabras" => array:5 [
            0 => "Doen&#231;as autoimunes"
            1 => "L&#250;pus eritematoso cut&#226;neo"
            2 => "L&#250;pus eritematoso discoide"
            3 => "L&#250;pus eritematoso sist&#234;mico"
            4 => "Paniculite l&#250;pica"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:1 [
      "pt" => array:2 [
        "titulo" => "Resumo"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">O l&#250;pus eritematoso cut&#226;neo &#233; doen&#231;a autoimune de express&#227;o cl&#237;nica variada&#44; que pode apresentar&#8208;se como doen&#231;a exclusivamente cut&#226;nea ou ser uma das m&#250;ltiplas manifesta&#231;&#245;es do l&#250;pus eritematoso sist&#234;mico&#46; Sua classifica&#231;&#227;o engloba os subtipos agudo&#44; subagudo&#44; intermitente&#44; cr&#244;nico e bolhoso&#44; que s&#227;o usualmente identificados com base nas caracter&#237;sticas cl&#237;nicas e nos achados histopatol&#243;gicos e laboratoriais&#46; Outras manifesta&#231;&#245;es cut&#226;neas n&#227;o espec&#237;ficas podem estar associadas ao l&#250;pus eritematoso sist&#234;mico e geralmente guardam rela&#231;&#227;o com a atividade da doen&#231;a&#46; Fatores ambientais&#44; gen&#233;ticos e imunol&#243;gicos participam da patog&#234;nese das les&#245;es cut&#226;neas do l&#250;pus eritematoso&#46; Recentemente&#44; tem havido consider&#225;vel progresso na elucida&#231;&#227;o dos mecanismos envolvidos no seu desenvolvimento&#44; o que possibilita antever futuros alvos de tratamentos mais efetivos&#46; Esta revis&#227;o se prop&#245;e a discutir os principais aspectos etiopatog&#234;nicos&#44; cl&#237;nicos&#44; diagn&#243;sticos e terap&#234;uticos do l&#250;pus eritematoso cut&#226;neo&#44; visando &#224; atualiza&#231;&#227;o de internistas e de especialistas de diferentes &#225;reas&#46;</p></span>"
      ]
    ]
    "NotaPie" => array:2 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Como citar este artigo&#58; Vale EC&#44; Garcia LC&#46; Cutaneous lupus erythematosus&#58; a review of etiopathogenic&#44; clinical&#44; diagnostic and therapeutic aspects&#46; An Bras Dermatol&#46; 2023&#59;98&#58;355&#8211;72&#46;</p>"
      ]
      1 => array:2 [
        "etiqueta" => "&#9734;&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0025">Trabalho realizado no Servi&#231;o de Dermatologia&#44; Hospital das Cl&#237;nicas&#44; Universidade Federal de Minas Gerais&#44; Belo Horizonte&#44; MG&#44; Brasil&#46;</p>"
      ]
    ]
    "multimedia" => array:10 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figura 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 2634
            "Ancho" => 1675
            "Tamanyo" => 251439
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">L&#250;pus eritematoso cut&#226;neo agudo&#46; &#40;A&#41; Forma localizada&#58; eritema em asa de borboleta nas regi&#245;es malares&#46; &#40;B&#41; Forma disseminada&#58; erup&#231;&#227;o papuloescamosa sim&#233;trica acometendo tronco e membros superiores&#46;</p>"
        ]
      ]
      1 => array:7 [
        "identificador" => "fig0010"
        "etiqueta" => "Figura 2"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr2.jpeg"
            "Alto" => 1397
            "Ancho" => 2925
            "Tamanyo" => 255607
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; L&#250;pus eritematoso cut&#226;neo subagudo&#58; placas eritemato&#8208;papuloescamosas anulares confluentes no t&#243;rax e nos membros superiores&#46; &#40;B&#41; L&#250;pus eritematoso neonatal&#58; placas eritematosas circulares e polic&#237;clicas na face&#46;</p>"
        ]
      ]
      2 => array:7 [
        "identificador" => "fig0015"
        "etiqueta" => "Figura 3"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr3.jpeg"
            "Alto" => 1499
            "Ancho" => 2508
            "Tamanyo" => 346263
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">L&#250;pus eritematoso cut&#226;neo cr&#244;nico&#46; &#40;A&#41; Forma discoide localizada no couro cabeludo&#44; com alopecia cicatricial&#46; &#40;B&#41; Forma discoide afetando a mucosa jugal&#46;</p>"
        ]
      ]
      3 => array:7 [
        "identificador" => "fig0020"
        "etiqueta" => "Figura 4"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr4.jpeg"
            "Alto" => 1973
            "Ancho" => 2508
            "Tamanyo" => 377939
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">L&#250;pus eritematoso cut&#226;neo cr&#244;nico&#46; &#40;A&#41; Variante verrucosa localizada no membro superior&#46; &#40;B&#41; Paniculite l&#250;pica acometendo o bra&#231;o e evoluindo com lipoatrofia&#46;</p>"
        ]
      ]
      4 => array:7 [
        "identificador" => "fig0025"
        "etiqueta" => "Figura 5"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr5.jpeg"
            "Alto" => 3171
            "Ancho" => 1675
            "Tamanyo" => 439940
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">&#40;A&#41; L&#250;pus eritematoso t&#250;mido&#58; les&#245;es eritemato&#8208;edematosas arciformes e anulares na face e regi&#227;o cervical&#46; &#40;B&#41; L&#250;pus eritematoso bolhoso&#58; les&#245;es bolhosas&#44; ulcerocrostosas hem&#225;ticas e les&#245;es residuais hipocr&#244;micas&#44; localizadas na regi&#227;o cervical&#44; tronco&#44; axilas e membros superiores&#46;</p>"
        ]
      ]
      5 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Tabela 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">ACR&#44; American College of Rheumatology&#59; EULAR&#44; European League Against Rheumatism&#59; SLICC&#44; Systemic Lupus International Collaborating Clinics&#59; FAN&#44; fator antin&#250;cleo&#59; LEC&#44; l&#250;pus eritematoso cut&#226;neo&#59; LES&#44; l&#250;pus eritematoso sist&#234;mico&#46;</p><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">ACR 1997&#58; LES &#8805; 4&#160;crit&#233;rios&#46;</p><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">SLICC 2012&#58; LES &#8805;&#160;4&#160;crit&#233;rios&#44; ao menos um cl&#237;nico e um imunol&#243;gico&#59; quadro de nefrite l&#250;pica comprovada por bi&#243;psia&#44; com FAN ou anti&#8208;DNAn&#44; tamb&#233;m pode ser classificado como LES&#46;</p><p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">EULAR&#47;ACR 2019&#58; LES &#61; escore &#8805; 10&#160;pontos&#44; ao menos um cl&#237;nico &#40;considera&#8208;se somente o crit&#233;rio com a pontua&#231;&#227;o mais alta em cada dom&#237;nio&#41;&#46;</p><p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Os crit&#233;rios dermatol&#243;gicos est&#227;o destacados em negrito nos tr&#234;s sistemas de classifica&#231;&#227;o&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">ACR 1997<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">4</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">SLICC 2012<a class="elsevierStyleCrossRef" href="#bib0390"><span class="elsevierStyleSup">8</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">EULAR&#47;ACR 2019<a class="elsevierStyleCrossRef" href="#bib0395"><span class="elsevierStyleSup">9</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Crit&#233;rio de entrada&#58;</span> nenhum&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Crit&#233;rio de entrada&#58;</span> nenhum&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Crit&#233;rio de entrada&#58;</span> FAN&#160;&#8805;&#160;1&#58;80&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Crit&#233;rios cl&#237;nicos &#40;&#61; 9&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Crit&#233;rios cl&#237;nicos &#40;&#61; 11&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Crit&#233;rios cl&#237;nicos &#40;pontos&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Erup&#231;&#227;o malar</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">LEC agudo&#44; subagudo ou LE bolhoso</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Constitucional&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Erup&#231;&#227;o discoide</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">LEC cr&#244;nico &#40;inclui LEC t&#250;mido&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Febre &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Fotossensibilidade</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">&#218;lceras orais ou nasais</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hematol&#243;gicos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">&#218;lceras orais</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Alopecia n&#227;o cicatricial</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Leucopenia &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Artrite n&#227;o erosiva &#40;&#8805; 2&#160;articula&#231;&#245;es&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Sinovite &#40;&#8805; 2&#160;articula&#231;&#245;es&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Trombocitopenia &#40;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Serosite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Serosite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Hem&#243;lise autoimune &#40;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Pleurite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Pleurite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Neuropsiqui&#225;tricos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Pericardite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Pericardite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Del&#237;rio &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Derrame pleural ou peric&#225;rdico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Derrame pleural ou peric&#225;rdico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Psicose &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Acometimento renal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Doen&#231;a renal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Convuls&#227;o &#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Protein&#250;ria<span class="elsevierStyleHsp" style=""></span>&#62; 0&#44;5 g&#47;24 horas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Protein&#250;ria<span class="elsevierStyleHsp" style=""></span>&#62; 0&#44;5 g&#47;24 horas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mucocut&#226;neos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Cilindros celulares&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Cilindros hem&#225;ticos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleBold">Alopecia n&#227;o cicatricial &#40;2&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Altera&#231;&#245;es neurol&#243;gicas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Doen&#231;a neurol&#243;gica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleBold">&#218;lceras orais &#40;2&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Convuls&#245;es&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Convuls&#245;es&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleBold">LEC subagudo ou LE &#40;4&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Psicose&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Psicose&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleBold">LEC agudo &#40;6&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Altera&#231;&#245;es hematol&#243;gicas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Mononeurite m&#250;ltipla&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Serosite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anemia hemol&#237;tica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Mielite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Derrame pleural ou peric&#225;rdico &#40;5&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Leucopenia &#40;&#60; 4&#46;000&#160;mm<span class="elsevierStyleSup">3</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Neuropatia craniana ou perif&#233;rica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Pericardite aguda &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Linfopenia &#40;&#60; 1&#46;500&#160;mm<span class="elsevierStyleSup">3</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Estado confusional agudo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Musculoesquel&#233;tico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Trombocitopenia &#40;&#60; 100&#46;000&#47;mm<span class="elsevierStyleSup">3</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Altera&#231;&#245;es hematol&#243;gicas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Acometimento articular &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anemia hemol&#237;tica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Leucopenia &#40;&#60; 4&#46;000&#160;mm<span class="elsevierStyleSup">3</span>&#41; ou linfopenia &#40;&#60; 1&#46;000 mm<span class="elsevierStyleSup">3</span>&#41;Trombocitopenia &#40;&#60; 100&#46;000&#47;mm<span class="elsevierStyleSup">3</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Renais&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Protein&#250;ria<span class="elsevierStyleHsp" style=""></span>&#62; 0&#44;5&#160;g&#47;24 horas &#40;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Bi&#243;psia renal &#8211; nefrite l&#250;pica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Classe II ou V &#40;8&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Bi&#243;psia renal &#8211; nefrite l&#250;pica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Classe III ou IV &#40;10&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Crit&#233;rios imunol&#243;gicos &#40;&#61; 2&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Crit&#233;rios imunol&#243;gicos &#40;&#61; 6&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Crit&#233;rios imunol&#243;gicos &#40;pontos&#41;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">FAN&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">FAN&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anticorpos antifosfol&#237;pides&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Autoanticorpos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;DNAn&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anticardiolipina &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Anti&#8208;DNAn&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;Sm&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anti&#8208;&#946;2&#8208;glicoprote&#237;na 1 &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Anti&#8208;Sm&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anticorpo antifosfol&#237;pide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anticoagulante l&#250;pico &#40;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Anticorpo antifosfol&#237;pide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anticoagulante l&#250;pico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complemento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Teste n&#227;o trepon&#234;mico falso&#8208;positivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>C3 ou C4 baixo &#40;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anticardiolipina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>C3 e C4 baixos &#40;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anti&#8208;&#946;2&#8208;glicoprote&#237;na 1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anticorpos LES&#8208;espec&#237;ficos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complemento baixo &#40;C3&#44; C4 ou CH50&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anti&#8208;DNAn &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Coombs direto &#40;na aus&#234;ncia de anemia hemol&#237;tica&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Anti&#8208;Sm &#40;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3171299.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Crit&#233;rios de classifica&#231;&#227;o do l&#250;pus eritematoso sist&#234;mico &#8211; ACR 1997&#44; SLICC 2012 e EULAR&#47;ACR 2019</p>"
        ]
      ]
      6 => array:8 [
        "identificador" => "tbl0010"
        "etiqueta" => "Tabela 2"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at2"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">LE&#44; l&#250;pus eritematoso&#59; NET&#44; necr&#243;lise epid&#233;rmica t&#243;xica&#46;</p>"
          "tablatextoimagen" => array:2 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Subtipos de LE cut&#226;neo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Variantes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE cut&#226;neo agudo</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Localizado&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Disseminado&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">NET&#8208;s&#237;mile&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="4" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE cut&#226;neo subagudo</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anular polic&#237;clico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Papuloescamoso psoriasiforme&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">S&#237;ndrome de Rowell&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE neonatal&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE cut&#226;neo intermitente&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE t&#250;mido&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="7" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE cut&#226;neo cr&#244;nico</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE discoide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE discoide mucoso&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE hipertr&#243;fico&#47;verrucoso&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE profundo&#47;paniculite l&#250;pica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE perni&#243;tico&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE l&#237;quen plano&#8208;s&#237;mile&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE comedoniano&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE bolhoso&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#8211;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3171298.png"
              ]
            ]
            1 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Natureza da altera&#231;&#227;o&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Manifesta&#231;&#245;es inespec&#237;ficas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Vascular&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fen&#244;meno de Raynaud&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Livedo reticular&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Livedo racemoso&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Vasculites&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Vasculopatia livedoide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Papulose do tipo doen&#231;a de Degos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Necrose cut&#226;nea&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hemorragia em estilha&#231;o&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Tromboflebite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Neutrof&#237;lica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">LE bolhoso&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Urtic&#225;ria vasculite&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatose urticariana neutrof&#237;lica&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pustulose amicrobiana das dobras&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">S&#237;ndrome de Sweet&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pioderma gangrenoso&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="2" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#227;o definida&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alopecia n&#227;o cicatricial difusa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#218;lceras mucosas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">N&#243;dulos reumatoides&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatite granulomatosa intersticial&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dermatofibroma eruptivo&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3171297.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Subtipos cl&#237;nicos e manifesta&#231;&#245;es cut&#226;neas inespec&#237;ficas do l&#250;pus eritematoso</p>"
        ]
      ]
      7 => array:8 [
        "identificador" => "tbl0015"
        "etiqueta" => "Tabela 3"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at3"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0011" class="elsevierStyleSimplePara elsevierViewall">Adaptado de Borucki &#38; Werth&#44; 2020&#46;<a class="elsevierStyleCrossRef" href="#bib0465"><span class="elsevierStyleSup">23</span></a>&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Classe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Subclasse&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Medicamento&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;hipertensivos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Diur&#233;ticos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hidroclorotiazida&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " rowspan="5" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inibidores da enzima conversora da angiotensina</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Captopril&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cilazapril&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Enalapril&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Lisinopril&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ramipril&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Betabloqueadores&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Acebutolol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bloqueadores do canal de c&#225;lcio&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Diltiazem&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Nifedipina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Nitrendipina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Verapamil&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Inibidores da bomba de pr&#243;tons&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Esomeprazol<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Lasanoprazol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Omeprazol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pantoprazol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Antif&#250;ngicos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Griseofulvina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Terbinafina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anticonvulsivantes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Carbamazepina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fenito&#237;na&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Estatinas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pravastatina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Sinvastatina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;histam&#237;nicos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bromofeniramina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Cinarizina &#43; tietilperazina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ranitidina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Antibi&#243;ticos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Amoxicilina &#43; clavulanato&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ciprofloxacina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;inflamat&#243;rios n&#227;o esteroides&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Naproxeno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Piroxicam&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Quimioter&#225;picos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#8208;fluoruracil<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Capecitabina<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Docetaxel&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Doxorubicina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Gencitabina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Masitinibe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Mitotane&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Nivolumabe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Paclitaxel&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Palbociclibe<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pembrolizumabe<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Tamoxifeno&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Tegafur&#47;uracil<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Biol&#243;gicos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;TNF&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Adalimumabe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Etanercepte&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Golimumabe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Infliximabe<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;CD80&#47;86&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Abatacepte&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;CD11a&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Efalizumabe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;IL12&#47;23&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ustekinumabe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anti&#8208;IL17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Secukinumabe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Antidepressivos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Bupropiona&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="3" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Outras&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Alopurinol<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anastrazol&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Interferon&#8208;&#945; e &#946;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Imuglobulina intravenosa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Leflunomida<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Leuprorrelina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Ticlopidina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Tiotr&#243;pio&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3171295.png"
              ]
            ]
          ]
          "notaPie" => array:1 [
            0 => array:3 [
              "identificador" => "tblfn0005"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Tamb&#233;m desencadeantes de l&#250;pus eritematoso cut&#226;neo cr&#244;nico&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Medicamentos referidos como desencadeantes de l&#250;pus eritematoso cut&#226;neo subagudo</p>"
        ]
      ]
      8 => array:8 [
        "identificador" => "tbl0020"
        "etiqueta" => "Tabela 4"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at4"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0090" class="elsevierStyleSimplePara elsevierViewall">Adaptado de Kuhn et al&#46;&#44; 2014&#46;<a class="elsevierStyleCrossRef" href="#bib0590"><span class="elsevierStyleSup">48</span></a>&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Exames de rotina</span> &#40;suspeita de LEC&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hemograma&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Velocidade de hemossedimenta&#231;&#227;o eritrocit&#225;ria&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Prote&#237;na C reativa&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">FAN &#40;HEp&#8208;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Enzimas hep&#225;ticas &#40;TGO&#44; TGP&#44; FA&#44; GGT&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fun&#231;&#227;o renal &#40;ureia&#44; creatinina&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Urina &#40;EAS&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Exames especiais</span> &#40;LEC confirmado&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anticorpos espec&#237;ficos &#40;anti&#8208;DNAn&#44; &#8208;Sm&#44; &#8208;Ro&#47;SS&#8208;A&#44; &#8208;La&#47;SS&#8208;B&#44; &#8208;RNPn&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Complemento s&#233;rico &#40;C3&#44; C4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Anticorpos antifosfol&#237;pides &#40;anticardiolipinas IgG e IgM&#59;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">anticoagulante l&#250;pico&#59; &#946;2&#8208;glicoprote&#237;na I&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Fator reumatoide&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Imunoglobulinas &#40;imunoeletroforese&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">TSH&#44; T4&#44; anticorpos antitireoidianos&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Prote&#237;nas urin&#225;rias 24 horas&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Clearance</span> da creatinina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Glicose&#8208;6&#8208;fosfato desidrogenase&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3171300.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">Avalia&#231;&#227;o laboratorial recomendada no l&#250;pus eritematoso cut&#226;neo &#40;LEC&#41;</p>"
        ]
      ]
      9 => array:8 [
        "identificador" => "tbl0025"
        "etiqueta" => "Tabela 5"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at5"
            "detalle" => "Tabela "
            "rol" => "short"
          ]
        ]
        "tabla" => array:3 [
          "leyenda" => "<p id="spar0100" class="elsevierStyleSimplePara elsevierViewall">Adaptado de Yan et al&#46;&#44; 2020&#46;&#91;58&#93;&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Medica&#231;&#227;o&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&#237;vel de evid&#234;ncia<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">a</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Grau de recomenda&#231;&#227;o<a class="elsevierStyleCrossRef" href="#tblfn0015"><span class="elsevierStyleSup">b</span></a>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Hidroxicloroquina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Acitretina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Isotretino&#237;na&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Metotrexato&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Dapsona&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Talidomida&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">A&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Micofenolato de mofetila&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Azatioprina&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Belimumabe&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">B&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3171296.png"
              ]
            ]
          ]
          "notaPie" => array:2 [
            0 => array:3 [
              "identificador" => "tblfn0010"
              "etiqueta" => "a"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0010">N&#237;vel de evid&#234;ncia&#58; 1 &#8211; Ensaio cl&#237;nico randomizado &#40;ECR&#41;&#44; revis&#245;es sistem&#225;ticas &#40;RS&#41;&#47;metan&#225;lise de ECR&#59; 2 &#8211; RS de estudos de coorte&#44; coortes&#59; 3 &#8211; RS de estudos caso&#8208;controle&#44; estudos de caso&#8208;controle&#59; 4 &#8211; S&#233;rie de casos&#44; coorte e caso&#8208;controle de baixa qualidade&#59; 5 &#8211; Opini&#227;o de especialistas&#46;</p>"
            ]
            1 => array:3 [
              "identificador" => "tblfn0015"
              "etiqueta" => "b"
              "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Grau de recomenda&#231;&#227;o&#58; A &#8211; Estudos observacionais ou experimentais de maior consist&#234;ncia &#40;metan&#225;lises ou ECR&#41;&#59; B &#8211; Estudos observacionais de menor consist&#234;ncia &#40;outros ensaios cl&#237;nicos n&#227;o randomizados ou observacionais ou caso&#8208;controle&#41;&#59; C &#8211; Relatos ou s&#233;ries de casos &#40;estudos n&#227;o controlados&#41;&#59; D &#8211; Opini&#227;o desprovida de avalia&#231;&#227;o cr&#237;tica&#44; baseadas em consensos&#44; estudos fisiol&#243;gicos ou modelos animais&#46;</p>"
            ]
          ]
        ]
        "descripcion" => array:1 [
          "pt" => "<p id="spar0095" class="elsevierStyleSimplePara elsevierViewall">N&#237;vel de evid&#234;ncia e grau de recomenda&#231;&#227;o dos principais medicamentos de uso sist&#234;mico no l&#250;pus eritematoso cut&#226;neo</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "Refer&#234;ncias"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:70 [
            0 => array:3 [
              "identificador" => "bib0355"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus erythematosus&#58; new insights into pathogenesis and therapeutic strategies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [
                            0 => "J&#46; Wenzel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1038/s41584-019-0272-0"
                      "Revista" => array:6 [
                        "tituloSerie" => "Nat Rev Rheumatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "15"
                        "paginaInicial" => "519"
                        "paginaFinal" => "532"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31399711"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0360"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous manifestations of &#8220;lupus&#8221;&#58; systemic lupus erythematosus and beyond"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "E&#46;E&#46; Cooper"
                            1 => "C&#46;E&#46; Pisano"
                            2 => "S&#46;C&#46; Shapiro"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Int J Rheumatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "2021"
                        "paginaInicial" => "6610509"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0365"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus erythematosus&#58; clinico&#8208;pathologic correlation"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "R&#46; Filotico"
                            1 => "V&#46; Mastrandrea"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.23736/S0392-0488.18.05929-1"
                      "Revista" => array:6 [
                        "tituloSerie" => "G Ital Dermatol Venereol&#46;"
                        "fecha" => "2018"
                        "volumen" => "153"
                        "paginaInicial" => "216"
                        "paginaFinal" => "229"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29368845"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0370"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus erythematosus&#58; progress and challenges"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46;J&#46; Petty"
                            1 => "L&#46; Floyd"
                            2 => "C&#46; Henderson"
                            3 => "M&#46;W&#46; Nicholas"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s11882-020-00906-8"
                      "Revista" => array:5 [
                        "tituloSerie" => "Curr Allergy Asthma Rep&#46;"
                        "fecha" => "2020"
                        "volumen" => "20"
                        "paginaInicial" => "12"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32248318"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0375"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A review of cutaneous lupus erythematosus&#58; improving outcomes with a multidisciplinary approach"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "P&#46; Jarrett"
                            1 => "V&#46;P&#46; Werth"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2147/JMDH.S179623"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Multidiscip Healthc&#46;"
                        "fecha" => "2019"
                        "volumen" => "12"
                        "paginaInicial" => "419"
                        "paginaFinal" => "428"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31213824"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0380"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus erythematosus&#58; a review of the literature"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "S&#46;C&#46; Blake"
                            1 => "B&#46;S&#46; Daniel"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ijwd.2019.07.004"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Womens Dermatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "5"
                        "paginaInicial" => "320"
                        "paginaFinal" => "329"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31909151"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0385"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A quality&#8208;of&#8208;life study of cutaneous lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46; Batalla"
                            1 => "I&#46; Garc&#237;a-Doval"
                            2 => "G&#46; Pe&#243;n"
                            3 => "C&#46; de la Torre"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2013.04.005"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr&#46;"
                        "fecha" => "2013"
                        "volumen" => "104"
                        "paginaInicial" => "800"
                        "paginaFinal" => "806"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23787361"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0390"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Petri"
                            1 => "A&#46;M&#46; Orbai"
                            2 => "G&#46;S&#46; Alarc&#243;n"
                            3 => "C&#46; Gordon"
                            4 => "J&#46;T&#46; Merrill"
                            5 => "P&#46;R&#46; Fortin"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/art.34473"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arthritis Rheum&#46;"
                        "fecha" => "2012"
                        "volumen" => "64"
                        "paginaInicial" => "2677"
                        "paginaFinal" => "2686"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22553077"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0395"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2019 European League Against Rheumatism&#47;American College of Rheumatology classification criteria for systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Aringer"
                            1 => "K&#46; Costenbader"
                            2 => "D&#46; Daikh"
                            3 => "R&#46; Brinks"
                            4 => "M&#46; Mosca"
                            5 => "R&#46; Ramsey-Goldman"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Arthritis Rheumatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "71"
                        "paginaInicial" => "1400"
                        "paginaFinal" => "1412"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0400"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The performance of different classification criteria for systemic lupus erythematosus in a real&#8208;world rheumatology department"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "B&#46;C&#46;H&#46; Tan"
                            1 => "I&#46; Tang"
                            2 => "J&#46; Bonin"
                            3 => "R&#46; Koelmeyer"
                            4 => "A&#46; Hoi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Rheumatology &#40;Oxford&#41;&#46;"
                        "fecha" => "2022"
                        "volumen" => "00"
                        "paginaInicial" => "1"
                        "paginaFinal" => "5"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0405"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The cutaneous spectrum of lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "S&#46; Ribero"
                            1 => "S&#46; Sciascia"
                            2 => "L&#46; Borradori"
                            3 => "D&#46; Lipsker"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s12016-017-8627-2"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Rev Allergy Immunol&#46;"
                        "fecha" => "2017"
                        "volumen" => "53"
                        "paginaInicial" => "291"
                        "paginaFinal" => "305"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28752372"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0410"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus erythematosus&#58; an update on pathogenesis&#44; diagnosis and treatment"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "E&#46;Z&#46; Hejazi"
                            1 => "V&#46;P&#46; Werth"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40257-016-0173-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Am J Clin Dermatol&#46;"
                        "fecha" => "2016"
                        "volumen" => "17"
                        "paginaInicial" => "135"
                        "paginaFinal" => "146"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26872954"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0415"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Creation and validation of classification criteria for discoid lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "S&#46;A&#46; Elman"
                            1 => "C&#46; Joyce"
                            2 => "K&#46; Braudis"
                            3 => "B&#46;F&#46; Chong"
                            4 => "A&#46;P&#46; Fernandez"
                            5 => "F&#46; Furukawa"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2020"
                        "volumen" => "156"
                        "paginaInicial" => "901"
                        "paginaFinal" => "906"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0420"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus erythematosus&#58; current and future pathogenesis&#8208;directed therapies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A&#46;J&#46; Little"
                            1 => "M&#46;D&#46; Vesely"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:6 [
                        "tituloSerie" => "Yale J Biol Med&#46;"
                        "fecha" => "2020"
                        "volumen" => "93"
                        "paginaInicial" => "81"
                        "paginaFinal" => "95"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32226339"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0425"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus erythematosus&#58; clinical aspects and molecular pathogenesis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "V&#46; Oke"
                            1 => "M&#46; Wahren-Herlenius"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/joim.12057"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Intern Med&#46;"
                        "fecha" => "2013"
                        "volumen" => "273"
                        "paginaInicial" => "544"
                        "paginaFinal" => "554"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23464352"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0430"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "An update on the pathogenesis of skin damage in lupus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "Q&#46; Li"
                            1 => "H&#46; Wu"
                            2 => "S&#46; Zhou"
                            3 => "M&#46; Zhao"
                            4 => "Q&#46; Lu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Curr Rheumatol Rep&#46;"
                        "fecha" => "2020"
                        "volumen" => "22"
                        "paginaInicial" => "16"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0435"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Current insights in cutaneous lupus erythematosus immunopathogenesis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "C&#46;J&#46; Garelli"
                            1 => "M&#46;A&#46; Refat"
                            2 => "P&#46;P&#46; Nanaware"
                            3 => "Z&#46;G&#46; Ramirez-Ortiz"
                            4 => "M&#46; Rashighi"
                            5 => "J&#46;M&#46; Richmond"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3389/fimmu.2020.01353"
                      "Revista" => array:5 [
                        "tituloSerie" => "Front Immunol&#46;"
                        "fecha" => "2020"
                        "volumen" => "11"
                        "paginaInicial" => "1353"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32714331"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0440"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Immunopathogenesis of skin injury in systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "G&#46;A&#46; Hile"
                            1 => "J&#46;M&#46; Kahlenberg"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/BOR.0000000000000770"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Opin Rheumatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "33"
                        "paginaInicial" => "173"
                        "paginaFinal" => "180"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33315653"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0445"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "A comprehensive review of immune&#8208;mediated dermatopathology in systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "Q&#46; Li"
                            1 => "H&#46; Wu"
                            2 => "W&#46; Liao"
                            3 => "M&#46; Zhao"
                            4 => "V&#46; Chan"
                            5 => "L&#46; Li"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaut.2018.07.007"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Autoimmun&#46;"
                        "fecha" => "2018"
                        "volumen" => "93"
                        "paginaInicial" => "1"
                        "paginaFinal" => "15"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30017673"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0450"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The prevalence of oral mucosal lesions and related factors in systemic lupus erythematosus patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "M&#46; Kudsi"
                            1 => "L&#46;D&#46; Nahas"
                            2 => "R&#46; Alsawah"
                            3 => "A&#46; Hamsho"
                            4 => "A&#46; Omar"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s13075-021-02614-8"
                      "Revista" => array:5 [
                        "tituloSerie" => "Arthritis Res Ther&#46;"
                        "fecha" => "2021"
                        "volumen" => "23"
                        "paginaInicial" => "229"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34479636"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0455"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Toxic epidermal necrolysis&#8208;like lupus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "E&#46;J&#46; Roberts"
                            1 => "V&#46; Melchionda"
                            2 => "G&#46; Saldanha"
                            3 => "S&#46; Shaffu"
                            4 => "J&#46; Royle"
                            5 => "K&#46;E&#46; Harman"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ced.14648"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Exp Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "46"
                        "paginaInicial" => "1299"
                        "paginaFinal" => "1303"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33760256"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0460"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Oral lesions in lupus erythematosus&#58; correlation with cutaneous lesions"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "M&#46;M&#46; Nico"
                            1 => "M&#46;A&#46; Vilela"
                            2 => "E&#46;A&#46; Rivitti"
                            3 => "S&#46;V&#46; Louren&#231;o"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Eur J Dermatol&#46;"
                        "fecha" => "2008"
                        "volumen" => "18"
                        "paginaInicial" => "376"
                        "paginaFinal" => "381"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0465"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus erythematosus induced by drugs &#8208; novel insights"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "R&#46; Borucki"
                            1 => "V&#46;P&#46; Werth"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/17512433.2020.1698290"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Rev Clin Pharmacol&#46;"
                        "fecha" => "2020"
                        "volumen" => "13"
                        "paginaInicial" => "35"
                        "paginaFinal" => "42"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31774327"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0470"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Drug&#8208;induced lupus erythematosus&#58; an update on drugs and mechanisms"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "Y&#46; He"
                            1 => "A&#46;H&#46; Sawalha"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/BOR.0000000000000522"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Opin Rheumatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "30"
                        "paginaInicial" => "490"
                        "paginaFinal" => "497"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29870500"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0475"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "An update in drug&#8208;induced subacute cutaneous lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "T&#46;C&#46; Michaelis"
                            1 => "R&#46;D&#46; Sontheimer"
                            2 => "G&#46;C&#46; Lowe"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Dermatol Online J&#46;"
                        "fecha" => "2017"
                        "volumen" => "23"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            25 => array:3 [
              "identificador" => "bib0480"
              "etiqueta" => "26"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous drug&#8208;induced lupus erythematosus&#58; clinical and immunological characteristics and update on new associated drugs"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Bataille"
                            1 => "F&#46; Chasset"
                            2 => "J&#46;B&#46; Monfort"
                            3 => "T&#46; De Risi-Pugliese"
                            4 => "A&#46; Soria"
                            5 => "C&#46; Franc&#232;s"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.annder.2021.02.006"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Dermatol Venereol&#46;"
                        "fecha" => "2021"
                        "volumen" => "148"
                        "paginaInicial" => "211"
                        "paginaFinal" => "220"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34711400"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            26 => array:3 [
              "identificador" => "bib0485"
              "etiqueta" => "27"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Trigger factors of cutaneous lupus erythematosus&#58; a review of current literature"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "J&#46; Szcz&#281;ch"
                            1 => "D&#46; Samotij"
                            2 => "V&#46;P&#46; Werth"
                            3 => "A&#46; Reich"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/0961203317691369"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lupus&#46;"
                        "fecha" => "2017"
                        "volumen" => "26"
                        "paginaInicial" => "791"
                        "paginaFinal" => "807"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28173739"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            27 => array:3 [
              "identificador" => "bib0490"
              "etiqueta" => "28"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The last word on the so&#8208;called&#8217;Rowell&#39;s syndrome&#8217;&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "E&#46; Antiga"
                            1 => "M&#46; Caproni"
                            2 => "D&#46; Bonciani"
                            3 => "V&#46; Bonciolini"
                            4 => "P&#46; Fabbri"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/0961203311430513"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lupus&#46;"
                        "fecha" => "2012"
                        "volumen" => "21"
                        "paginaInicial" => "577"
                        "paginaFinal" => "585"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22170759"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            28 => array:3 [
              "identificador" => "bib0495"
              "etiqueta" => "29"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Neonatal lupus erythematosus &#8208; practical guidelines"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;M&#46; Derdulska"
                            1 => "L&#46; Rudnicka"
                            2 => "A&#46; Szykut-Badaczewska"
                            3 => "D&#46; Mehrholz"
                            4 => "R&#46;J&#46; Nowicki"
                            5 => "W&#46; Bara&#324;ska-Rybak"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1515/jpm-2020-0543"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Perinat Med&#46;"
                        "fecha" => "2021"
                        "volumen" => "49"
                        "paginaInicial" => "529"
                        "paginaFinal" => "538"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33470961"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            29 => array:3 [
              "identificador" => "bib0500"
              "etiqueta" => "30"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Recognition and management of cutaneous connective tissue diseases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "K&#46;J&#46;B&#46; Kus"
                            1 => "A&#46;H&#46; LaChance"
                            2 => "R&#46;A&#46; Vleugels"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.mcna.2021.04.011"
                      "Revista" => array:6 [
                        "tituloSerie" => "Med Clin North Am&#46;"
                        "fecha" => "2021"
                        "volumen" => "105"
                        "paginaInicial" => "757"
                        "paginaFinal" => "782"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34059249"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            30 => array:3 [
              "identificador" => "bib0505"
              "etiqueta" => "31"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Development of chronic cutaneous lupus erythematosus during biologic therapy&#58; a systematic review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46; Mirali"
                            1 => "A&#46; Mufti"
                            2 => "R&#46;P&#46; Lansang"
                            3 => "M&#46; Sachdeva"
                            4 => "J&#46; Yeung"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "84"
                        "paginaInicial" => "835"
                        "paginaFinal" => "838"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            31 => array:3 [
              "identificador" => "bib0510"
              "etiqueta" => "32"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Oral manifestations of lupus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "S&#46; Menzies"
                            1 => "F&#46; O&#39;Shea"
                            2 => "S&#46; Galvin"
                            3 => "B&#46; Wynne"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s11845-017-1622-z"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ir J Med Sci&#46;"
                        "fecha" => "2018"
                        "volumen" => "187"
                        "paginaInicial" => "91"
                        "paginaFinal" => "93"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28470356"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            32 => array:3 [
              "identificador" => "bib0515"
              "etiqueta" => "33"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lupus erythematosus&#47;lichen planus overlap syndrome&#58; successful treatment with acitretin"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "D&#46;J&#46; Lospinoso"
                            1 => "C&#46; Fernelius"
                            2 => "K&#46;D&#46; Edhegard"
                            3 => "D&#46;R&#46; Finger"
                            4 => "N&#46;S&#46; Arora"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/0961203313492243"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lupus&#46;"
                        "fecha" => "2013"
                        "volumen" => "22"
                        "paginaInicial" => "851"
                        "paginaFinal" => "854"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23761099"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            33 => array:3 [
              "identificador" => "bib0520"
              "etiqueta" => "34"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Seven&#8208;year itch&#58; a perplexing case of lichen planus&#8208;lupus erythematosus overlap syndrome"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "S&#46; Schmitz"
                            1 => "M&#46; Vatanchi"
                            2 => "U&#46; Alapati"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Dermatol Online J&#46;"
                        "fecha" => "2018"
                        "volumen" => "24"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            34 => array:3 [
              "identificador" => "bib0525"
              "etiqueta" => "35"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Association of chilblain lupus and anti&#8208;Ro&#47;SSA and anti&#8208;La&#47;SSB antibodies&#58; a study of 30 cases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "D&#46; Canu"
                            1 => "J&#46;F&#46; Viallard"
                            2 => "E&#46; Lazaro"
                            3 => "M&#46;S&#46; Doutre"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/ijd.15553"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "60"
                        "paginaInicial" => "e509"
                        "paginaFinal" => "e511"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34021592"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            35 => array:3 [
              "identificador" => "bib0530"
              "etiqueta" => "36"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Chilblains in immune mediated inflammatory diseases&#58; a review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46; Dubey"
                            1 => "N&#46; Joshi"
                            2 => "O&#46; Stevenson"
                            3 => "C&#46; Gordon"
                            4 => "J&#46;A&#46; Reynolds"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:3 [
                        "tituloSerie" => "Rheumatology &#40;Oxford&#41;&#46;"
                        "fecha" => "2022"
                        "volumen" => "12"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            36 => array:3 [
              "identificador" => "bib0535"
              "etiqueta" => "37"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comedonal variant of chronic cutaneous lupus erythematosus causing mutilation of the earlobe"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "E&#46; Cozzani"
                            1 => "A&#46; Herzum"
                            2 => "M&#46; Burlando"
                            3 => "A&#46; Parodi"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jdcr.2020.06.009"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAAD Case Rep&#46;"
                        "fecha" => "2020"
                        "volumen" => "6"
                        "paginaInicial" => "843"
                        "paginaFinal" => "844"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32875034"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            37 => array:3 [
              "identificador" => "bib0540"
              "etiqueta" => "38"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comedonic lupus&#58; an unusual presentation of cutaneous lupus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "C&#46; Chess&#233;"
                            1 => "M&#46;J&#46; Fern&#225;ndez-Tapia"
                            2 => "F&#46; Borzotta"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Actas Dermosifiliogr &#40;Engl Ed&#41;&#46;"
                        "fecha" => "2021"
                        "volumen" => "112"
                        "paginaInicial" => "370"
                        "paginaFinal" => "371"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            38 => array:3 [
              "identificador" => "bib0545"
              "etiqueta" => "39"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Comedogenic lupus&#58; a rare variant of chronic cutaneous lupus erythematosus &#8208; case series"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "L&#46;C&#46; Garcia"
                            1 => "I&#46;B&#46; Morato"
                            2 => "R&#46;F&#46;Q&#46; Melo"
                            3 => "E&#46;C&#46;S&#46; Vale"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "An Bras Dermatol&#46;"
                        "fecha" => "2023"
                        "volumen" => "98"
                        "paginaInicial" => "159"
                        "paginaFinal" => "167"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            39 => array:3 [
              "identificador" => "bib0550"
              "etiqueta" => "40"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lupus erythematosus tumidus&#58; clinical perspectives"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "N&#46; Patsinakidis"
                            1 => "O&#46; Kautz"
                            2 => "B&#46;F&#46; Gibbs"
                            3 => "U&#46; Raap"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2147/CCID.S166723"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Cosmet Investig Dermatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "12"
                        "paginaInicial" => "707"
                        "paginaFinal" => "719"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31632119"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            40 => array:3 [
              "identificador" => "bib0555"
              "etiqueta" => "41"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lupus erythematosus tumidus is a separate subtype of cutaneous lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "V&#46; Schmitt"
                            1 => "A&#46;M&#46; Meuth"
                            2 => "S&#46; Amler"
                            3 => "E&#46; Kuehn"
                            4 => "M&#46; Haust"
                            5 => "G&#46; Messer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/j.1365-2133.2009.09401.x"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2010"
                        "volumen" => "162"
                        "paginaInicial" => "64"
                        "paginaFinal" => "73"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19712116"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            41 => array:3 [
              "identificador" => "bib0560"
              "etiqueta" => "42"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "L&#250;pus eritematoso sist&#234;mico bolhoso"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "V&#46; Aoki"
                            1 => "E&#46;C&#46;S&#46; Vale"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "LibroEditado" => array:5 [
                        "editores" => "V&#46;Aoki, C&#46;W&#46;Maruta, C&#46;G&#46;Santi"
                        "titulo" => "Dermatoses bolhosas autoimunes&#46;"
                        "paginaInicial" => "119"
                        "paginaFinal" => "128"
                        "serieFecha" => "2016"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            42 => array:3 [
              "identificador" => "bib0565"
              "etiqueta" => "43"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical&#44; histological&#44; immunological presentations and outcomes of bullous systemic lupus erythematosus&#58; 10 new cases and a literature review of 118 cases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; de Risi-Pugliese"
                            1 => "F&#46; Cohen-Aubart"
                            2 => "J&#46; Haroche"
                            3 => "P&#46; Moguelet"
                            4 => "S&#46; Grootenboer-Mignot"
                            5 => "A&#46; Mathian"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.semarthrit.2017.11.003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Semin Arthritis Rheum&#46;"
                        "fecha" => "2018"
                        "volumen" => "48"
                        "paginaInicial" => "83"
                        "paginaFinal" => "89"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29191376"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            43 => array:3 [
              "identificador" => "bib0570"
              "etiqueta" => "44"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Vesiculobullous diseases in relation to lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "S&#46; Rutnin"
                            1 => "K&#46; Chanprapaph"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.2147/CCID.S220906"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Cosmet Investig Dermatol&#46;"
                        "fecha" => "2019"
                        "volumen" => "12"
                        "paginaInicial" => "653"
                        "paginaFinal" => "667"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31564947"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            44 => array:3 [
              "identificador" => "bib0575"
              "etiqueta" => "45"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lupus erythematosus&#58; significance of dermatologic findings"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "C&#46; Lenormand"
                            1 => "D&#46; Lipsker"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.annder.2020.08.052"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Dermatol Venereol&#46;"
                        "fecha" => "2021"
                        "volumen" => "148"
                        "paginaInicial" => "6"
                        "paginaFinal" => "15"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33483145"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            45 => array:3 [
              "identificador" => "bib0580"
              "etiqueta" => "46"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Skin manifestations associated with systemic diseases &#8208; Part I"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46;L&#46; Sampaio"
                            1 => "A&#46;L&#46; Bressan"
                            2 => "B&#46;N&#46; Vasconcelos"
                            3 => "A&#46;C&#46; Gripp"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.abd.2021.02.008"
                      "Revista" => array:6 [
                        "tituloSerie" => "An Bras Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "96"
                        "paginaInicial" => "655"
                        "paginaFinal" => "671"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34544638"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            46 => array:3 [
              "identificador" => "bib0585"
              "etiqueta" => "47"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous manifestations of lupus erythematosus&#58; a practical clinicopathological review for pathologists"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "C&#46; Bitar"
                            1 => "T&#46;D&#46; Menge"
                            2 => "M&#46;P&#46; Chan"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Histopathology&#46;"
                        "fecha" => "2022"
                        "volumen" => "80"
                        "paginaInicial" => "233"
                        "paginaFinal" => "250"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            47 => array:3 [
              "identificador" => "bib0590"
              "etiqueta" => "48"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The classification and diagnosis of cutaneous lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "A&#46; Kuhn"
                            1 => "A&#46; Landmann"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "J Autoimmun&#46;"
                        "fecha" => "2014"
                        "paginaInicial" => "48"
                        "paginaFinal" => "49"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            48 => array:3 [
              "identificador" => "bib0595"
              "etiqueta" => "49"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Histologic features of cutaneous lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "M&#46; Baltaci"
                            1 => "P&#46; Fritsch"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.autrev.2008.12.014"
                      "Revista" => array:6 [
                        "tituloSerie" => "Autoimmun Rev&#46;"
                        "fecha" => "2009"
                        "volumen" => "8"
                        "paginaInicial" => "467"
                        "paginaFinal" => "473"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19162243"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            49 => array:3 [
              "identificador" => "bib0600"
              "etiqueta" => "50"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Assessment of clinical and laboratory use of the cutaneous direct immunofluorescence assay"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "J&#46;D&#46;R&#46; Reimann"
                            1 => "S&#46;P&#46; Moynihan"
                            2 => "T&#46;D&#46; Horn"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "JAMA Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "157"
                        "paginaInicial" => "1343"
                        "paginaFinal" => "1348"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            50 => array:3 [
              "identificador" => "bib0605"
              "etiqueta" => "51"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Autoantibodies associated with connective tissue diseases&#58; what meaning for clinicians&#63;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "K&#46; Didier"
                            1 => "L&#46; Bolko"
                            2 => "D&#46; Giusti"
                            3 => "S&#46; Toquet"
                            4 => "A&#46; Robbins"
                            5 => "F&#46; Antonicelli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3389/fimmu.2018.00541"
                      "Revista" => array:5 [
                        "tituloSerie" => "Front Immunol&#46;"
                        "fecha" => "2018"
                        "volumen" => "9"
                        "paginaInicial" => "541"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29632529"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            51 => array:3 [
              "identificador" => "bib0610"
              "etiqueta" => "52"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "New insights into the progression from cutaneous lupus to systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "W&#46; Zhou"
                            1 => "H&#46; Wu"
                            2 => "M&#46; Zhao"
                            3 => "Q&#46; Lu"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1080/1744666X.2020.1805316"
                      "Revista" => array:6 [
                        "tituloSerie" => "Expert Rev Clin Immunol&#46;"
                        "fecha" => "2020"
                        "volumen" => "16"
                        "paginaInicial" => "829"
                        "paginaFinal" => "837"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32746644"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            52 => array:3 [
              "identificador" => "bib0615"
              "etiqueta" => "53"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "The CLASI&#44; a validated tool for the evaluation of skin disease in lupus erythematosus&#58; a narrative review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "S&#46; Chakka"
                            1 => "R&#46;L&#46; Krain"
                            2 => "J&#46;S&#46;S&#46; Concha"
                            3 => "B&#46;F&#46; Chong"
                            4 => "J&#46;F&#46; Merola"
                            5 => "V&#46;P&#46; Werth"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.21037/atm-20-5048"
                      "Revista" => array:5 [
                        "tituloSerie" => "Ann Transl Med&#46;"
                        "fecha" => "2021"
                        "volumen" => "9"
                        "paginaInicial" => "431"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33842652"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            53 => array:3 [
              "identificador" => "bib0620"
              "etiqueta" => "54"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Use of the Cutaneous Lupus Disease Area and Severity Index as an outcome measure in clinical trials&#58; a descriptive study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "E&#46; Mack"
                            1 => "L&#46;S&#46; Exton"
                            2 => "M&#46;F&#46; Mohd-Mustapa"
                            3 => "C&#46; McCourt"
                            4 => "D&#46; O&#8217;Kane"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Clin Exp Dermatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "46"
                        "paginaInicial" => "147"
                        "paginaFinal" => "152"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            54 => array:3 [
              "identificador" => "bib0625"
              "etiqueta" => "55"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cutaneous lupus&#58; a brief review of old and new medical therapeutic options"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "F&#46; Nutan"
                            1 => "A&#46;G&#46; Ortega-Loayza"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jisp.2017.02.001"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Investig Dermatol Symp Proc&#46;"
                        "fecha" => "2017"
                        "volumen" => "18"
                        "paginaInicial" => "S64"
                        "paginaFinal" => "S68"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28941497"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            55 => array:3 [
              "identificador" => "bib0630"
              "etiqueta" => "56"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of cutaneous lupus erythematosus&#58; current approaches and future strategies"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "H&#46; Shi"
                            1 => "J&#46;E&#46; Gudjonsson"
                            2 => "J&#46;M&#46; Kahlenberg"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/BOR.0000000000000704"
                      "Revista" => array:6 [
                        "tituloSerie" => "Curr Opin Rheumatol&#46;"
                        "fecha" => "2020"
                        "volumen" => "32"
                        "paginaInicial" => "208"
                        "paginaFinal" => "214"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32141953"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            56 => array:3 [
              "identificador" => "bib0635"
              "etiqueta" => "57"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Management of cutaneous manifestations of lupus erythematosus&#58; a systematic review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "J&#46;L&#46; Fairley"
                            1 => "S&#46; Oon"
                            2 => "A&#46;M&#46; Saracino"
                            3 => "M&#46; Nikpour"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "Semin Arthritis Rheum&#46;"
                        "fecha" => "2020"
                        "volumen" => "50"
                        "paginaInicial" => "95"
                        "paginaFinal" => "127"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            57 => array:3 [
              "identificador" => "bib0640"
              "etiqueta" => "58"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Candidate drug replacements for quinacrine in cutaneous lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "D&#46; Yan"
                            1 => "R&#46; Borucki"
                            2 => "R&#46;D&#46; Sontheimer"
                            3 => "V&#46;P&#46; Werth"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Lupus Sci Med&#46;"
                        "fecha" => "2020"
                        "volumen" => "7"
                        "paginaInicial" => "e000430"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            58 => array:3 [
              "identificador" => "bib0645"
              "etiqueta" => "59"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Interventions for cutaneous disease in systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "C&#46;W&#46; Hannon"
                            1 => "C&#46; McCourt"
                            2 => "H&#46;C&#46; Lima"
                            3 => "S&#46; Chen"
                            4 => "C&#46; Bennett"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/14651858.CD007478.pub2"
                      "Revista" => array:5 [
                        "tituloSerie" => "Cochrane Database Syst Rev&#46;"
                        "fecha" => "2021"
                        "volumen" => "3"
                        "paginaInicial" => "CD007478"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33687069"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            59 => array:3 [
              "identificador" => "bib0650"
              "etiqueta" => "60"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Current concepts and future approaches in the treatment of cutaneous lupus erythematosus&#58; a comprehensive review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "F&#46; Chasset"
                             …1
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s40265-019-01151-8"
                      "Revista" => array:6 [
                        "tituloSerie" => "Drugs&#46;"
                        "fecha" => "2019"
                        "volumen" => "79"
                        "paginaInicial" => "1199"
                        "paginaFinal" => "1215"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            60 => array:3 [
              "identificador" => "bib0655"
              "etiqueta" => "61"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "S2k guideline for treatment of cutaneous lupus erythematosus &#8211; guided by the European Dermatology Forum &#40;EDF&#41; in cooperation with the European Academy of Dermatology and Venereology &#40;EADV&#41;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:5 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol&#46;"
                        "fecha" => "2017"
                        "volumen" => "31"
                        "paginaInicial" => "389"
                        "paginaFinal" => "404"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            61 => array:3 [
              "identificador" => "bib0660"
              "etiqueta" => "62"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatments for disease damage in cutaneous lupus erythematosus&#58; a narrative review"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Dermatol Ther&#46;"
                        "fecha" => "2021"
                        "volumen" => "34"
                        "paginaInicial" => "e15034"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            62 => array:3 [
              "identificador" => "bib0665"
              "etiqueta" => "63"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Which interventions are effective for cutaneous disease in systemic lupus erythematosus&#63;&#46; A Cochrane Review summary with commentary"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:1 [ …1]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/1756-185X.14215"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Rheum Dis&#46;"
                        "fecha" => "2021"
                        "volumen" => "24"
                        "paginaInicial" => "1540"
                        "paginaFinal" => "1542"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            63 => array:3 [
              "identificador" => "bib0670"
              "etiqueta" => "64"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes&#58; a systematic review and meta&#8208;analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [ …5]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.15312"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol&#46;"
                        "fecha" => "2017"
                        "volumen" => "177"
                        "paginaInicial" => "188"
                        "paginaFinal" => "196"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            64 => array:3 [
              "identificador" => "bib0675"
              "etiqueta" => "65"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity&#8208;mediated inflammatory rheumatic diseases"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1186/s42358-020-00134-8"
                      "Revista" => array:5 [
                        "tituloSerie" => "Adv Rheumatol&#46;"
                        "fecha" => "2020"
                        "volumen" => "60"
                        "paginaInicial" => "32"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            65 => array:3 [
              "identificador" => "bib0680"
              "etiqueta" => "66"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "2019 update of the EULAR recommendations for the management of systemic lupus erythematosus"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1136/annrheumdis-2019-215089"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ann Rheum Dis&#46;"
                        "fecha" => "2019"
                        "volumen" => "78"
                        "paginaInicial" => "736"
                        "paginaFinal" => "745"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            66 => array:3 [
              "identificador" => "bib0685"
              "etiqueta" => "67"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Lupus erythematosus&#58; considerations about clinical&#44; cutaneous and therapeutic aspects"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1590/abd1806-4841.20142146"
                      "Revista" => array:6 [
                        "tituloSerie" => "An Bras Dermatol&#46;"
                        "fecha" => "2014"
                        "volumen" => "89"
                        "paginaInicial" => "118"
                        "paginaFinal" => "125"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            67 => array:3 [
              "identificador" => "bib0690"
              "etiqueta" => "68"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Dapsone as second&#8208;line treatment for cutaneous lupus erythematosus&#63;&#46; A retrospective analysis of 34 patients and a review of the literature"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [ …3]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1159/000441054"
                      "Revista" => array:6 [
                        "tituloSerie" => "Dermatology&#46;"
                        "fecha" => "2016"
                        "volumen" => "232"
                        "paginaInicial" => "91"
                        "paginaFinal" => "96"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            68 => array:3 [
              "identificador" => "bib0695"
              "etiqueta" => "69"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Thalidomide and lenalidomide for refractory systemic&#47;cutaneous lupus erythematosus treatment&#58; a narrative review of literature for clinical practice"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1097/RHU.0000000000001160"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Clin Rheumatol&#46;"
                        "fecha" => "2021"
                        "volumen" => "27"
                        "paginaInicial" => "248"
                        "paginaFinal" => "259"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            69 => array:3 [
              "identificador" => "bib0700"
              "etiqueta" => "70"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus&#58; a systematic review and meta&#8208;analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [ …6]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.jaad.2017.09.059"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Am Acad Dermatol&#46;"
                        "fecha" => "2018"
                        "volumen" => "78"
                        "paginaInicial" => "342"
                        "paginaFinal" => "350"
                        "link" => array:1 [
                          0 => array:2 [ …2]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "pt"
  "url" => "/26662752/0000009800000003/v3_202305121556/S2666275223000504/v3_202305121556/pt/main.assets"
  "Apartado" => array:4 [
    "identificador" => "81730"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Revis&#227;o"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/26662752/0000009800000003/v3_202305121556/S2666275223000504/v3_202305121556/pt/main.pdf?idApp=UINPBA00008Z&text.app=https://clinics.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2666275223000504?idApp=UINPBA00008Z"
]
Article information
ISSN: 26662752
Original language: Portuguese
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 161 68 229
2024 October 2111 500 2611
2024 September 3904 443 4347
2024 August 3350 520 3870
2024 July 2438 359 2797
2024 June 2144 375 2519
2024 May 1810 367 2177
2024 April 2054 486 2540
2024 March 2601 521 3122
2024 February 2344 332 2676
2024 January 2259 259 2518
2023 December 2344 268 2612
2023 November 3472 449 3921
2023 October 3405 519 3924
2023 September 3153 448 3601
2023 August 3322 352 3674
2023 July 2395 276 2671
2023 June 2452 363 2815
2023 May 2101 480 2581
2023 April 530 154 684
2023 March 99 70 169
Show all

Follow this link to access the full text of the article

Idiomas
Anais Brasileiros de Dermatologia
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.